WO2001009121A2 - 2-pyrazolin-5-ones_as tyrosine kinase inhibitors - Google Patents

2-pyrazolin-5-ones_as tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2001009121A2
WO2001009121A2 PCT/US2000/020628 US0020628W WO0109121A2 WO 2001009121 A2 WO2001009121 A2 WO 2001009121A2 US 0020628 W US0020628 W US 0020628W WO 0109121 A2 WO0109121 A2 WO 0109121A2
Authority
WO
WIPO (PCT)
Prior art keywords
methylene
pyrazolin
pyrrol
methyl
pyrazinyl
Prior art date
Application number
PCT/US2000/020628
Other languages
French (fr)
Other versions
WO2001009121A3 (en
Inventor
Marina M. Moset
Jose Maria Castellano Berlanga
Isabel F. Fernandez
David J. Calderwood
Paul Rafferty
Lee Arnold
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001514324A priority Critical patent/JP2003506368A/en
Priority to IL14775700A priority patent/IL147757A0/en
Priority to BR0012896-1A priority patent/BR0012896A/en
Priority to AU63889/00A priority patent/AU6388900A/en
Priority to HU0400540A priority patent/HUP0400540A3/en
Priority to EP00950852A priority patent/EP1218373A2/en
Priority to PL00354144A priority patent/PL354144A1/en
Priority to MXPA02001088A priority patent/MXPA02001088A/en
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Priority to CA002380644A priority patent/CA2380644A1/en
Priority to NZ516850A priority patent/NZ516850A/en
Priority to SK151-2002A priority patent/SK1512002A3/en
Priority to KR1020027001343A priority patent/KR20020091829A/en
Publication of WO2001009121A2 publication Critical patent/WO2001009121A2/en
Priority to NO20020487A priority patent/NO20020487L/en
Priority to BG106392A priority patent/BG106392A/en
Publication of WO2001009121A3 publication Critical patent/WO2001009121A3/en
Priority to HK02109301.3A priority patent/HK1049154A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to certain 2-pyrazolin-5-ones which are inhibitors of protein kinases, particularly tyrosine kinases and serine/threonine kinases, of which some are novel compounds, to pharmaceutical compositions containing these pyrazolinones and to processes for preparing these pyrazolinones.
  • protein kinases There are at least 400 enzymes identified as protein kinases. These enzymes catalyze the phosphorylation of target protein substrates.
  • the phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate.
  • the specific structure in the target substrate to which the phosphate is transferred is a tyrosine, serine or threonine residue. Since these amino acid residues are the target structures for the phosphoryl transfer, these protein kinase enzymes are commonly referred to as tyrosine kinases or serine/threonine kinases.
  • the phosphorylation reactions, and counteracting phosphatase reactions, at the tyrosine, serine and threonine residues are involved in countless cellular processes that underlie responses to diverse intracellular signals (typically mediated through cellular receptors), regulation of cellular functions, and activation or deactivation of cellular processes.
  • a cascade of protein kinases often participate in intracellular signal transduction and are necessary for the realization of these cellular processes. Because of their ubiquity in these processes, the protein kinases can be found as an integral part of the plasma membrane or as cytoplasmic enzymes or localized in the nucleus, often as components of enzyme complexes.
  • Protein tyrosine kinases are enzymes which catalyze the phosphorylation of specific tyrosine residues in cellular proteins. This post-translational modification of these substrate proteins, often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation or differentiation (for review, see Schlessinger and Ulrich, 1992, Neuron 9:383-391).
  • PTKs Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease.
  • endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas) .
  • Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).
  • RTKs Receptor Tyrosine Kinases
  • the RTKs comprise a large family of transmembrane receptors with diverse biological activities. At present, at least nineteen (19) distinct RTK subfamilies have been identified.
  • the receptor tyrosine kinase (RTK) family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell 61 :243-254, 1990).
  • RTKs The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, Cell 61 :203-212).
  • receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans- phosphorylation.
  • Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response, (e.g., cell division, differentiation, metabolic effects, changes in the extracellular microenvironment) see Schlessinger and Ullrich, 1992, Neuron 9:1-20.
  • Proteins with SH2 (src homology -2) or phosphotyrosine binding (PTB) domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of the domains recognize phosphotyrosine.
  • substrates which have a catalytic domain may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al, 1993, Cell 72:767-778).
  • substrates which have a catalytic domain may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al, 1993, Cell 72:767-778).
  • the specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. For example, differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors correlate with the observed differences in their substrate phosphorylation profiles (Songyang et al
  • phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.
  • FLK-1 fetal liver kinase 1
  • KDR kinase insert domain-containing receptor
  • FLK- 1/KDR vascular endothelial cell growth factor receptor 2
  • VEGFR-2 vascular endothelial cell growth factor receptor 2
  • DNAs encoding mouse, rat and human FLK-1 have been isolated, and the nucleotide and encoded amino acid sequences reported (Matthews et al, Proc. Natl. Acad. Sci. USA, 88:9026-30, 1991; Terman et al, 1991, supra; Terman et al, Biochem. Biophys. Res. Comm.
  • VEGF and FLK-l/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells, and formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.
  • Flt-1 Fls-like tyrosine kinase- 1
  • FLK-1/KDR FLK-1/KDR
  • Flt-1 vascular endothelial cell growth factor receptor 1
  • VEGF vascular endothelial cell growth factor
  • VEGF vascular endothelial cell growth factor
  • VEGF vascular endothelial cell growth factor
  • Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, supra). Expression of Flt-1 in adult organs such as kidney glomeruli suggests an additional function for this receptor that is not related to cell growth (Mustonen and Alitalo, supra).
  • VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman et al, Endocrinology 133: 848-859, 1993; Kolch et al, Breast Cancer Research and Treatment 36: 139-155, 1995; Ferrara et ⁇ /., Endocrine Reviews 18(1); 4-25, 1997; Ferrara et al., Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232, 1997).
  • VEGF has been implicated in the control and enhancement of vascular permeability (Connolly, et al, J. Biol. Chem. 264: 20017- 20024, 1989; Brown et al, Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269, 1997).
  • VEGF vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • PIGF has been reported to potentiate both the vascular permeability and mitogenic effect of VEGF on endothelial cells when VEGF is present at low concentrations (purportedly due to heterodimer formation) (Park et al, supra).
  • VEGF-B is produced as two isoforms (167 and 185 residues) that also appear to bind Flt-1 /VEGFR-1. It may play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(20): 11709-11714).
  • VEGF-C was originally cloned as a ligand for VEGFR-3/Flt-4 which is primarily expressed by lymphatic endothelial cells. In its fully processed form,
  • VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells in vitro and angiogenesis in in vivo models ( Lymboussaki et al, Am. J. Pathol. (1998), 153(2): 395-403; Witzenbichler et al, Am. J. Pathol. (1998), 153(2), 381-394).
  • the transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected.
  • the expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J. Biol. Chem. (1998), 273(14),8413-8418).
  • VEGF-D is structurally very similar to VEGF- C.
  • VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR VEGFR-2. It was originally cloned as a c-fos inducible mitogen for fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(2), 548-553 and references therein).
  • VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability in vivo in a Miles assay when injected into cutaneous tissue (PCT/US97/14696; WO98/07832, Witzenbichler et al, supra).
  • PCT/US97/14696; WO98/07832, Witzenbichler et al, supra The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.
  • VEGF-E vascular endothelial growth factor-E
  • NZ-7 VEGF vascular endothelial growth factor
  • VEGF-E sequences possess about 25% homology to mammalian VEGF and are encoded by the parapoxvirus Orf virus (OV). This parapoxvirus that affects sheep and goats and occasionally, humans, to generate lesions with angiogenesis.
  • VEGF-E is a dimer of about 20 kDa with no basic domain nor affinity for heparin, but has the characteristic cysteine knot motif present in all mammalian VEGFs, and was surprisingly found to possess potency and bioactivities similar to the heparin-binding VEGF 165 isoform of VEGF- A, i.e. both factors stimulate the release of tissue factor (TF), the proliferation, chemotaxis and sprouting of cultured vascular endothelial cells in vitro and angiogenesis in vivo.
  • tissue factor TF
  • VEGF-E Like VEGF 165, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation and a biphasic rise in free intracellular Ca2+ concentrations, while in contrast to VEGF 165, VEGF-E did not bind to VEGF receptor-1 (Flt-1). Based upon emerging discoveries of other homologues of VEGF and
  • the Non-Receptor Tyrosine Kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty- four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified.
  • the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk.
  • the Src subfamily of enzymes has been linked to oncogenesis and immune responses.
  • a more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogene 8:2025-2031, which is incorporated herein by reference.
  • tyrosine kinases whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including cancer, psoriasis, and other hyperproliferative disorders or hyper-immune responses.
  • RNA ligands (Jellinek, et al, Biochemistry 33: 10450- 56; Takano, et al, 1993, Mol. Bio. Cell 4:358A; Kinsella, et al. 1992, Exp. Cell Res. 199:56-62; Wright, et al, 1992, J. Cellular Phys. 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, et al, 1994, Proc. Am. Assoc. Cancer Res. 35:2268).
  • PCT WO 94/03427 selenoindoles and selenides
  • PCT WO 92/21660 tricyclic polyhydroxylic compounds
  • PCT WO 91/15495 benzylphosphonic acid compounds
  • Anilinocinno lines PCT WO97/34876
  • quinazoline derivative compounds PCT WO97/22596; PCT WO97/42187
  • Plk-1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk-1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.
  • Cdc2/Cyclin B Kinase Inhibitors (Cdc2) is also known as cdkl)
  • Cdc2/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, which is the hallmark of cancer is dependent upon elevated cdk activities in these cells. The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.
  • cdks cyclin-dependent kinase
  • the identification of effective small compounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of receptor and non-receptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism is therefore desirable.
  • the identification of methods and compounds that specifically inhibit the function of a tyrosine kinase which is essential for angiogenic processes or the formation of vascular hyperpermeability leading to edema, ascites, effusions, exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial.
  • This invention is directed to compounds of the formula
  • R is a substituted or unsubstituted aliphatic, aromatic, heterocyclic or aralkyl group
  • R 2 is a hydrogen, lower alkyl group or aryl group.
  • R 1 is hydrogen or -A-Z, wherein A is - (CH 2 ) n -, -(CH 2 ) n NH-, -(CH 2 ) n O-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or -(CH 2 ) n S(O) 2 -; and Z is -H, a lower alkyl, aralkyl, trihalomethyl, R 3 CO-, trihalomethylcarbonyl, R 3 OC(O)- , -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloal
  • R 3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group.
  • R 4 and R 5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamo holino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group,
  • Suitable substitutents for R include halogens, lower alkyl groups, R 3 O-, hydroxy, HOC(O)-, R 3 OC(O)-, R 3 OC(O)R 6 -, R 3 OR 6 -, trihalomethyl, trihalomethylcarbonyl, nitro, -C(O)NR 4 R 5 , -NR 4 R 5 , R 3 CO-, -(CH 2 ) n -R 7 , - C(O)(CH 2 ) n -R 7 , -C(O)-(CH 2 ) n -C(O)-R 7 , -O(CH 2 ) n R 7 , -C(O)NR 4 (CH 2 ) n R 7 , - C(O)O(CH 2 ) n R 7 , -OC(O)(CH 2 ) n R 7 , -NR 4 C(O)(CH 2 ) n R 7 , -R 6
  • R 6 is a lower alkyl group or an aryl group.
  • R 7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxy, R 3 O-, R 3 C(O)- or -NR 4 R 5 .
  • Suitable substituents for R 3 , R 4 and R 5 include one or more moieties selected from the group consisting of halogens, lower alkyl, hydroxy, lower alkoxy, carboxy, lower alkyl ester, trihalomethyl preferrably trifluoromethyl, nitro, phenyl, phenyl- lower alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )cycloalkyl-alkyl, CN, amino, alkylamino, dialkylamino, -C(O)NH 2 , -C(O)NH(alkyl) and -C(O)N(alkyl) 2 .
  • Aliphatic groups include straight chained or branched C,-C 18 hydrocarbons, or cyclic C 3 -C I8 hydrocarbons which are completely saturated or which contain one or more units of unsaturation.
  • Lower alkyl groups are straight chained or branched C,-C 6 hydrocarbons or C 3 -C 6 cyclic hydrocarbons which are completely saturated.
  • Aromatic groups, as used herein, include carbocyclic ring systems (e.g. benzyl and cinnamylidene) and fused polycyclic aromatic ring systems (e.g. naphthyl).
  • aromatic groups includes heteroaryl ring systems (e.g.
  • heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic non-aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings (e.g. benzimidazole, benzothiazole, indole, tetrahydroindole, azaindole, indazole, isoxazole, isothiazole, imidazole and quinoline).
  • An aryl group refers to an aromatic group having five or six atoms.
  • An aralkyl group is an aromatic substituent that is linked to a compound by an aliphatic group having from one to six carbon atoms.
  • a heterocyclic group refers to a mono-, bi- or tri-cyclic heterocyclic group that is not aromatic or has a degree of unsaturation wherein the unsaturation does not make the group an aromatic group.
  • R 2 is hydrogen
  • R is, preferably, a substituted indole, or a substituted or unsubstituted imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, pyrrole, pyrazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene or pyrazine.
  • R 2 is hydrogen, n is zero, and Z is a cyclopropyl, 3-pyridyl or pyrazinyl group.
  • R 2 is hydrogen, A is -O-, n is 0 and Z is ethyl, propyl or isopropyl.
  • R 2 is hydrogen, A is CH 2 , n is 2 and Z is benzene which is optionally substituted with halogen, trihalomethyl, hydroxy, -NR 4 R 5 , nitro, -C(O)NR 4 R 5 , lower alkyl group, R 3 O-, -C(O)OR 4 or -OC(O)R 3 .
  • the present invention is directed to a compound represented by the following formula: and physiologically acceptable salts thereof, wherein: R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole; R 1 is hydrogen or -A-Z;
  • A is -(CH 2 ) n -, -(CH 2 ) n NH-, -(CH 2 ) n O-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or - (CH 2 ) n S(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 OC(O)-, -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 CO-, R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens,
  • R 3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 - C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
  • R 4 and R 5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 -C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an a
  • the present invention is directed to a compound represented by the following structural formula: and physiologically acceptable salts thereof, wherein:
  • R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole;
  • R 1 is hydrogen or -A-Z
  • A is -(CH 2 ) n -, -(CH 2 ) n NH-, -(CH 2 ) n O-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or - (CH 2 ) n S(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 OC(O)-, -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 CO-, R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens,
  • R 3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl- alkyl group and a heterocyclyl-alkyl group;
  • R 4 and R 5 for each occurrence are each, independently, hydrogen or is selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a
  • the present invention is directed to a compound represented by the following structural fo ⁇ nula: and physiologically acceptable salts thereof, wherein:
  • R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole; R 1 is hydrogen or -A-Z;
  • A is -(CH-),,-, -(CH 2 ) n NH-, -(CH 2 ) n O-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or - (CH 2 ) disregardS(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 OC(O)-, -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 CO-, R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens,
  • R 3 for each occurrence is, independently, selected from the group consisting of a substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, a (C 3 - C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
  • R 4 and R s for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 -C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an a
  • the present invention is directed to a compound represented by the following structural formula: and physiologically acceptable salts thereof, wherein:
  • R is substituted pyrrole or is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrazole, oxazole and thiazole; R 1 is hydrogen or -A-Z;
  • A is -(CH 2 ) protest-, -(CH 2 ) n NH-, -(CH 2 ) n O-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or - (CH 2 ) n S(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 OC(O)-, -NR R 5 , -C(O)NR 4 R 5 , R 3 CO-, R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower
  • R 3 for each occurrence is, independently, selected from the group consisting of: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C 3 - C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 -C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
  • R 4 and R 5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 -C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aral
  • R 3 OR 6 -, trihalomethyl, trihalomethylcarbonyl, -(CH 2 ) p -R 7 , -O(CH 2 ) p R 7 ,
  • R 6 N(R 4 )C(O)(CH 2 ) p R 7 , -R 6 CH(C(O)OR 4 )(N(R 4 )C(O)R 4 ), a substituted aryl or aralkyl group, wherein:
  • R 6 for each occurrence is independently a lower alkyl group or an aryl group
  • R 7 for each occurrence is independently an alkoxy, haloalkyl, lower alkylpiperazine, hydroxy, R 3 O-, R 3 C(O)- or NR 4 R 5 ; and p is an integer from 1-3; b) when R is indol-3-yl, the indol-3-yl is substituted with R 3 OC(O)R 6 , R 3 OR 6 -, trihalomethyl, trihalomethylcarbonyl, -(CH 2 ) p -R 7 , -O(CH 2 ) p R 7 , -C(O)N(R 4 )(CH 2 ) p R 7 , -C(O)O(CH 2 ) p R 7 , -OC(O)(CH 2 ) p R 7 , - N(R 4 )C(O)(CH 2 ) p R 7 , -R 6 NR 4 R 5 , -R 6 N(R 4 )-R 6
  • R 6 N(R 4 )C(O)(CH 2 ) p R 7 , -R 6 CH(C(O)OR 4 )(N(R 4 )C(O)R 4 ) or a substituted aryl or aralkyl group; and c) when R is pyrazol-3-yl, the pyrazol-3-yl is substituted with R 3 OC(O)R ⁇ , R 3 OR 6 -, trihalomethyl, trihalomethylcarbonyl, -(CH 2 ) p -R 7 , -O(CH 2 ) p R 7 , -C(O)N(R 4 )(CH 2 ) p R 7 , -C(O)O(CH 2 ) p R 7 , -OC(O)(CH 2 ) p R 7 , -
  • R is substituted pyrrole or is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1 ,2,4-triazole, benzimidazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrazole, oxazole and thiazole; R 1 is hydrogen or -A-Z;
  • A is -(CH 2 ) n -, -(CH 2 ) n NH-, -(CHAP-, -(CH 2 ) admirS-, -(CH 2 ) n S(O)- or - (CH 2 ) n S(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 OC(O)-, -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 CO-, R 3 O-, or a ring system selected from the group consisting of a C 3 -C 6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens,
  • R 3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 - C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
  • R 4 and R 5 for each occu ⁇ ence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C 3 -C 6 )cycloalkyl group, heterocyclic group, aralkyl group, (C 3 -C 6 )cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an
  • R 6 C(O)N(R 4 )(CH 2 ) p R 7 , -R 6 C(O)O(CH 2 ) p R 7 , -R 6 OC(O)(CH 2 ) p R 7 , - R 6 N(R 4 )C(O)(CH 2 ) p R 7 , -R 6 CH(C(O)OR 4 )(N(R 4 )C(O)R 4 ), a substituted aryl or aralkyl group, wherein: R 6 for each occurrence is independently a lower alkyl group or an aryl group; R 7 for each occurrence is independently an alkoxy, haloalkyl, lower alkylpiperazine, hydroxy, R 3 O-, R 3 C(O)- or NR 4 R 5 ; and p is an integer from 1-3; g) when R is indol-3-yl, the indol-3-yl is substituted with R 3 OC(O)R
  • the present invention is directed to any of the foregoing compounds wherein A is -NH-, -O-, -S-, -S(O)- or -S(O) 2 - ; and Z is cyclopropyl, 3 -pyridyl or pyrazinyl.
  • the present invention is directed to any of the foregoing compounds wherein A is -O-; and Z is ethyl, n-propyl or isopropyl.
  • the present invention is directed to any of the foregoing compounds wherein A is -CH 2 -; and Z is phenyl, wherein said phenyl is optionally substituted with one or more moieties selected from the group consisting of halogens, trihalomethyl, hydroxy, -NR 4 R 5 , nitro, -CONR 4 R 5 , lower alkyl group, R 3 O-, -C(O)OR 4 and -OC(O)R 4 .
  • the present invention is directed to any of the foregoing compounds wherein R is substituted with one or more substituents, each independently selected from the group consisting of halogens, lower alkyl groups, R 3 O-, hydroxy, HOC(O)-, R 3 OC(O)-, R 3 OC(O)R 6 -, R 3 OR 6 -, trihalomethyl, trihalomethylcarbonyl, nitro, -C(O)NR R 5 , -NR 4 R 5 , R 3 CO-, -(CH 2 ) n -R 7 , - C(O)(CH 2 ) n -R 7 , -C(O)-(CH 2 ) n -C(O)-R 7 , -O(CH 2 ) n R 7 , -C(O)NR 4 (CH 2 ) n R 7 , - C(O)O(CH 2 ) n R 7 , -OC(O)(CH 2 ) n R
  • the optionally substituted aryl and optionally substituted aralkyl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxy, - NR 4 R 5 , nitro, -CONR 4 R 5 , lower alkyl group, R 3 O-, -C(O)OR 4 and -OC(O)R 3 .
  • R ⁇ is a lower alkyl group or an aryl group.
  • R 7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxy, R 3 O-, R 3 C(O)- or -NR 4 R 5 .
  • R is pyrrolyl, indolyl, azaindolyl, phenyl, pyrazolyl, imidazolyl, thienyl, 4,5,6,7-tetrahydroindolyl, or quinolinyl.
  • R is pyrrol-2-yl, pyrrol-3-yl, indol-2-yl, indol-3-yl, azaindol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, thien-2-yl or quinolin-5-yl.
  • the present invention is directed to any of the foregoing compounds wherein R 1 is trifluoromethyl, amino, cyclopropylamino, methyl, ethyl, propyl, isopropyl, cyclopropyl, 2- methylcyclopropyl, 2,2,3,3-tetramethylcyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2 ) p -O-phenyl, -(CH 2 ) p -O-(4- methoxyphenyl), -(CH 2 ) p -O-(4-chlorophenyl), -(CH 2 ) p -O-(4-methylphenyl), -(CH 2 ) p - O-(3-methylphenyl), -(CH 2 ) p -O-(4-phenylphenyl), -(CH(CH 2 )
  • R is optionally substituted with one or more moieties selected from the group consisting of Br, Cl, F, aminomethyl, N,N-dimethylaminomethyl, carboxy, carboxymethyl, carboxyethyl, carbonylmethyl, carbonylethyl, methoxycarbonyl, ethoxycarbonyl, phenyl, 4-morpholinomethyl, -C(O)-O-(CH 2 ) 2 -N(Me) 2 , -C(O)-O- (CH 2 ) 2 -N(Et) 2 , -C(O)-O-CH 2 -N(Me) 2 , -C(O)-O-(CH 2 ) 2 -N(Me) 2 , -C(O)-NH-(CH 2 ) 2 - N(Me) 2 , -CH 2 -NH-C(O)-CF 3 and an optionally substituted moiety selected from
  • the present invention provides a pharmaceutical composition comprising any one or more of the compounds of the present invention, as defined herein, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a method of inhibiting one or more protein kinase activity comprising the administration of a compound represented by the formula: and physiologically acceptable salts and biologically active metabolites thereof, wherein:
  • R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
  • R 1 is hydrogen or -A-Z
  • R 2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C 3 - C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 - C 6 )cycloalkyl-alkyl group, a heterocyclyl-alkyl group;
  • A is -(CH 2 ) n -, -(CH 2 ) n NH-, -(CH 2 ),P-, -(CH 2 ) n S-, -(CH 2 ) n S(O)- or - (CH 2 ) n S(O) 2 -;
  • Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R 3 CO-, R 3 OC(O)-, -NR 4 R 5 , -C(O)NR 4 R 5 , R 3 O-, or a ring system selected from the group consisting of a (C 3 -C 6 )cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alky
  • R 3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
  • R 4 and R 5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a heterocyclic group, an aralkyl group, a (C 3 -C 6 )cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R 4 and R 5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C 3 -C 6 )cycloalkyl group, a hetero
  • a preferred method of the foregoing method is where the inhibition of the protein kinase is in a recipient in need thereof.
  • a preferred method of any of the foregoing methods is where the compound is a mixture of stereoisomers.
  • a preferred method of any of the foregoing methods is where the stereoisomers are enantiomers.
  • a preferred method of any of the foregoing methods is where the stereoisomers are E and Z isomers.
  • a preferred method of any of the foregoing methods is where the compound is a mixture of structural isomers.
  • a prefe ⁇ ed method of any of the foregoing methods is where the structural isomers are tautomers.
  • a preferred method of any of the foregoing methods is where said protein kinase is either a receptor tyrosine kinase or a non-receptor tyrosine kinase.
  • a preferred method of any of the foregoing methods is where said tyrosine kinase is selected from the group consisting of KDR, Flt-1, TIE-2, FGFR, PDGFR, IGF-l-R, c-Met, Lck, Src, fyn, Lyn, Blk, and yes.
  • the present invention is directed to a method of treating or essentially inhibiting hyperproliferative disorders or inflammatory diseases in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein.
  • the present invention is directed to a method of treating or inhibiting angiogenesis in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein.
  • the present invention is directed to a method of inducing an anti-angiogenic effect in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein.
  • the present invention is directed to a method of treating or inhibiting the progression of a disease or condition in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention, as defined herein, where said disease or condition is selected from the group consisting of cancer, arthritis, atherosclerosis, restenosis, psoriasis, hemangioma, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, corneal disease, rubeosis, neovascular glaucoma, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, virally induced angiogenic disorders, fractures, diabetic retinopathy, Crohn's disease, inflammatory bowel disorder, cat scratch fever, retinopathy or prematurity, ulcers, thyroid hyperplasia, burns, trauma, acute lung injury, chronic lung disease, stroke, polyps, cysts, synovitis, chronic and allergic inflammation, ovarian hyperstimulation syndrome
  • the present invention is directed to a method of affecting vascular hyperpermeability or the production of edema in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention, as defined herein.
  • a preferred method of the immediately foregoing method is where the effect on the production of edema is antiedematous.
  • a preferred method of any of the foregoing methods is where the protein kinase is a serine kinase.
  • a preferred method of any of the foregoing methods is where the protein kinase is a threonine kinase.
  • Particularly preferred compounds of the present invention are:
  • 2-pyrazolin-5-one - [(3 ,5 -Dimethyl-4- [( 1 -pyrrolidinylmethylpyrrol-2-yl)methylene]-3 -ethoxy-2-pyrazolin- 5-one, -[(4-Diethylaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
  • 2-pyrazolin-5-one - ⁇ [3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene ⁇ -3-(imidazol-2-yl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpy ⁇ Ol-2-yl)methylene]-3- (imidazol-2-yl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
  • 2-pyrazolin-5-one - ⁇ [3,5-Dimethyl-4-(l-pyrrolidinylmethyl)py ⁇ ol-2-yl]methylene ⁇ -3-(2-furyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin- 5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepy ⁇ ol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin
  • (2-thienyl) -2-pyrazolin-5-one -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -Cyclopropoxy-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
  • 2-pyrazolin-5-one -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[4-(4-Mo ⁇ holinoethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-
  • 2-pyrazolin-5-one - ⁇ [3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene ⁇ -3-(2-phenylethyl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- (2-phenylethyl)-2-pyrazolin-5 -one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpy ⁇ ol-2-yl)methylene]- 3-
  • 2-pyrazolin-5 -one -[2-(4-hydroxyphenyl)ethyl]-4-[4-(4-mo ⁇ holinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, - [2-(4-hydroxyphenyl)ethyl] -4- [3 -(4-mo ⁇ holinoethoxycarbonylindol-2-yl)methylene] - 2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[3-(4-mo ⁇ holinoethylaminocarbonylindol-2- yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpy ⁇ ol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]
  • 2-pyrazolin-5-one - ⁇ [3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene ⁇ -3-(4- pyrimidinyl)-2-pyrazolin-5-one, -(4-Pyrimidinyl)-4- ⁇ [3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yljmethylene ⁇ -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4- pyrimidinyl)pyrazolin-5-one, -[(4-Diethylaminoethy
  • 2-pyrazolin-5-one - ⁇ [3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene ⁇ -3-(5- pyrimidinyl)-2-pyrazolin-5-one, -(5 -Pyrimidinyl)-4- ⁇ [3-( 1 -pyrrolidinyl)methyl-4, 5-tetramethylenepyrrol-2- yl]methylene ⁇ -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylamin
  • 2-pyrazolin-5 -one -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
  • 2-pyrazolin-5-one -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-M ⁇ holinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, - ⁇ [3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene ⁇ -3- (2-pyrimidinyl)-2-pyrazolin-5-one, -(2-Pyrimidinyl)-4- ⁇ [3-(l-pyrrolidinyl)methyl-
  • 2-pyrazolin-5-one -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)- 2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(2-pyrimidinyl)-2-pyra
  • 2-pyrazolin-5-one -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3-Mo ⁇ holinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, - ⁇ [3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene ⁇ -3-
  • 2-pyrazolin-5-one -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(3-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)- 2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-
  • 2-pyrazolin-5-one -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Mo ⁇ holinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene
  • 2-pyrazolin-5-one -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(4-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
  • 2-pyrazolin-5-one -[(4-Oxo- 1 ,5,6,7-tetrahydroindol-2-yl)methylene]-3-(4-pyridazinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-mo ⁇ holinomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4- ⁇ [(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene ⁇ -3-(5- isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-
  • 2-pyrazolin-5-one -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5- isoxazolyl)-2-pyrazolin-5-one, -(5-Isoxazolyl)4- ⁇ [3-(4-methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene ⁇ 2-pyrazolin-5-one, -(5-isoxazolyl)-4- ⁇ [3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yljmethylene ⁇ -2-pyrazolin-5-one, -(5-Isoxazolyl)-4- [(3 -piperidinomethy 1-4,5 -tetramethylenepyrrol-2-yl)methylene] - 2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7
  • 2-pyrazolin-5-one 4- ⁇ ⁇ 3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl ⁇ methylene ⁇ -3-(4- pyrimidinyl)-2-pyrazolin-5-one, 4- ⁇ [4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene ⁇ -3-(4-pyrimidinyl)-2- pyrazolin-5-one,
  • 2-pyrazolin-5-one 4- ⁇ ⁇ 3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl ⁇ methylene ⁇ -3-(5- pyrimidiny l)-2-pyrazolin-5 -one, 4- ⁇ [4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene ⁇ -3-(5-pyrimidinyl)-2- pyrazolin-5-one,
  • 2-pyrazolin-5-one 4- ⁇ 3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl ⁇ methylene ⁇ -3-(2- pyrimidinyl)-2-pyrazolin-5-one, 4- ⁇ [4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene ⁇ -3-(2-pyrimidinyl)-2- pyrazolin-5-one,
  • 2-pyrazolin-5-one 4- ⁇ ⁇ 3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl ⁇ methylene ⁇ -3-(3- pyridazinyl)-2-pyrazolin-5-one, 4- ⁇ [4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene ⁇ -3-(3-pyridazinyl)-2- pyrazolin-5-one,
  • 2-pyrazolin-5-one 4- ⁇ 3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl ⁇ methylene ⁇ -3-(4- pyridazinyl)-2-pyrazolin-5-one, 4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one,
  • Compounds of formula I may exist as salts with pharmaceutically acceptable acids.
  • the present invention includes such salts.
  • examples of such salts include hydrochlorides, hydrobromides, sulphates, methanesulphonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g., (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid.
  • These salts may be prepared by methods known to those skilled in the art.
  • Certain compounds of formula I which have acidic substituents may exist as salts with pharmaceutically acceptable bases.
  • the present invention includes such salts.
  • Example of such salts include sodium salts, potassium salts, lysine salts and arginine salts. These salts may be prepared by methods known to those skilled in the art.
  • Certain compounds of formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof. Certain compounds of formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.
  • Certain compounds of formula I may contain one or more chiral centers, and exist in different optically active forms. When compounds of formula I contain one chiral center, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers.
  • the enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.
  • a compound of formula I When a compound of formula I contains more than one chiral center it may exist in diastereoisomeric forms.
  • the diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.
  • the present invention includes each diastereoisomer of compounds of formula I and mixtures thereof.
  • Certain compounds of formula I may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer of compounds of formula I and mixtures thereof.
  • Certain compounds of formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers.
  • the present invention includes each conformational isomer of compounds of formula I and mixtures thereof.
  • Certain compounds of formula I may exist in zwitterionic form and the present invention includes each zwitterionic form of compounds of formula I and mixtures thereof.
  • the compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases.
  • compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hype ⁇ roliferative diseases, especially in the process of angiogenesis.
  • certain of these compounds are inhibitors of such receptor kinases as KDR, Flt-1, FGFR, PDGFR, c-Met, or IGF-l-R. Since these compounds are anti-angiogenic, they are important substances for inhibiting the progression disease states where angiogenesis is an important component.
  • Certain compounds of the invention are effective as inhibitors of such serine/threonine kinases as erk, MAP kinases, cdks, Plk-1 or Raf-1. These compounds are useful in the treatment of cancer, and hype ⁇ roliferative disorders.
  • certain compounds are effective inhibitors of non-receptor kinases such as src, lyn, lck, fyn, blk, hck. These compounds are useful in the treatment of cancer, hype ⁇ roliferative disorders and immunologic diseases.
  • the present invention provides a method of inhibiting the kinase activity of tyrosine kinases and serine/threonine kinases comprising the administration of a compound represented by formula I to said kinase in sufficient concentration to inhibit the enzyme activity of said kinase.
  • the present invention further includes the use of these compounds in pharmaceutical compositions with a pharmaceutically effective amount of the above- described compounds and a pharmaceutically acceptable carrier or excipient.
  • These pharmaceutical compositions can be administered to individuals to slow or halt the process of angiogenesis in angiogenesis-aided diseases, or to treat edema, effusions, exudates, or ascites and other conditions associated with vascular hype ⁇ ermeability.
  • Certain pharmaceutical compositions can be administered to individuals to treat cancer and hype ⁇ roliferative disorders by inhibiting serine/threonine kinases such as cdk,
  • the compounds of this invention have antiangiogenic properties. These antiangiogenic properties are due at least in part to the inhibition of protein tyrosine kinases essential for angiogenic processes. For this reason, these compounds can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, virally-induced angiogemc disorders, fractures, Crow-Fukase syndrome (POEMS), preeclampsia, menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy, retinopathy of prematurity, or age-related macular degeneration.
  • POEMS Crow-Fukase syndrome
  • some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hype ⁇ roliferative disorders such as thyroid hype ⁇ lasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma characteristic of polycystic ovarian syndrome (Stein-Leventhal syndrome)) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.
  • thyroid hype ⁇ lasia especially Grave's disease
  • cysts such as hypervascularity of ovarian stroma characteristic of polycystic ovarian syndrome (Stein-Leventhal syndrome)
  • some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, delayed-type hypersensitivity, ovarian hyperstimulation syndrome, brain tumor- associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hype ⁇ ermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease.
  • the compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g.
  • VEGF production potentiates inflammatory processes such as monocyte recruitment and activation.
  • the compounds of this invention will also be useful in treating inflammatory disorders such as inflammatory bowel disease (IBD) and Crohn's disease.
  • VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hype ⁇ ermeability and the formation of edema. Indeed, vascular hype ⁇ ermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production. Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF mediated responses.
  • VEGF-mediated hype ⁇ ermeability can significantly contribute to disorders with these etiologic features. It is envisaged that the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the KDR/VEGFR-2 and/or the Flt-l/VEGFR-1 tyrosine kinases.
  • Certain compounds of the invention are also effective inhibitors of FGFR, PDGFR, c-Met and IGF-l-R. These receptor kinases can directly or indirectly potentiate angiogenic and hype ⁇ roliferative responses in various disorders, hence their inhibition can impede disease progression.
  • the compounds of this invention have inhibitory activity against protein kinases. That is, these compounds modulate signal transduction by protein kinases.
  • Compounds of this invention inhibit protein kinases from serine/threonine and tyrosine kinase classes. In particular, these compounds selectively inhibit the activity of the KDR/FLK-1 /VEGFR-2 tyrosine kinases.
  • Certain compounds of this invention also inhibit the activity of additional tyrosine kinases such as Flt- 1/VEGFR-l, FGFR, PDGFR, IGF-1R, c-Met, Src-subfamily kinases such as Lck, Src, fyn, yes, etc.
  • some compounds of this invention significantly inhibit serine/threonine kinases such as PKC, MAP kinases, erk, CDKs, Plk-1, or Raf-1 which play an essential role in cell proliferation and cell-cycle progression.
  • the potency and specificity of the generic compounds of this invention towards a particular protein kinase can often be altered and optimized by variations in the nature, number and arrangement of the substituents (i.e., Rute R 2 , R 3 , R 4 , R 5 , Rg and R 7 ) of and conformational restrictions.
  • the metabolites of certain compounds may also possess significant protein kinase inhibitory activity.
  • the compounds of this invention when administered to individuals in need of such compounds, inhibit vascular hype ⁇ ermeability and the formation of edema in these individuals. These compounds act, it is believed, by inhibiting the activity of KDR tyrosine kinase which is involved in the process of vascular hype ⁇ ermeability and edema formation.
  • the KDR tyrosine kinase may also be referred to as FLK-1 tyrosine kinase, NYK tyrosine kinase or VEGFR-2 tyrosine kinase.
  • KDR tyrosine kinase is activated when vascular endothelial cell growth factor (VEGF) or another activating ligand (such as VEGF-C, VEGF-D, VEGF-E or HIV Tat protein) binds to a KDR tyrosine kinase receptor which lies on the surface of vascular endothelial cells.
  • VEGF vascular endothelial cell growth factor
  • another activating ligand such as VEGF-C, VEGF-D, VEGF-E or HIV Tat protein
  • KDR tyrosine kinase stimulation results in the proliferation and chemotaxis of vascular endothelial cells and formation of new vessels.
  • KDR tyrosine kinase activity By inhibiting KDR tyrosine kinase activity, either by blocking the production of the activating ligand, by blocking the activating ligand binding to the KDR tyrosine kinase receptor, by preventing receptor dimerization and transphosphorylation, by inhibiting the enzyme activity of the KDR tyrosine kinase (inhibiting the phosphorylation function of the enzyme) or by some other mechanism that interrupts its downstream signaling (D. Mukhopedhyay et al, Cancer Res. 58: 1278-1284 (1998) and references therein), hype ⁇ ermeability, as well as associated extravasation, subsequent edema formation and matrix deposition, and angiogenic responses, may be inhibited and minimized.
  • One group of preferred compounds of this invention have the property of inhibiting KDR tyrosine kinase activity without significantly inhibiting Flt-1 tyrosine kinase activity (Flt-1 tyrosine kinase is also referred to as VEGFR-1 tyrosine kinase). Both KDR tyrosine kinase and Flt-1 tyrosine kinase are activated by VEGF binding to KDR tyrosine kinase receptors and to Flt-1 tyrosine kinase receptors, respectively.
  • Certain preferred compounds of this invention are unique because they inhibit the activity of one VEGF-receptor tyrosine kinase (KDR) that is activated by activating ligands but do not inhibit other receptor tyrosine kinases, such as Flt-1, that are also activated by certain activating ligands.
  • KDR VEGF-receptor tyrosine kinase
  • the preferred compounds of this invention are, therefore, selective in their tyrosine kinase inhibitory activity.
  • the compounds of the present invention are also useful in the treatment of ulcers - bacterial, fungal, Mooren ulcers and ulcerative colitis.
  • the compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as He ⁇ es simplex, He ⁇ es Zoster, AIDS, parapoxvirus, psoriasis, Kaposi's sarcoma, protozoan infections and toxoplasmosis, endometriosis, ovarian hyperstimulation syndrome, preeclampsia, menometro ⁇ hagia, systemic lupus, sarcoidosis, synovitis, inflammatory bowel disease, Crohn's disease, sickle cell anaemia, Lyme's disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osier- Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, rhe
  • the compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.
  • the compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, vascular occlusion and carotid obstructive disease.
  • the compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor-induced pleural or pericardial effusions, and malignant ascites.
  • cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor-induced pleural or pericardial effusions, and malignant ascites.
  • the compounds of the present invention are also useful in the treatment of Crow-Fukase (POEMS) syndrome and diabetic conditions such as glaucoma, diabetic retinopathy and microangiopathy.
  • POEMS Crow-Fukase
  • the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the VEGF receptors (e.g. KDR and Flt-1).
  • VEGF receptors e.g. KDR and Flt-1
  • KDR and Flt-1 protein tyrosine kinase activity involving the VEGF receptors
  • the progression of the listed disorders is inhibited because the angiogenic component of the disease state is severely curtailed.
  • the action of the compounds of this invention by their selectivity for specific tyrosine kinases, result in a minimization of side effects that would occur if less selective tyrosine kinase inhibitors were used.
  • the present invention provides compounds of formula I as defined initially above (including the provisos) for use as medicaments, particularly as inhibitors of protein kinase activity for example tyrosine kinase activity, serine kinase activity and threonine kinase activity.
  • the present invention provides the use of compounds of formula I as defined initially above (including the provisos) in the manufacture of a medicament for use in the inhibition of protein kinase activity.
  • the following definitions are applicable:
  • Physiologically acceptable salts refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or organic acids such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, lactic acid, tartaric acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or organic acids such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, lactic acid, tartaric acid and the like.
  • Alkyl refers to a saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups having 1 to 6 carbons or cyclic hydrocarbons having 3 to 6 carbons.
  • Alkoxy refers to an "O-alkyl” group, where “alkyl” is defined as described above.
  • the compounds of this invention can be administered to a human patient by themselves or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate vascular hype ⁇ ermeability, edema and associated disorders. Mixtures of these compounds can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions.
  • a therapeutically effective dose further refers to that amount of the compound or compounds sufficient to result in the prevention or attenuation of inappropriate neovascularization, progression of hype ⁇ roliferative disorders, edema, VEGF- associated hype ⁇ ermeability and/or VEGF-related hypotension.
  • routes of administration may, for example, include oral, eyedrop, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
  • parenteral delivery including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
  • one may administer the compound in a local rather than a systemic manner, for example, via injection of the compound directly into an edematous site, often in a depot or sustained release formulation.
  • composition/Formulation may be administered in a targeted drug delivery system, for example, in a liposome coated with endothelial cell-specific antibody.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art.
  • the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained by combining the active compound with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifiuoromethane, trichlorofiuoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifiuoromethane, trichlorofiuoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the compounds may be formulated for parenteral administration by injection, e.g. bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly or by intramuscular injection).
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • An example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • the cosolvent system may be the VPD co-solvent system.
  • VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution.
  • This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
  • the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
  • identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
  • other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethysulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are well known by those skilled in the art.
  • Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
  • additional strategies for protein stabilization may be employed.
  • the pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • organic molecule compounds of the invention may be provided as salts with pharmaceutically compatible counterions.
  • Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the co ⁇ esponding free base forms. Effective Dosage
  • compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended pu ⁇ ose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art.
  • the therapeutically effective dose can be estimated initially from cellular assays. For example, a dose can be formulated in cellular and animal models to achieve a circulating concentration range that includes the IC 50 as determined in cellular assays (i.e., the concentration of the test compound which achieves a half-maximal inhibition of a given protein kinase activity).
  • IC 50 in the presence of 3 to 5% serum albumin since such a determination approximates the binding effects of plasma protein on the compound. Such information can be used to more accurately determine useful doses in humans. Further, the most preferred compounds for systemic administration effectively inhibit protein kinase signaling in intact cells at levels that are safely achievable in plasma.
  • a therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) and the ED 50 (effective dose for 50% maximal response).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between MTD and ED 50 .
  • Compounds which exhibit high therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 pi).
  • the administration of an acute bolus or an infusion approaching the MTD may be required to obtain a rapid response.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC).
  • MEC minimal effective concentration
  • the MEC will vary for each compound but can be estimated from in vitro data; e.g. the concentration necessary to achieve 50-90% inhibition of protein kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
  • Dosage intervals can also be determined using the MEC value.
  • Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90% until the desired amelioration of symptoms is achieved. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
  • the amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. Packaging
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
  • active compound denotes any compound of the invention but particularly any compound which is the final product of one of the preceding
  • Capsules In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose can be de-aggregated and blended. The mixture can be filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound. b) Tablets
  • Tablets can be prepared from the following ingredients. Parts by weight
  • the active compound, the lactose and some of the starch can be de-aggregated, blended and the resulting mixture can be granulated with a solution of the polyvinylpyrrolidone in ethanol.
  • the dry granulate can be blended with the magnesium stearate and the rest of the starch.
  • the mixture is then compressed in a tabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.
  • Tablets can be prepared by the method described in (b) above.
  • the tablets can be enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanohdichloromethane (1:1). d) Suppositories
  • 100 parts by weight of active compound can be inco ⁇ orated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
  • the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
  • the compounds of this invention can be administered in combination with one or more additional pharmaceutical agents that inhibit or prevent the production of VEGF, attenuate intracellular responses to VEGF, block intracellular signal transduction, inhibit vascular hype ⁇ ermeability, reduce inflammation, or inhibit or prevent the formation of edema or neovascularization.
  • the compounds of the invention can be administered prior to, subsequent to or simultaneously with the additional pharmaceutical agent, whichever course of administration is appropriate.
  • the additional pharmaceutical agents include but are not limited to anti-edemic steroids, NSAIDS, ras inhibitors, anti-TNF agents, anti-IL-1 agents, antihistamines, PAF-antagonists, COX-1 inhibitors, COX-2 inhibitors, NO synthase inhibitors, PKC inhibitors and PI3 kinase inhibitors.
  • the compounds of the invention and the additional pharmaceutical agents act either additively or synergistically.
  • the administration of such a combination of substances that inhibit angiogenesis, vascular hype ⁇ ermeability and/or inhibit the formation of edema can provide greater relief from the deleterious effects of a hype ⁇ roliferative disorder, angiogenesis, vascular hype ⁇ ermeability or edema than the administration of either substance alone.
  • the present invention also comprises the use of a compound of formula I as a medicament.
  • the Src family currently includes Fyn, Lck, Fgr, Fes, Lyn, Src, Yes, Hck, and Blk.
  • the Syk family is currently understood to include only Zap and Syk.
  • the Janus family of kinases is involved in the transduction of growth factor and proinflammatory cytokine signals through a number of receptors.
  • BTK and ITK members of the Tec family of kinases, play a less well understood role in immunobiology, their modulation by an inhibitor may prove therapeutically beneficial.
  • the kinases RIP, IRAK-1, IRAK-2, NIK, TPL-2/COT, IKK-1 and IKK- 2 are involved in the signal transduction pathways for the key pro-inflammatory cytokines TNF and IL-1.
  • compounds of formula I may function as immunomodulatory agents useful for the maintenance of allografts and the treatment of autoimmune disorders. Through their ability to regulate T cell activation or the potentiation of an inflammatory process, these compounds could be used to treat such autoimmune diseases.
  • Transplants due to rejection phenomena are limited by the toxicity of cu ⁇ ently available immunosuppressive agents and would benefit from an efficacious drug with improved therapeutic index.
  • Gene targeting experiments have demonstrated the essential role of Src in the biology of osteoclasts, the cells responsible for bone reso ⁇ tion.
  • Compounds of formula I may also be useful in the treatment of osteoporosis, osteopetrosis, Paget's disease, tumor- induced hypercalcemia and in the treatment of bone metastases.
  • Chromosome breakage at the ltk kinase break point on chromosome 5
  • translocation as in the case of the Abl gene with BCR (Philadelphia chromosome)
  • truncation in instances such as c-Kit or EGFR
  • mutation e.g., Met
  • oncogenesis is driven by an autocrine or paracrine ligand/growth factor receptor interactions.
  • src-family kinases are typically involved in downstream signal transduction thereby potentiating the oncogenesis and themselves may become oncogenic by over-expression or mutation. By inhibiting the protein kinase activity of these proteins the disease process may be disrupted.
  • Vascular restenosis may involve process of FGF and/or PDGF - promoted smooth muscle and endothelial cell proliferation.
  • the ligand stimulation of FGFR, PDGFR, IGF1-R and c-Met in vivo is proangiogenic, and potentiates angiogenesis dependent disorders. Inhibition of FGFr, PDGFr , c-Met, or IGF1-R kinase activity may be an efficacious strategy for inhibiting these phenomena.
  • compounds of formula I which inhibit the kinase activity of normal or abe ⁇ ant c-kit, c-met, c-fms, src-family members, EGFr, erbB2, erbB4, BCR-Abl, PDGFr, FGFr, IGF1-R and other receptor or cytosolic tyrosine kinases may be of value in the treatment of benign and neoplastic proliferative diseases.
  • pathological conditions for example, solid primary tumors and metastases, Kaposi's sarcoma, rheumatoid arthritis, blindness due to inappropriate ocular neovascularization, psoriasis and atherosclerosis
  • disease progression is contingent upon persistent angiogenesis.
  • Polypeptide growth factors often produced by the disease tissue or associated inflammatory cells, and their corresponding endothelial cell specific receptor tyrosine kinases (e.g., KDR/VEGFR-2, Flt- 1/VEGFR-l, Tie-2/Tek and Tie) are essential for the stimulation of endothelial cell growth, migration, organization, differentiation and the establishment of the requisite new functional vasculature.
  • VEGF- stimulation of a VEGFR kinase is also believed to play an important role in the formation of tumor ascites, cerebral and pulmonary edema, pleural and pericardial effusions, delayed-type hypersensitivity reactions, tissue edema and organ dysfunction following trauma, burns, ischemia, diabetic complications, endomefriosis, adult respiratory distress syndrome (ARDS), post-cardiopulmonary bypass-related hypotension and hype ⁇ ermeability, and ocular edema leading to glaucoma or blindness due to inappropriate neovascularization.
  • ARDS adult respiratory distress syndrome
  • Tie-2 is expressed also in a select population of hematopoietic stem cells in which it may play a role in their recruitment, adhesion, regulation and differentiation (Blood , 4317-4326 (1997)); this Tie-2 expressing population may serve as circulating angiogenic endothelial progenitors. Certain agents according to formula I capable of blocking the kinase activity of endothelial cell specific kinases could therefore inhibit disease progression involving these situations.
  • the compounds of formula I or a salt thereof or pharmaceutical compositions containing a therapeutically effective amount thereof may be used in the treatment of benign and neoplastic proliferative diseases and disorders of the immune system.
  • diseases include autoimmune diseases, such as rheumatoid arthritis, thyroiditis, type 1 diabetes, multiple sclerosis, sarcoidosis, inflammatory bowel disease, Crohn's disease, myasthenia gravis and systemic lupus erythematosus; psoriasis, organ transplant rejection (eg.
  • kidney rejection graft versus host disease
  • benign and neoplastic proliferative diseases human cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), and diseases involving inappropriate vascularization for example diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization due to age-related macular degeneration, and infantile hemangiomas in human beings.
  • inhibitors may be useful in the treatment of disorders involving VEGF mediated edema, ascites, effusions, and exudates, including for example macular edema, cerebral edema, acute lung injury and adult respiratory distress syndrome (ARDS).
  • ARDS adult respiratory distress syndrome
  • the compounds of the present invention may also be useful in the prophylaxis of the above diseases.
  • a further aspect of the present invention provides the use of a compound of formula I or a salt thereof in the manufacture of a medicament for treating vascular hype ⁇ ermeability, angiogenesis-dependent disorders, proliferative diseases and/or disorders of the immune system in mammals, particularly human beings.
  • the present invention also provides a method of treating vascular hype ⁇ ermeability, inappropriate neovascularization, proliferative diseases and/or disorders of the immune system which comprises the administration of a therapeutically effective amount of a compound of formula I to a mammal, particularly a human being, in need thereof.
  • the in vitro potency of compounds in inhibiting these protein kinases may be determined by the procedures detailed below.
  • the potency of compounds can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., synthetic peptide (Z. Songyang et al, Nature. 373:536-539) by a test compound relative to control.
  • an exogenous substrate e.g., synthetic peptide (Z. Songyang et al, Nature. 373:536-539)
  • the coding sequence for the human KDR intra-cellular domain was generated through PCR using cDNAs isolated from HUVEC cells. A poly-His6 sequence was introduced at the N-terminus of this protein as well. This fragment was cloned into transfection vector pVL1393 at the Xba 1 and Not 1 site. Recombinant baculovirus (BV) was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 cells were grown in SF-900-II medium at 2 x 106/ml, and were infected at 0.5 plaque forming units per cell (MOI). Cells were harvested at 48 hours post infection. Purification of KDR
  • SF-9 cells expressing (His) 6 KDR(aa789-1354) were lysed by adding 50 ml of Triton X-100 lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, lmM PMSF, lO ⁇ g/ml aprotinin, 1 ⁇ g/ml leupeptin) to the cell pellet from 1L of cell culture.
  • the lysate was centrifuged at 19,000 ⁇ m in a Sorval SS-34 rotor for 30 min at 4°C.
  • the cell lysate was applied to a 5 ml NiCl 2 chelating sepharose column, equilibrated with 50 mM HEPES, pH7.5, 0.3 M NaCl.
  • KDR was eluted using the same buffer containing 0.25 M imidazole.
  • Column fractions were analyzed using SDS-PAGE and an ELISA assay (below) which measures kinase activity.
  • the purified KDR was exchanged into 25mM HEPES, pH7.5, 25mM NaCl, 5 mM DTT buffer and stored at -80°C.
  • the coding sequence for the human Tie-2 infra-cellular domain (aa775-l 124) was generated through PCR using cDNAs isolated from human placenta as a template. A poly-His 6 sequence was introduced at the N-terminus and this construct was cloned into transfection vector pVL 1939 at the Xba 1 and Not 1 site. Recombinant BV was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis.
  • SF-9 insect cells were grown in SF-900-II medium at 2 x 106/ml, and were infected at MOI of 0.5. Purification of the His-tagged kinase used in screening was analogous to that described for KDR. Human Flt-1 Tyrosine Kinase Production and Purification
  • the baculoviral expression vector pVL1393 (Phar Mingen, Los Angeles, CA) was used. A nucleotide sequence encoding poly-His6 was placed 5' to the nucleotide region encoding the entire intracellular kinase domain of human Flt-1 (amino acids 786-1338). The nucleotide sequence encoding the kinase domain was generated through PCR using cDNA libraries isolated from HUVEC cells. The histidine residues enabled affinity purification of the protein as a manner analogous to that for KDR and ZAP70. SF-9 insect cells were infected at a 0.5 multiplicity and harvested 48 hours post infection.
  • EGFR was purchased from Sigma (Cat # E-3641 ; 500 units/50 ⁇ l) and the EGF ligand was acquired from Oncogene Research Products/Calbiochem (Cat #
  • the baculoviral expression vector used was pVL1393. (Pharmingen, Los
  • the nucleotide sequence encoding amino acids M(H)6 LVPR ⁇ ,S was placed 5' to the region encoding the entirety of ZAP70 (amino acids 1-619).
  • the nucleotide sequence encoding the ZAP70 coding region was generated through PCR using cDNA libraries isolated from Jurkat immortalized T-cells. The histidine residues enabled affinity purification of the protein (vide infra).
  • the LVPRgS bridge constitutes a recognition sequence for proteolytic cleavage by thrombin, enabling removal of the affinity tag from the enzyme.
  • SF-9 insect cells were infected at a multiplicity of infection of 0.5 and harvested 48 hours post infection.
  • SF-9 cells were lysed in a buffer consisting of 20 mM Tris, pH 8.0, 137 mM
  • Fusion protein was eluted with 250 mM imidazole.
  • the enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50 mM NaCl and 5 mM
  • Lck or truncated forms of Lck may be commercially obtained ( e.g. from
  • Enzyme linked immunosorbent assays were used to detect and measure the presence of tyrosine kinase activity.
  • the ELISA were conducted according to known protocols which are described in, for example, Voller, et al, 1980, "Enzyme-Linked Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology, Washington, D.C.
  • the disclosed protocol was adapted for determining activity with respect to a specific PTK.
  • preferred protocols for conducting the ELISA experiments is provided below. Adaptation of these protocols for determining a compound's activity for other members of the receptor PTK family, as well as non- receptor tyrosine kinases, are well within the abilities of those in the art.
  • a universal PTK substrate e.g., random copolymer of poly(Glu 4 Tyr), 20,000-50,000 MW
  • ATP typically 5 ⁇ M
  • ATP Store aliquots of lOOmM at -20°C. Dilute to 20 ⁇ M in water Washing Buffer: PBS with 0.1% Tween 20 Antibody Diluting Buffer: 0.1% bovine serum albumin (BSA) in PBS TMB Substrate: mix TMB substrate and Peroxide solutions 9:1 just before use or use K-Blue Substrate from Neogen Stop Solution: 1M Phosphoric Acid
  • the Reaction Buffer utilized was 100 mM MOPSO, pH 6.5, 4 mM MnCl 2 ,
  • Compounds of formula I may have therapeutic utility in the treatment of diseases involving both identified, including those not mentioned herein, and as yet unidentified protein tyrosine kinases which are inhibited by compounds of formula I.
  • All compounds exemplified herein significantly inhibit KDR kinase at concentrations of 50 micromolar or below. Some compounds of this invention also significantly inhibit other PTKs such as lck at concentrations of 50 micromolar or below.
  • the human recombinant enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly, MA. USA) or purified from known natural or recombinant sources using conventional methods.
  • reaction was carried out in a buffer consisting of 50mM Tris pH 7.5, lOOmM NaCl, ImM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and lOmM MgCl 2 (commercial buffer) supplemented with fresh 300 ⁇ M ATP (31 ⁇ Ci/ml) and 30 ⁇ g/ml histone type IIIss final concentrations.
  • a reaction volume of 50mM Tris pH 7.5, lOOmM NaCl, ImM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and lOmM MgCl 2 commercial buffer
  • 300 ⁇ M ATP 31 ⁇ Ci/ml
  • 30 ⁇ g/ml histone type IIIss final concentrations 30 ⁇ g/ml histone type IIIss final concentrations.
  • Certain compounds of this invention significantly inhibit cdc2 at concentrations below 50 uM.
  • PKC kinase source PKC kinase source
  • the catalytic subunit of PKC may be obtained commercially (Calbiochem).
  • a radioactive kinase assay was employed following a published procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M., Sakurai, A., Nishizuka, Y. Biochemical and Biophysical Research Communication 5:166, 1220-1227 (1990)). Briefly, all reactions were performed in a kinase buffer consisting of 50 mM Tris- HCl pH7.5, lOmM MgCl 2 , 2mM DTT, ImM EGTA, 100 ⁇ M ATP, 8 ⁇ M peptide, 5% DMSO and 33 P ATP (8Ci/mM).
  • the recombinant murine enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly MA. USA) or purified from known natural or recombinant sources using conventional methods. Erk2 enzyme assay In brief, the reaction was carried out in a buffer consisting of 50 mM Tris pH
  • T-cells Upon activation by mitogen or antigen, T-cells are induced to secrete IL-2, a growth factor that supports their subsequent proliferative phase. Therefore, one may measure either production of IL-2 from or cell proliferation of, primary T-cells or appropriate T-cell lines as a surrogate for T-cell activation. Both of these assays are well described in the literature and their parameters well documented (in Current Protocols in Immunology, Vol 2, 7.10.1-7.11.2).
  • T-cells may be activated by co-culture with allogenic stimulator cells, a process termed the one-way mixed lymphophocyte reaction.
  • Responder and stimulator peripheral blood mononuclear cells are purified by Ficoll-Hypaque gradient (Pharmacia) per directions of the manufacturer.
  • Stimulator cells are mitotically inactivated by treatment with mitomycin C (Sigma) or gamma irradiation.
  • Responder and stimulator cells are co-cultured at a ratio of two to one in the presence or absence of the test compound.
  • 10 5 responders are mixed with 5 x 10 4 stimulators and plated (200 ⁇ l volume) in a U bottom microtiter plate (Costar Scientific).
  • the cells are cultured in RPMI 1640 supplemented with either heat inactivated fetal bovine serum (Hyclone Laboratories) or pooled human AB serum from male donors, 5 x 10 "5 M 2mercaptoethanol and 0.5% DMSO,
  • the cultures are pulsed with 0.5 ⁇ Ci of 3 H thymidine (Amersham) one day prior to harvest (typically day three).
  • the cultures are harvested (Betaplate harvester, Wallac) and isotope uptake assessed by liquid scintillation (Betaplate, Wallac).
  • the same culture system may be used for assessing T-cell activation by measurement of IL-2 production. Eighteen to twenty- four hours after culture initiation, the supernatants are removed and the IL-2 concentration is measured by ELISA (R and D Systems) following the directions of the manufacturer.
  • T-cells can be activated in vivo by ligation of the constant portion of the T-cell receptor with a monoclonal anti-CD3 antibody (Ab).
  • Ab monoclonal anti-CD3 antibody
  • BALB/c mice are given lO ⁇ g of anti-CD 3 Ab intraperitoneally two hours prior to exsanguination. Animals to receive a test drug are pre-treated with a single dose of the compound one hour prior to anti-CD3 Ab administration.
  • Serum levels of the proinflammatory cytokines interferon- ⁇ (IFN- ⁇ ) and tumor necrosis factor- ⁇ (TNF- ⁇ ), indicators of T-cell activation are measured by ELISA.
  • a similar model employs in vivo T-cell priming with a specific antigen such as keyhole limpet hemocyanin (KLH) followed by a secondary in vitro challenge of draining lymph node cells with the same antigen.
  • KLH keyhole limpet hemocyanin
  • measurement of cytokine production is used to assess the activation state of the cultured cells. Briefly, C57BL/6 mice are immunized subcutaneously with 100 ⁇ g KLH emulsified in complete Freund's adjuvant (CFA) on day zero.
  • CFA complete Freund's adjuvant
  • mice or rats are immunized with an emulsion of myelin basic protein (MBP), or neurogenic peptide derivatives thereof, and CFA.
  • MBP myelin basic protein
  • Acute disease can be induced with the addition of bacterial toxins such as bordetella pertussis. Relapsing/remitting disease is induced by adoptive transfer of T-cells from MBP/ peptide immunized animals.
  • CIA may be induced in DBA 1 mice by immunization with type II collagen (J. Immunol: 142(7):2237-2243). Mice will develop signs of arthritis as early as ten days following antigen challenge and may be scored for as long as ninety days after immunization. In both the EAE and CIA models, a compound may be administered either prophylactically or at the time of disease onset. Efficacious drugs should reduce severity and/or incidence.
  • Certain compounds of this invention which inhibit one or more angiogenic receptor PTK, and/or a protein kinase such as lck involved in mediating inflammatory responses can reduce the severity and incidence of arthritis in these models.
  • mice can also be tested in mouse allograft models, either skin (reviewed in Ann. Rev. Immunol., 10:333-58, 1992; Transplantation: 57(12): 1701-17D6, 1994) or heart (Am.J.Anat.: l 13:273, 1963).
  • full thickness skin grafts are transplanted from C57BL/6 mice to BALB/c mice.
  • the grafts can be examined daily, beginning at day six, for evidence of rejection.
  • neonatal heart transplant model neonatal hearts are ectopically transplanted from C57BL/6 mice into the ear pinnae of adult CBA/J mice. Hearts start to beat four to seven days post transplantation and rejection may be assessed visually using a dissecting microscope to look for cessation of beating.
  • HUVEC cells (from pooled donors) were purchased from Clonetics
  • EBM media (Clonetics). 2. For evaluating a compound's inhibitory activity, cells were trypsinized and seeded at 0.5-1.0 x 10 5 cells/well in each well of 6-well cluster plates (Costar; Cambridge, MA).
  • Equal amounts of proteins were then precipitated by addition of cold (-20 C) Ethanol (2 volumes) for a minimum of 1 hour or a maximum of overnight. Pellets were reconstituted in Laemli sample buffer containing 5% -mercaptoethanol (BioRad; Hercules, CA) and boiled for 5min. The proteins were resolved by polyacrylamide gel electrophoresis (6%, 1.5mm Novex, San Deigo, CA) and transfe ⁇ ed onto a nitrocellulose membrane using the Novex system.
  • This assay measures the capacity of compounds to inhibit the acute increase in uterine weight in mice which occurs in the first few hours following estrogen stimulation.
  • This early onset of uterine weight increase is known to be due to edema caused by increased permeability of uterine vasculature.
  • Cullinan-Bove and Koss demonstrated a close temporal relationship of estrogen-stimulated uterine edema with increased expression of VEGF mRNA in the uterus.
  • mice (Balb/c, 8-12 weeks old) were purchased from Taconic (Germantown, NY) and housed in a pathogen-free animal facility in accordance with institutional Animal Care and Use Committee Guidelines. Method:
  • mice were randomized and divided into groups of 5-10. Test compounds were administered by i.p., i.v. or p.o. routes depending on solubility and vehicle at doses ranging from 1-100 mg/kg. Vehicle control group received vehicle only and two groups were left untreated.
  • Certain compounds of this invention which are inhibitors of angiogenic receptor tyrosine kinases can also be shown active in a Matrigel implant model of neovascularization.
  • the Matrigel neovascularization model involves the formation of new blood vessels within a clear "marble" of extracellular matrix implanted subcutaneously which is induced by the presence of proangiogenic factor producing tumor cells (for examples see: Passaniti, A., et al, Lab. Investig. (1992), 67(4), 519- 528; Anat. Rec. (1997), 249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701 ; Vase. Biol. (1995), 15(11), 1857-6).
  • the model preferably runs over 3-4 days and endpoints include macroscopic visual/image scoring of neovascularization, microscopic microvessel density determinations, and hemoglobin quantitation (Drabkin method) following removal of the implant versus controls from animals untreated with inhibitors.
  • the model may alternatively employ bFGF or HGF as the stimulus.
  • Certain compounds of this invention which inhibit one or more oncogenic, protooncogenic, or proliferation-dependent protein kinases, or angiogenic receptor PTK also inhibit the growth of primary murine, rat or human xenograft tumors in mice, or inhibit metastasis in murine models.
  • Example 1 3-Cyclopropyl-4-[(4,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin- 5-one.
  • Example 40 3-Tert-butylureido-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one.
  • a reaction mixture of 3-amino-4-[(py ⁇ ol-2-yl)methylene]-2-pyrazoline-5- one (1.7 mmol) and tert-butylisocyanate (1 mL) in ethyl acetate 5 mL was stirred at 80°C for 2 h. The product was collected by filtration and recrystallized from ethanol.
  • Example 88 4- ⁇ [4-(2-Dimethylaminoethoxycarbonyl)-3, 5 -dimethy lpyrrol-2- yljmethylene ⁇ -3-isopropoxy-2-pyrazolin-5-one.
  • Example 194 4- ⁇ [4-(2-Diethylaminoethyl)-3,5-dimethylpyrrole-2-yl]methylene ⁇ - 3 -pyrazinyl-2 -pyrazolin-5 -one N-oxide
  • Example 176 A mixture of Example 176 (0.2 g, 0.54 mmol) and m-chloroperbenzoic acid (0.2 g, 1.1 mmol) in chloroform (50 ml) was stirred at room temperature over 48 hrs. The solvent was removed to dryness and the residue purified by flash chromatography (dichloromethane/ethanol 9:1). Yield 30%, mp 192°C (ethanol) Table 1 : Other compounds synthesized having structural formula V.
  • Footnote Maleate salts were formed by the addition of an ethanolic solution of maleic acid to the free base in ethanol at room temperature, followed by cooling, and filtration of the crystalline product
  • Example 210 3-Benzyl-4-[(mdol-3-yl)methylene]-2-pyrazolm-5-one.
  • the molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
  • Maleate salts were formed by the addition of an ethanolic solution of maleic acid to the free base in ethanol at room temperature, followed by cooling, and filtration of the crystalline product.
  • the molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
  • Table 4A Physical data for compounds synthesized having structural formula VIII.
  • the molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
  • Table 6A Physical data for compounds synthesized having structural formula X.
  • Table 7A Physical data for compounds synthesized having structural formula XI. VIII. 4-[(Imidazol-4-yl)methylene]-2-pyrazolin-5-ones (XII) IX.
  • Table 8 A Physical data for compounds synthesized having structural formula XII.
  • Table 9A Physical data for compounds synthesized having structural formula XIII.
  • Table 10A Physical data for compounds synthesized having structural formula XIV.
  • Table 11 Compound synethesized having structural formu a XV.
  • Table 11 A Physical data for compounds synthesized having structural formula XV.
  • Table 12 A Physical data for compounds synthesized having structural formula XVI.
  • Example 377 Ethyl 3-(6-methoxybenzothiazol-2-yl)-3-oxopropionate.
  • Example 378 Ethyl 4-(4-phenylphenyloxy)-3-oxobutanoate.
  • DMF dimethyl formamide
  • Scheme III Synthesis of ethyl alkyloxy or aryloxy carbonimidoyl acetate hydrochloride (R 9 is a substituted or unsubstituted aliphatic or aromatic group).
  • Example 381 Synthesis of ethyl cyclopentyloxycarbonimidoyl acetate hydrochloride (XXII).
  • Scheme V Method 1 for synthesizing 2-pyrazolin-5-ones.
  • Scheme VI Method 2 for synthesizing 2-pyrazolin-5-ones.
  • Scheme VIII Method 4 for synthesizing 2-pyrazolin-5-ones.
  • Example 383 3-(2,2,3,3-Tetramethylcyclopropyl)-2-pyrazolin-5-one.
  • Example 426 l-(4-Acetoxybutyl)-azaindole-3-carboxaldehyde A solution of 7-azaindole-3 -carboxaldehyde (4.19 g, 28 mmol) in dry N,N dimehylformamide (50 ml) was added dropwise, keeping the temperature between 5- 10°C, to a stirring suspension of 60% sodium hydride (oil dispersion) (1.2 g, 30 mmol) in dry DMF (65 ml) under nitrogen atmosphere.
  • 60% sodium hydride oil dispersion
  • Example 427 l-(4-Hydroxybutyl)-7-azaindole-3-carboxaldehyde A solution of sodium hydroxide (0.2 g, 17.5 mmol) in water (35 ml) was added to a solution of l-(4-acetoxybutyl)-7-azaindole-3-carboxaldehyde (2.3 g, 8.8 mmol) in methanol (40 ml). The mixture was heated at 60°C for 0.5 h, then the solvent was evaporated to dryness. The residue was dissolved in a mixture of ethyl acetate and water (50 ml : 50 ml) and the water layer was separated out.
  • Example 429 3-Isopropyl-5-methylpyrrole-2-carboxaldehyde

Abstract

Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

Description

2-PY AZOLIN-5-ONES RELATED APPLICATION(S)
This application claims the benefit of U.S. Provisional Application No.: 60/146,563, filed July 30, 1999, the entire teachings of which are incorporated herein by reference.
This invention relates to certain 2-pyrazolin-5-ones which are inhibitors of protein kinases, particularly tyrosine kinases and serine/threonine kinases, of which some are novel compounds, to pharmaceutical compositions containing these pyrazolinones and to processes for preparing these pyrazolinones.
BACKGROUND OF THE INVENTION
There are at least 400 enzymes identified as protein kinases. These enzymes catalyze the phosphorylation of target protein substrates. The phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate. The specific structure in the target substrate to which the phosphate is transferred is a tyrosine, serine or threonine residue. Since these amino acid residues are the target structures for the phosphoryl transfer, these protein kinase enzymes are commonly referred to as tyrosine kinases or serine/threonine kinases. The phosphorylation reactions, and counteracting phosphatase reactions, at the tyrosine, serine and threonine residues are involved in countless cellular processes that underlie responses to diverse intracellular signals (typically mediated through cellular receptors), regulation of cellular functions, and activation or deactivation of cellular processes. A cascade of protein kinases often participate in intracellular signal transduction and are necessary for the realization of these cellular processes. Because of their ubiquity in these processes, the protein kinases can be found as an integral part of the plasma membrane or as cytoplasmic enzymes or localized in the nucleus, often as components of enzyme complexes. In many instances, these protein kinases are an essential element of enzyme and structural protein complexes that determine where and when a cellular process occurs within a cell. Protein Tyrosine Kinases. Protein tyrosine kinases (PTKs) are enzymes which catalyze the phosphorylation of specific tyrosine residues in cellular proteins. This post-translational modification of these substrate proteins, often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation or differentiation (for review, see Schlessinger and Ulrich, 1992, Neuron 9:383-391). Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease. In addition, endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas) .
Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).
Receptor Tyrosine Kinases (RTKs). The RTKs comprise a large family of transmembrane receptors with diverse biological activities. At present, at least nineteen (19) distinct RTK subfamilies have been identified. The receptor tyrosine kinase (RTK) family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell 61 :243-254, 1990). The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, Cell 61 :203-212). Thus, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans- phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response, (e.g., cell division, differentiation, metabolic effects, changes in the extracellular microenvironment) see Schlessinger and Ullrich, 1992, Neuron 9:1-20. Proteins with SH2 (src homology -2) or phosphotyrosine binding (PTB) domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of the domains recognize phosphotyrosine. (Fantl et al, 1992, Cell 69:413-423; Songyang et al., 1994, Mol. Cell. Biol. 14:2777-2785; Songyang et al., 1993, Cell 72:767-778; and Koch et al, 1991, Science 252:668-678; Shoelson, Curr. Opin. Chem. Biol. (1997), 1(2), 227- 234; Cowbum, Curr. Opin. Struct. Biol. (1997), 7(6), 835-838). Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al, 1993, Cell 72:767-778). The specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. For example, differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors correlate with the observed differences in their substrate phosphorylation profiles (Songyang et al., 1993, Cell 72:767-778). Observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor as well as the timing and duration of those stimuli. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.
Several receptor tyrosine kinases such as FGFR-1, PDGFR, and c-Met, and growth factors that bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol. 129:895-898, 1995). One such receptor tyrosine kinase, known as "fetal liver kinase 1" (FLK-1), is a member of the type III subclass of RTKs. An alternative designation for human FLK-1 is "kinase insert domain-containing receptor" (KDR) (Terman et al, Oncogene 6:1677-83, 1991). Another alternative designation for FLK- 1/KDR is "vascular endothelial cell growth factor receptor 2" (VEGFR-2) since it binds VEGF with high affinity. The murine version of FLK-1 /VEGFR-2 has also been called NYK (Oelrichs et al, Oncogene 8(1): 11-15, 1993). DNAs encoding mouse, rat and human FLK-1 have been isolated, and the nucleotide and encoded amino acid sequences reported (Matthews et al, Proc. Natl. Acad. Sci. USA, 88:9026-30, 1991; Terman et al, 1991, supra; Terman et al, Biochem. Biophys. Res. Comm. 187:1579-86, 1992; Sarzani et al, supra; and Millauer et al, Cell 72:835-846, 1993). Numerous studies such as those reported in Millauer et al, supra, suggest that VEGF and FLK-l/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells, and formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.
Another type III subclass RTK designated "fms-like tyrosine kinase- 1" (Flt- 1) is related to FLK-1/KDR (DeVries et al. Science 255;989-991, 1992; Shibuya et al., Oncogene 5:519-524, 1990). An alternative designation for Flt-1 is "vascular endothelial cell growth factor receptor 1" (VEGFR-1). To date, members of the FLK-1/ KDR/VEGFR-2 and Flt-1/ VEGFR-1 subfamilies have been found expressed primarily on endothelial cells. These subclass members are specifically stimulated by members of the vascular endothelial cell growth factor (VEGF) family of ligands (Klagsburn and D'Amore, Cytokine & Growth Factor Reviews 7: 259- 270, 1996). Vascular endothelial cell growth factor (VEGF) binds to Flt-1 with higher affinity than to FLK- 1/KDR and is mitogenic toward vascular endothelial cells (Terman et al., 1992, supra; Mustonen et al. supra; DeVries et al., supra). Flt- 1 is believed to be essential for endothelial organization during vascular development. Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, supra). Expression of Flt-1 in adult organs such as kidney glomeruli suggests an additional function for this receptor that is not related to cell growth (Mustonen and Alitalo, supra).
As previously stated, recent evidence suggests that VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman et al, Endocrinology 133: 848-859, 1993; Kolch et al, Breast Cancer Research and Treatment 36: 139-155, 1995; Ferrara et α/., Endocrine Reviews 18(1); 4-25, 1997; Ferrara et al., Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232, 1997). In addition, VEGF has been implicated in the control and enhancement of vascular permeability (Connolly, et al, J. Biol. Chem. 264: 20017- 20024, 1989; Brown et al, Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269, 1997).
Different forms of VEGF arising from alternative splicing of mRNA have been reported, including the four species described by Ferrara et al. (J. Cell. Biochem. 47:211-218, 1991). Both secreted and predominantly cell-associated species of VEGF have been identified by Ferrara et al. supra, and the protein is known to exist in the form of disulfide linked dimers.
Several related homologues of VEGF have recently been identified. However, their roles in normal physiological and disease processes have not yet been elucidated. In addition, the members of the VEGF family are often coexpressed with VEGF in a number of tissues and are, in general, capable of forming heterodimers with VEGF. This property likely alters the receptor specificity and biological effects of the heterodimers and further complicates the elucidation of their specific functions as illustrated below (Korpelainen and Alitalo, Curr. Opin. Cell Biol, 159-164, 1998 and references cited therein). Placenta growth factor (PIGF) has an amino acid sequence that exhibits significant homology to the VEGF sequence (Park et al, J. Biol. Chem. 269:25646- 54, 1994; Maglione et al. Oncogene 8:925-31, 1993). As with VEGF, different species of PIGF arise from alternative splicing of mRNA, and the protein exists in dimeric form (Park et al, supra). P1GF-1 and PlGF-2 bind to Flt-1 with high affinity, and PlGF-2 also avidly binds to neuropilin-1 (Migdal et al, J. Biol. Chem. 273 (35): 22272-22278), but neither binds to FLK-1/KDR (Park et al, supra). PIGF has been reported to potentiate both the vascular permeability and mitogenic effect of VEGF on endothelial cells when VEGF is present at low concentrations (purportedly due to heterodimer formation) (Park et al, supra).
VEGF-B is produced as two isoforms (167 and 185 residues) that also appear to bind Flt-1 /VEGFR-1. It may play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(20): 11709-11714). VEGF-C was originally cloned as a ligand for VEGFR-3/Flt-4 which is primarily expressed by lymphatic endothelial cells. In its fully processed form,
VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells in vitro and angiogenesis in in vivo models ( Lymboussaki et al, Am. J. Pathol. (1998), 153(2): 395-403; Witzenbichler et al, Am. J. Pathol. (1998), 153(2), 381-394). The transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected. Unlike VEGF, the expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J. Biol. Chem. (1998), 273(14),8413-8418).
The most recently discovered VEGF-D is structurally very similar to VEGF- C. VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR VEGFR-2. It was originally cloned as a c-fos inducible mitogen for fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(2), 548-553 and references therein).
As for VEGF, VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability in vivo in a Miles assay when injected into cutaneous tissue (PCT/US97/14696; WO98/07832, Witzenbichler et al, supra). The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.
There has been recently reported a virally encoded, novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), which preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain (Meyer et al, EMBO J. (1999), 18(2), 363-374; Ogawa et al, J. Biol. Chem. (1998), 273(47), 31273-31282.). VEGF-E sequences possess about 25% homology to mammalian VEGF and are encoded by the parapoxvirus Orf virus (OV). This parapoxvirus that affects sheep and goats and occasionally, humans, to generate lesions with angiogenesis. VEGF-E is a dimer of about 20 kDa with no basic domain nor affinity for heparin, but has the characteristic cysteine knot motif present in all mammalian VEGFs, and was surprisingly found to possess potency and bioactivities similar to the heparin-binding VEGF 165 isoform of VEGF- A, i.e. both factors stimulate the release of tissue factor (TF), the proliferation, chemotaxis and sprouting of cultured vascular endothelial cells in vitro and angiogenesis in vivo. Like VEGF 165, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation and a biphasic rise in free intracellular Ca2+ concentrations, while in contrast to VEGF 165, VEGF-E did not bind to VEGF receptor-1 (Flt-1). Based upon emerging discoveries of other homologues of VEGF and
VEGFRs and the precedents for ligand and receptor heterodimerization, the actions of such VEGF homologues may involve formation of VEGF ligand heterodimers, and/or heterodimerization of receptors, or binding to a yet undiscovered VEGFR (Witzenbichler et al, supra). Also, recent reports suggest neuropilin-1 (Migdal et al, supra) or VEGFR-3/Flt-4 (Witzenbichler et al, supra), or receptors other than KDR/VEGFR-2 may be involved in the induction of vascular permeability (Stacker, S.A., Vitali, A., Domagala, T., Nice, E., and Wilks, A.F., "Angiogenesis and Cancer" Conference, Amer. Assoc. Cancer Res., Jan. 1998, Orlando, FL; Williams, Diabetelogia 40: SI 18-120 (1997)). Until now, no direct evidence for the essential role of KDR in VEGF-mediated vascular hyperpermeability has been disclosed. The Non-Receptor Tyrosine Kinases. The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty- four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogene 8:2025-2031, which is incorporated herein by reference. Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including cancer, psoriasis, and other hyperproliferative disorders or hyper-immune responses.
Development of Compounds to Modulate the PTKs. In view of the surmised importance of PTKs to the control, regulation, and modulation of cell proliferation, the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Application No. 4,966,849), soluble receptors and antibodies (Application No. WO 94/10202; Kendall & Thomas, 1994, Proc. Natl. Acad. Sci 90: 10705-09; Kim et al, 1993, Nature 362:841-844), RNA ligands (Jellinek, et al, Biochemistry 33: 10450- 56; Takano, et al, 1993, Mol. Bio. Cell 4:358A; Kinsella, et al. 1992, Exp. Cell Res. 199:56-62; Wright, et al, 1992, J. Cellular Phys. 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, et al, 1994, Proc. Am. Assoc. Cancer Res. 35:2268).
More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642) and vinylene-azaindole derivatives (PCT WO 94/14808) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 Al; Expert Opin. Ther. Pat. (1998), 8(4): 475-478), selenoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer. Anilinocinno lines (PCT WO97/34876) and quinazoline derivative compounds (PCT WO97/22596; PCT WO97/42187) have been described as inhibitors of angiogenesis and vascular permeability.
In addition, attempts have been made to identify small molecules which act as serine/threonine kinase inhibitors. For example, bis(indolylmaleimide) compounds have been described as inhibiting particular PKC serine/threonine kinase isoforms whose signal transducing function is associated with altered vascular permeability in VEGF-related diseases (PCT WO97/40830; PCT WO97/40831). Plk-1 Kinase Inhibitors
Plk-1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk-1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.
Cdc2/Cyclin B Kinase Inhibitors (Cdc2 is also known as cdkl)
Cdc2/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, which is the hallmark of cancer is dependent upon elevated cdk activities in these cells. The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.
The identification of effective small compounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of receptor and non-receptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism is therefore desirable. In particular, the identification of methods and compounds that specifically inhibit the function of a tyrosine kinase which is essential for angiogenic processes or the formation of vascular hyperpermeability leading to edema, ascites, effusions, exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial.
SUMMARY OF THE INVENTION
This invention is directed to compounds of the formula
Figure imgf000011_0001
and physiologically acceptable salts thereof, wherein, R is a substituted or unsubstituted aliphatic, aromatic, heterocyclic or aralkyl group, and R2 is a hydrogen, lower alkyl group or aryl group. R1 is hydrogen or -A-Z, wherein A is - (CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or -(CH2)nS(O)2-; and Z is -H, a lower alkyl, aralkyl, trihalomethyl, R3CO-, trihalomethylcarbonyl, R3OC(O)- , -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, thiophene, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole, benzothiazole, tetrahydrofuran, triazine and the applicable N-oxides thereof which can be optionally substituted with one or more halogens, a lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 or -NR4R5. R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group. R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamo holino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; Numerical index n is an integer from 0 to 3.
Suitable substitutents for R include halogens, lower alkyl groups, R3O-, hydroxy, HOC(O)-, R3OC(O)-, R3OC(O)R6-, R3OR6-, trihalomethyl, trihalomethylcarbonyl, nitro, -C(O)NR4R5, -NR4R5, R3CO-, -(CH2)n-R7, - C(O)(CH2)n-R7, -C(O)-(CH2)n-C(O)-R7, -O(CH2)nR7, -C(O)NR4(CH2)nR7, - C(O)O(CH2)nR7, -OC(O)(CH2)nR7, -NR4C(O)(CH2)nR7, -R6NR4R5, -R6N(R4)-R6-R7, - R6N[R6-R7]2, -R6C(O)NR4(CH2)nR7, -R6C(O)O(CH2)nR7, -R6OC(O)(CH2)nR7, - R6NR4C(O)(CH2)nR7, -R6CH[C(O)OR4] [NR5C(O)R4] or a substituted aryl or aralkyl group, wherein the substituent is selected from the group consisting of halogen, trihalomethyl, hydroxy, -NR4RS, nitro, -CONR4R5, lower alkyl group, R3O-, - C(O)OR4 or -OC(O)R3. R6 is a lower alkyl group or an aryl group. R7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxy, R3O-, R3C(O)- or -NR4R5. Suitable substituents for R3, R4 and R5 include one or more moieties selected from the group consisting of halogens, lower alkyl, hydroxy, lower alkoxy, carboxy, lower alkyl ester, trihalomethyl preferrably trifluoromethyl, nitro, phenyl, phenyl- lower alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-alkyl, CN, amino, alkylamino, dialkylamino, -C(O)NH2, -C(O)NH(alkyl) and -C(O)N(alkyl)2. Aliphatic groups include straight chained or branched C,-C18 hydrocarbons, or cyclic C3-CI8 hydrocarbons which are completely saturated or which contain one or more units of unsaturation. Lower alkyl groups are straight chained or branched C,-C6 hydrocarbons or C3-C6 cyclic hydrocarbons which are completely saturated. Aromatic groups, as used herein, include carbocyclic ring systems (e.g. benzyl and cinnamylidene) and fused polycyclic aromatic ring systems (e.g. naphthyl). In addition, aromatic groups includes heteroaryl ring systems (e.g. pyridine, thiophene, furan, pyrrole, imidazole, oxazole, thiazole, pyrazole, triazole, pyrimidine and pyrazine) and heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic non-aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings (e.g. benzimidazole, benzothiazole, indole, tetrahydroindole, azaindole, indazole, isoxazole, isothiazole, imidazole and quinoline). An aryl group, as used herein, refer to an aromatic group having five or six atoms. An aralkyl group is an aromatic substituent that is linked to a compound by an aliphatic group having from one to six carbon atoms. A heterocyclic group, as used herein, refers to a mono-, bi- or tri-cyclic heterocyclic group that is not aromatic or has a degree of unsaturation wherein the unsaturation does not make the group an aromatic group.
Tautomers, stereoisomers, enantiomers and mixtures of these compounds are included in this invention. Pharmaceutically acceptable addition salts of these compounds are also included in this invention. In one embodiment, R2 is hydrogen, and R is, preferably, a substituted indole, or a substituted or unsubstituted imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, pyrrole, pyrazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene or pyrazine.
In a preferred embodiment, R2 is hydrogen, n is zero, and Z is a cyclopropyl, 3-pyridyl or pyrazinyl group. In another preferred embodiment, R2 is hydrogen, A is -O-, n is 0 and Z is ethyl, propyl or isopropyl. In yet another preferred embodiment, R2 is hydrogen, A is CH2, n is 2 and Z is benzene which is optionally substituted with halogen, trihalomethyl, hydroxy, -NR4R5, nitro, -C(O)NR4R5, lower alkyl group, R3O-, -C(O)OR4 or -OC(O)R3. In a preferred embodiment, the present invention is directed to a compound represented by the following formula:
Figure imgf000013_0001
and physiologically acceptable salts thereof, wherein: R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole; R1 is hydrogen or -A-Z;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR4R5 or - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3- C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that when R is an unsubstituted indol-3-yl then R1 is not -NH2.
In another preferred embodiment, the present invention is directed to a compound represented by the following structural formula:
Figure imgf000015_0001
and physiologically acceptable salts thereof, wherein:
R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole;
R1 is hydrogen or -A-Z;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR4R5 or - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl- alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or is selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that: when R is unsubstituted indol-3-yl then R1 is not -NH2; and when R is a substituted or unsubstituted benzene or an unsubstituted imidazole, 1,2,3-triazole, 1 ,2,4-triazole, pyridine, pyrimidine, pyrazine, pyπole, pyrazole, oxazole or thiazole; then R1 is not a lower alkyl, a (C3-C6)cycloalkyl, benzene, or -C(O)NR4R5, wherein R4 and R5 are each independently H, a lower alkyl or a carbocyclic aryl.
In another preferred embodiment, the present invention is directed to a compound represented by the following structural foπnula:
Figure imgf000016_0001
and physiologically acceptable salts thereof, wherein:
R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7- tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole; R1 is hydrogen or -A-Z;
A is -(CH-),,-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)„S(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR4R5 or - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of a substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
R4 and Rs for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that: a) R is not pyrrol-3-yl or pyrrol-3-yl substituted with an alkyl or a carbocyclic aryl group; b) R is not indol-3-yl or indol-3-yl substituted with an alkyl or a carbocyclic aryl group; and c) R is not azaindole or azaindole substituted at the 2-position with an alkyl or a carbocyclic aryl group.
In another preferred embodiment, the present invention is directed to a compound represented by the following structural formula:
Figure imgf000018_0001
and physiologically acceptable salts thereof, wherein:
R is substituted pyrrole or is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrazole, oxazole and thiazole; R1 is hydrogen or -A-Z;
A is -(CH2)„-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR R5 or - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C3- C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that: a) when R is substituted pyrrole, the pyrrole is substituted with R3OC(O)R6,
R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7,
-C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, -
N(R4)C(O)(CH2)pR7, -R6NR4R5, -R6N(R4)-R6-R7, -R6N(R6-R7)2, - R6C(O)N(R )(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, -
R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4), a substituted aryl or aralkyl group, wherein:
R6 for each occurrence is independently a lower alkyl group or an aryl group;
R7 for each occurrence is independently an alkoxy, haloalkyl, lower alkylpiperazine, hydroxy, R3O-, R3C(O)- or NR4R5; and p is an integer from 1-3; b) when R is indol-3-yl, the indol-3-yl is substituted with R3OC(O)R6, R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7, -C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, - N(R4)C(O)(CH2)pR7, -R6NR4R5, -R6N(R4)-R6-R7, -R6N(R6-R7)2, - R6C(O)N(R4)(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, -
R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4) or a substituted aryl or aralkyl group; and c) when R is pyrazol-3-yl, the pyrazol-3-yl is substituted with R3OC(O)Rδ, R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7, -C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, -
N(R4)C(O)(CH2)pR7, -R6NR4R5, -R6N(R4)-R6-R7, -R6N(R6-R7)2, - R6C(O)N(R4)(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, - R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4) or a substituted aryl or aralkyl group. In another preferred embodiment, the present invention is directed to a compound represented by the following structural formula:
Figure imgf000020_0001
and physiologically acceptable salts thereof, wherein:
R is substituted pyrrole or is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1 ,2,4-triazole, benzimidazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrazole, oxazole and thiazole; R1 is hydrogen or -A-Z;
A is -(CH2)n-, -(CH2)nNH-, -(CHAP-, -(CH2)„S-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR4R5 or - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3- C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
R4 and R5 for each occuπence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that: a) when R is an unsubstituted indol-3-yl then R1 is not -NH2; b) when R is a substituted or unsubstituted benzene or an unsubstituted imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyrimidine, pyrazine, pyrrole, pyrazole, oxazole or thiazole; then R1 is not a lower alkyl, a (C3- C6)cycloalkyl, benzene, or -C(O)NR4R5, wherein R4 and R5 are each independently H, a lower alkyl or a carbocyclic aryl; c) R is not pyrrol-3-yl or pyrrol-3-yl substituted with an alkyl or a carbocyclic aryl group; d) R is not indol-3-yl or indol-3-yl substituted with an alkyl or a carbocyclic aryl group; e) R is not azaindole or azaindole substituted at the 2-position with an alkyl or a carbocyclic aryl group f) when R is substituted pyrrole, the pyrrole is substituted with R3OC(O)R6, R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7, -C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, - N(R4)C(O)(CH2)pR7, -R6NR RS, -R6N(R4)-R6-R7, -R6N(R6-R7)2, -
R6C(O)N(R4)(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, - R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4), a substituted aryl or aralkyl group, wherein: R6 for each occurrence is independently a lower alkyl group or an aryl group; R7 for each occurrence is independently an alkoxy, haloalkyl, lower alkylpiperazine, hydroxy, R3O-, R3C(O)- or NR4R5; and p is an integer from 1-3; g) when R is indol-3-yl, the indol-3-yl is substituted with R3OC(O)R6, R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7, -C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, -
N(R4)C(O)(CH2)pR7, -R6NR4RS, -R6N(R4)-R6-R7, -R6N(R6-R7)2, - R6C(O)N(R4)(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, - R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4) or a substituted aryl or aralkyl group; and h) when R is pyrazol-3-yl, the pyrazol-3-yl is substituted with R3OC(0)Rδ, R3OR6-, trihalomethyl, trihalomethylcarbonyl, -(CH2)p-R7, -O(CH2)pR7, -C(O)N(R4)(CH2)pR7, -C(O)O(CH2)pR7, -OC(O)(CH2)pR7, -N(R4)C(O)(CH2)pR7, -R6NR4R5, -R6N(R4)-R6-R7, -R6N(R6-R7)2, - R6C(O)N(R4)(CH2)pR7, -R6C(O)O(CH2)pR7, -R6OC(O)(CH2)pR7, - R6N(R4)C(O)(CH2)pR7, -R6CH(C(O)OR4)(N(R4)C(O)R4) or a substituted aryl or aralkyl group. In a more preferred embodiment, the present invention is directed to any of the foregoing compounds wherein A is -NH-, -O-, -S-, -S(O)- or -S(O)2- ; and Z is cyclopropyl, 3 -pyridyl or pyrazinyl.
In yet another more preferred embodiment, the present invention is directed to any of the foregoing compounds wherein A is -O-; and Z is ethyl, n-propyl or isopropyl.
In still another more preferred embodiment, the present invention is directed to any of the foregoing compounds wherein A is -CH2-; and Z is phenyl, wherein said phenyl is optionally substituted with one or more moieties selected from the group consisting of halogens, trihalomethyl, hydroxy, -NR4R5, nitro, -CONR4R5, lower alkyl group, R3O-, -C(O)OR4 and -OC(O)R4.
In still another preferred embodiment, the present invention is directed to any of the foregoing compounds wherein R is substituted with one or more substituents, each independently selected from the group consisting of halogens, lower alkyl groups, R3O-, hydroxy, HOC(O)-, R3OC(O)-, R3OC(O)R6-, R3OR6-, trihalomethyl, trihalomethylcarbonyl, nitro, -C(O)NR R5, -NR4R5, R3CO-, -(CH2)n-R7, - C(O)(CH2)n-R7, -C(O)-(CH2)n-C(O)-R7, -O(CH2)nR7, -C(O)NR4(CH2)nR7, - C(O)O(CH2)nR7, -OC(O)(CH2)nR7, -NR4C(O)(CH2)nR7, -R6NR4R5, -R6N(R4)-R6-R7, - R6N(Rδ-R7)2, -R6C(O)NR4(CH2)nR7, -R6C(O)O(CH2)„R7, -R6OC(O)(CH2)nR7, - R6NR4C(O)(CH2)„R7, -RδCH(C(O)OR4)(NR5C(O)R4), an optionally substituted aryl and an optionally substituted aralkyl group. The optionally substituted aryl and optionally substituted aralkyl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxy, - NR4R5, nitro, -CONR4R5, lower alkyl group, R3O-, -C(O)OR4 and -OC(O)R3. Rδ is a lower alkyl group or an aryl group. R7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxy, R3O-, R3C(O)- or -NR4R5. In one aspect of this embodiment, R is pyrrolyl, indolyl, azaindolyl, phenyl, pyrazolyl, imidazolyl, thienyl, 4,5,6,7-tetrahydroindolyl, or quinolinyl. In another aspect of this embodiment, R is pyrrol-2-yl, pyrrol-3-yl, indol-2-yl, indol-3-yl, azaindol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, thien-2-yl or quinolin-5-yl. In still another preferred embodiment, the present invention is directed to any of the foregoing compounds wherein R1 is trifluoromethyl, amino, cyclopropylamino, methyl, ethyl, propyl, isopropyl, cyclopropyl, 2- methylcyclopropyl, 2,2,3,3-tetramethylcyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH2)p-O-phenyl, -(CH2)p-O-(4- methoxyphenyl), -(CH2)p-O-(4-chlorophenyl), -(CH2)p-O-(4-methylphenyl), -(CH2)p- O-(3-methylphenyl), -(CH2)p-O-(4-phenylphenyl), -(CH2)p-O-(4-hydroxyphenyl), - (CH2)p-O-(4-nitrophenyl), -(CH2)p-O-(4-aminophenyl), -(CH2)p-O-(4- carbamoy Iphenyl), -(CH2)p-O-(4-methoxycarbonylphenyl), -NH-phenyl, -NH-(4- methoxyphenyl), -NH-(4-chlorophenyl), -NH-(4-fluorophenyl), -NH-(4- isopropylphenyl), isopropoxy, ethoxy, cyclopentyloxy, -(CH2)p-indolyl, -(CH2)p- pyridyl, -(CH2)p-benzothiazolyl, -(CH2)p-pyrrolyl, -(CH2)p-tetrahydrofuryl, -(CH2)p- pyrazinyl, -(CH2)p-furyl, -(CH2)p-thienyl, -(CH2)p-phenyl, -(CH2)p-isoxazolyl, - (CH2)p-(5-methylisoxazolyl), -(CH2)p-pyrimidinyl, -(CH2)p-pyridazinyl, -(CH2)n- C(O)-OMe, -(CH2)n-C(O)-OEt or benzyl optionally substituted with one or more of Cl, F, OMe, methyl or amino. p is an integer from 1 to 3. In one aspect of this embodiment, R is optionally substituted with one or more moieties selected from the group consisting of Br, Cl, F, aminomethyl, N,N-dimethylaminomethyl, carboxy, carboxymethyl, carboxyethyl, carbonylmethyl, carbonylethyl, methoxycarbonyl, ethoxycarbonyl, phenyl, 4-morpholinomethyl, -C(O)-O-(CH2)2-N(Me)2, -C(O)-O- (CH2)2-N(Et)2, -C(O)-O-CH2-N(Me)2, -C(O)-O-(CH2)2-N(Me)2, -C(O)-NH-(CH2)2- N(Me)2, -CH2-NH-C(O)-CF3 and an optionally substituted moiety selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl and phenyl, where the optionally substituted moiety is optionally substituted with one or more of Br, Cl, F, hydroxy, nitro, amino or lower alkyl.
In another aspect, the present invention provides a pharmaceutical composition comprising any one or more of the compounds of the present invention, as defined herein, and a pharmaceutically acceptable carrier or diluent. In another aspect, the present invention provides a method of inhibiting one or more protein kinase activity comprising the administration of a compound represented by the formula:
Figure imgf000025_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein:
R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z;
R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group;
A is -(CH2)n-, -(CH2)nNH-, -(CH2),P-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and - NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
A preferred method of the foregoing method is where the inhibition of the protein kinase is in a recipient in need thereof.
A preferred method of any of the foregoing methods is where the compound is a mixture of stereoisomers. A preferred method of any of the foregoing methods is where the stereoisomers are enantiomers.
A preferred method of any of the foregoing methods is where the stereoisomers are E and Z isomers.
A preferred method of any of the foregoing methods is where the compound is a mixture of structural isomers. A prefeπed method of any of the foregoing methods is where the structural isomers are tautomers.
A preferred method of any of the foregoing methods is where said protein kinase is either a receptor tyrosine kinase or a non-receptor tyrosine kinase. A preferred method of any of the foregoing methods is where said tyrosine kinase is selected from the group consisting of KDR, Flt-1, TIE-2, FGFR, PDGFR, IGF-l-R, c-Met, Lck, Src, fyn, Lyn, Blk, and yes.
In another aspect, the present invention is directed to a method of treating or essentially inhibiting hyperproliferative disorders or inflammatory diseases in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein.
In another aspect, the present invention is directed to a method of treating or inhibiting angiogenesis in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein. In another aspect, the present invention is directed to a method of inducing an anti-angiogenic effect in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention as defined herein. In another aspect, the present invention is directed to a method of treating or inhibiting the progression of a disease or condition in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention, as defined herein, where said disease or condition is selected from the group consisting of cancer, arthritis, atherosclerosis, restenosis, psoriasis, hemangioma, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, corneal disease, rubeosis, neovascular glaucoma, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, virally induced angiogenic disorders, fractures, diabetic retinopathy, Crohn's disease, inflammatory bowel disorder, cat scratch fever, retinopathy or prematurity, ulcers, thyroid hyperplasia, burns, trauma, acute lung injury, chronic lung disease, stroke, polyps, cysts, synovitis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, pulmonary and cerebral edema, keloid, fibrosis, cirrhosis, carpal tunnel syndrome, sepsis, adult respiratory distress syndrome, multiple-organ dysfunction syndrome, ascites and tumor-associated effusions and edema.
In another aspect, the present invention is directed to a method of affecting vascular hyperpermeability or the production of edema in a recipient in need thereof comprising the administration to said recipient of any of the compounds of the present invention, as defined herein. A preferred method of the immediately foregoing method is where the effect on the production of edema is antiedematous.
A preferred method of any of the foregoing methods is where the protein kinase is a serine kinase. A preferred method of any of the foregoing methods is where the protein kinase is a threonine kinase.
Particularly preferred compounds of the present invention are:
3-Cyclopropyl-4- { [(3 , 5 -dimethyl-4-(4-methy- 1 -piperazinylmethyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-(l -pyrrolidinylmethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Cyclopropyl-4-[(4-diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(3-dimethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one, 3- Cyclopropyl-4-[(3-morpholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-
2-pyrazolin-5-one, 3- Cyclopropyl-4-[(3-diethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one, 3- Cyclopropyl-4-{[3-(4-methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2- yl]methylene} -2-ρyrazolin-5-one,
3-Cyclopropyl-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene]-2- pyrazolin-5-one, 3- Cyclopropyl-4-[(4-diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3- Cyclopropyl-4-(3,5-dibromo-4-hydroxybenzylidene)-2-pyrazolin-5-one, - Cyclopropyl -4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5- one, - Cyclopropyl -4-[(4-dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, -Cyclopropyl-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropyl-4-[4-(2-dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[4-(2-dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropyl-4-[3-(2-dimethylaminoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-
5 -one, -Cyclopropyl-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[4-(4-morpholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Cyclopropyl-4-[4-(4-morpholinoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[3-(4-morpholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, -Cyclopropyl-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-cyclopropyl-2-pyrazolin-5-one,-Cyclopropyl-4-[(5-ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -Cyclopropyl-4-[(5-chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- y l)methylene] -2-pyrazolin- 5 -one, -[(3,5-Dimethyl-4-morpholinomethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5 -one, -{[(3,5-Dimethyl-4-[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(3- pyridyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(3-pyridyl) -2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Morpholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(3- pyridyl)-2-pyrazolin-5 -one, -(3-Pyridyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(3-pyridyl)-2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(3-pyridyl-2-pyrazolin-5-one, -(3-Pyridyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[4-(4-Morpholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[4-(4-Morpholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[3-(4-Mθφholinoethoxycarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3 -(3 -pyridyl)- 2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-(3-pyridyl)-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(3-pyridyl)-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(3 -pyridyl)-2-pyrazolin-5 -one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3-
(3-pyridyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-
5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin- 5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -Isopropoxy-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -Isopropoxy-4-{[3-(4-methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -Isopropoxy-4- {[3-(l -pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene} -2- pyrazolin-5-one, -Isopropoxy 4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- -2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-isopropoxy-2-, pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-isopropoxy-2-pyrazolin-5-one, -Isopropoxy-4-[(4-oxo-l ,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(4-Bromopyπol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-isopropoxy-2-ρyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, -Isopropoxy-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyπol-2-yl)methylene]-3-isopropoxy-2-pyrazolin- 5 -one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-isopropoxy-2-pyrazolin- 5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -Isopropoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Isopropoxy-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Isopropoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, -Isopropoxy-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2-pyrazolin-
5-one, -[(3,4-Diethoxycarbonylpyπol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- isopropoxy-2-pyrazolin-5 -one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- isopropoxy-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-ethoxy-
2-pyrazolin-5-one, - [(3 ,5 -Dimethyl-4- [( 1 -pyrrolidinylmethylpyrrol-2-yl)methylene]-3 -ethoxy-2-pyrazolin- 5-one, -[(4-Diethylaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5 -one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -Ethoxy-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -Ethoxy-4- {[3-(4-methyl- 1 -piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene}-2-pyrazolin-5-one, -Ethoxy-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5-one, -Ethoxy-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-ethoxy-2-pyrazolin-5- one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-ethoxy-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin- 5-one, -Ethoxy-4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5 -one, -Ethoxy-4-[(5-trifluoromethylpyπOl-2-yl)methylene]-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin- 5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5 -one, -Ethoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Ethoxy-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Ethoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Ethoxy-4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-ethoxy
2-pyrazolin-5-one, -Ethoxy-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-ethoxy-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-ethoxy-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- ethoxy -2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Mθφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-
5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-pyrazinyl-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[4-(4-Moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-
5 -one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[3-(4-Mθφholinoethylaminocarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl -2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one, -[(Indol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(l-Methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-pyrazinyl -2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3-pyrazinyl-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3- pyrazinyl -2- pyrazolin-5-one, - {[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3- pyrazinyl -2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene] -3- pyrazinyl -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3- pyrazinyl-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(imidazol-2yl)-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-(Imidazol-2-yl)-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -(Imidazol-2-yl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -(Imidazol-2-yl)-4-[4-(4-moφholinoethylaminocarbonylpyπOl-2-yl)methylene]-2- pyrazolin-5-one, -(Imidazol-2-yl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-
5-one, -(Imidazol-2-yl)-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, - [(3 ,5 -Dimethyl -4-ethylpyrrol-2-yl)methylene] -3 -(imidazol-2-yl)-2-pyrazolin-5 -one,-(Imidazol-2-yl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl) -2- pyrazolin-5-one, -(Imidazol-2-yl) -4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one,-(Imidazol-2-yl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-
(imidazol-2-yl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3- (imidazol-2-yl)-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(pyπol-2-yl)methylene]-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(mdol-2-yl)methylene]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl))- 2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3- (imidazol-2-yl) -
2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(imidazol-2-yl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyπOl-2-yl)methylene]-3- (imidazol-2-yl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(imidazol-2-yl)-2-pyrazolin-5-one, - [(4-Bromopyrrol-2-yl)methylene]-3 -( 1 -methylcyclopropyl)-2-pyrazolin-5 -one,-[(4-Chloropyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-[(5-Chloropyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-(l-Methylcyclopropyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-
5 -one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]- 2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene] -2-pyrazolin-5 -one, - [(3 ,5-Dimethyl-4-ethylpyrrol-2-yl)methylene] -3 -( 1 -methylcyclopropyl)-2- pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one,- [3 ,5 -Dimethy l-4-ethoxycarbonylpyrrol-2-yl)methylene]-3 -( 1 -methylcyclopropyl) -2- pyrazolin-5-one, -[(5-Methoxyindol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -(1 -Methylcyclopropyl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, - {[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene} -3-(l - methylcyclopropyl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[(Indol-3-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -[(Pyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, - [(3 ,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3 -( 1 -methylcyclopropyl))- 2-pyrazolin-
5-one, - {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-(l - methylcyclopropyl) -2-pyrazolin-5-one, - {[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene} -3-(l -methylcyclopropyl)-2- pyrazolin-5-one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- (1 -methylcyclopropyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(2-furyl)-
2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(l-pyrrolidinylmethyl)pyπol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin- 5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyπol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-2- pyrazolin-5-one, -[(3-Diethylaminoethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4- { [3 -(4-methyl- 1 -piperazinylmethyl)-4,5 -tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -(2-Furyl)-4- {[3-(l -pyrrolidinyl)methyl-4,5-tetramethylenepyπol-2-yl]methylene} -2- pyrazolin-5-one, -(2-Furyl)-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-furyl)-2-pyrazolin-
5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one,-(2-Furyl)-4-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-fiιryl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -(2-Furyl)-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -(2-Furyl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4- [3 -(4-moφholinoethylaminocarbonylindol-2-yl)methylene] -2-pyrazolin-5 - one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyπOl-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-(2-Furyl)-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,- {[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene} -3-(2- fury l)-2-pyrazo lin- 5 -one, - { [3 ,5 -Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene] -3 -(2- furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(3-(2-furyl))-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3- (2-furyl) -2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(2-furyl)-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(2-furyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(2- furyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(moφholinomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(4-methyl-l-piperazinyl)methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, - [(4-Diethylaminomethyl-3 , 5 -dimethy lpyrrol-2-yl)methylene] -3 -(2-thienyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, -{[3-(l-Pyrrolidinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-thienyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-thienyl)-2-pyrazolin-5-one, -[(4-Oxo-4,5,6,7-tetrahydroindol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -(2-Thienyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5 -one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[4-(4-Mθφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5-one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[(l-Methylindol-3-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[(5-Methoxyindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(4,5-Tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(2- thienyl) -2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl]methylene}-3-(2- thienyl) -2-pyrazolin-5-one, - [(Indol-3 -yl)methylene] -3-(2-thienyl)-2-pyrazolin-5 -one, -[(Pyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(2 -thienyl) -2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-(2-thienyl)-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(2-thienyl)-2-pyrazolin-5-one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(2-thienyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -Cyclopropoxy-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[4-(2-dimethylaminoethoxycarbonylpyπol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[4-(2-dimethylaminoethylaminocarbonylpyπol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[3-(2-dimethylaminoethoxycarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin- 5-one, -Cyclopropoxy-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-
5 -one, -Cyclopropoxy-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4- [3 ,5 -dimethy l-4-ethoxycarbonylpyrrol-2-yl)methylene] -2-pyrazolin- 5-one, -Cyclopropoxy-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-{[3,5-dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one, -Cyclopropoxy-4-{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2- yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4- [(pyrrol-2-yl)methylene] -2-pyrazolin-5-one, -Cyclopropoxy-4-[(Indol-2-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(3,4-diethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-cyclopropoxy -2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-cyclopropoxy-2-pyrazolin-5- one, -Cyclopropoxy-4-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- yl)methylene] -2-pyrazolin- 5 -one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- cyclopropoxy-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[(4-Chloropyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[(5-Chloropyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[2-(5-pyrimidinylethyl)]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5- one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-
2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[4-(4-Moφholinoethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-
2-pyrazolin-5-one, -[4-(4-Moφholinoethylaminocarbonylpyrrol-2-yl)methylene]- 3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2- pyrazolin-5-one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]- 3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-ethylρyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2- pyrazolin-5-one, -[(l-Methylindol-3-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] - 2-pyrazolin-5-one,-[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2- pyrazolin-5-one, -[(5-Methoxyindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2-pyrazolin-5-one,-[2-(5-pyrimidinylethyl)] -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, - { [3 ,5 -Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene} -3- [2-(5 - pyrimidinylethyl)] -2-pyrazolin-5-one, - { [3 ,5 -Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)nιethylene] -3 - [2-
(5-pyrimidinylethyl)] -2-pyrazolin-5-one, -[(Indol-3-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[2-(5-pyrimidinylethyl)]-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-
5 -one, - {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-[2-(5- pyrimidinylethyl)] -2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-[2-(5-pyrimidinylethyl)]-2- pyrazolin-5-one, - [(5 -Ethoxy-4-methoxycarbonylmethyl-3 -m ethoxycarbony lpyrrol-2-yl)methylene] -3-
[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -(2-phenylethyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-(2-phenylethyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[4-(4-Moφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)- 2- pyrazolin-5-one, -[4-(4-Mθφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[3-(4-Mθφholinoethoxycarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-
5-one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[(l-Methylindol-3-yl)methylene]- 3-(2-phenylethyl)-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-
5 -one, -[(5-Methoxyindol-2-yl)methylene]- 3-(2-phenylethyl) -2-pyrazolin-5-one,-(2-phenylethyl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(2- phenylethyl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-(2- phenylethyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-(2-phenylethyl)-
2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(2-phenylethyl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- (2-phenylethyl)-2-pyrazolin-5 -one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyπol-2-yl)methylene]- 3-
(2-phenylethyl)-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one,- [(4-Chloropyrrol-2-yl)methylene] -3 - [2-(4-hydroxyphenyι)ethyl]-2-pyrazolin-5 -one,-[(5-Chloropyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl] -2-pyrazolin-5-one,-[2-(4-hydroxyphenyl)ethyl]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-
5 -one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin- 5-one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5 -one, -[2-(4-hydroxyphenyl)ethyl]-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, - [2-(4-hydroxyphenyl)ethyl] -4- [3 -(4-moφholinoethoxycarbonylindol-2-yl)methylene] - 2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyπol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]
-2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one,-[2-(4-hydroxyphenyl)ethyl]-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-[2-
(4-hydroxyphenyl)ethyl] -2-pyrazolin- 5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]- 2- pyrazolin-5-one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-[2-(4- hydroxyphenyl) ethyl] -2-pyrazolin-5-one, - {[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene} -3-[2-(4-hydroxyphenyl)ethyl] -2- pyrazolin-5-one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene] -3- [2-(4-hydroxyphenyl)ethyl] -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3- [2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(4-bromopyrrol-2-yl)methylene] -2-pyrazolin-5-one,- 2-(4-aminophenyl)ethyl]-4-[(4-chloropyrrol-2-yl)methylene]- 2-pyrazolin-5-one,- 2-(4-aminophenyl)ethyl]-4-[(5-chloropyrrol-2-yl)methylene]-2-pyrazolin-5-one,- 2-(4-aminophenyl)ethyl]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, - 2-(4-aminophenyl)ethyl]-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -12-(4-aminophenyl)ethyl]-4-[4-(2-dimethylaminoethoxycarbonylpyrrol-2- yl)methylene]- 2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[4-(2-dimethylaminoethylaminocarbonylpyrrol-2- yl)methylene]- 2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, - 2-(4-aminophenyl)ethyl]-4-[3-(2-dimethylaminoethoxycarbonylindol-2- yl)methylene]- 2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methyl ene] -2-pyrazolin-5 -one, - 2-(4-aminophenyl)ethyl]- 4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5 -one, -| 2-(4-aminophenyl)ethyl]-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -12-(4-aminophenyl)ethyl]-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene]- 2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one,- 2-(4-aminophenyl)ethyl]-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, -12-(4-aminophenyl)ethyl]-4-{[3,5-dimethyl-4-(2-dimethylaminoethoxycarbonyl) pyrrol-2-yl]methylene}-2-pyrazolin-5-one, -12-(4-aminophenyl)ethyl]-4-{[3,5-dimethyl-4-(2-dimethylaminoethylamino carbonyl)pyrrol-2-yl]methylene}-2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(Indol-2-yl)methylene]-2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(3,4-diethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, - [3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-[2-(4- aminophenyl)ethyl]-2-pyrazolin-5-one, - [3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-[2-(4-aminophenyl)ethyl]-2- pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(5-ethoxy-4-methoxycarbonylmethyl-3- methoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, - 2-(4-aminophenyl)ethyl]-4-[(5-chloro-4-methoxycarbonylmethyl-3- methoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, - (3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyπol-2-yl)methylene]-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Mθφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-
2-pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -(4-Pyrimidinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yljmethylene} -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4- pyrimidinyl)pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(4-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahyα^oindol-2-yl)methylene]-3-(4-pyrimidinyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-diethylaminomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-
2-pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, -(5 -Pyrimidinyl)-4- { [3-( 1 -pyrrolidinyl)methyl-4, 5-tetramethylenepyrrol-2- yl]methylene}-2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(5-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(5-pyrimidinyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5 -one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Mθφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3- (2-pyrimidinyl)-2-pyrazolin-5-one, -(2-Pyrimidinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)- 2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(2-pyrimidinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5 -one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)- 2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3-
(3-pyridazinyl)-2-pyrazolin-5-one, -(3-Pyridazinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene}-2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(3-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)- 2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(3-pyridazinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5 -one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one, -(4-Pyridazinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene}-2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(4-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Oxo- 1 ,5,6,7-tetrahydroindol-2-yl)methylene]-3-(4-pyridazinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-
2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3 ,5 -dimethy lpyrrol-2-yl)methylene] -3 -(5 -isoxazolyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-Dimethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-
2-pyrazo lin- 5 -one, - [(3-Dimethylaminomethyl-4, 5 -tetramethyl enepyrrol-2-yl)methylene] -3 -(5 - isoxazolyl)-2-pyrazolin-5-one, -(5-Isoxazolyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5- isoxazolyl)-2-pyrazolin-5-one, -(5-Isoxazolyl)4-{[3-(4-methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene}~2-pyrazolin-5-one, -(5-isoxazolyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yljmethylene} -2-pyrazolin-5-one, -(5-Isoxazolyl)-4- [(3 -piperidinomethy 1-4,5 -tetramethylenepyrrol-2-yl)methylene] - 2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(5-isoxazolyl)-2-pyrazolin-5-one,-[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)nιethylene]-3-(5-isoxazolyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- methyl-3-isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-methyl-
3-isoxazolyl)-2-pyrazolin-5-one, -(5-Methyl-3-isoxazolyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]- 2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5 -one, -(5-Methyl-3-isoxazolyl)4-{[3-(4-methyl-l-piperazinyl)methyl-4,5- tetramethylenepyrrol-2-yl]methylene}~2-pyrazolin-5-one, -(5 -Methyl-3 -isoxazolyl)-4- { [3 -( 1 -pyrrolidinyl)methyl-4,5 -tetramethylenepyrrol-2 - yl]methylene}-2-pyrazolin-5-one, -(5-Methyl-3-isoxazolyl)4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, 4-[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, 4-(3,5-Dibromo-4-hydroxybenzylidene)-3-(5-methyl-3-isoxazolyl)-2-pyrazolin-5- one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, 3-(5-Methyl-3-isoxazolyl)-4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-2- pyrazolin-5-one, 4-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
3 -cyclopropy l-4-( 1 -3 - [(dimethylamino)methyl] -4,5, 6 ,7-tetrahydro- 1 H-2- indolylmethylidene)-4,5-dihydro-lH-5-pyrazolone, 3 -cyclopropy l-4-( 1 -4- [( 1 , 1 -dimethylammonio)methyl] -3 , 5 -dimethyl- 1 H-2- pyrrolylmethylidene)-4,5-dihydro- lH-5-pyrazolone maleate, 4-[l-(4-[[2-(dimethylamino)ethyl](methyl)amino]methyl-3,5-dimethyl-lH-2- pyrrolyl)methylidene]-3-(2-pyrazinyl)-4,5-dihydro-lH-5-pyrazolone 4-(l-4-[2-(diethylamino)ethyl]-3,5-dimethyl-lH-2-pyrrolylmethylidene)-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone, 4-l-[4-(3-chloropropanoyl)-3,5-dimethyl-lH-2-pyrrolyl]methylidene-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone,
4-(l-3-[(dimethylamino)methyl]-4,5,6,7-tetrahydro-lH-2-indolylmethylidene)-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone, 4-(l-4-[(dimethylamino)methyl]-3,5-dimethyl-lH-2-pyrrolylmethylidene)-3-(5- methyl-3-isoxazolyl)-4,5-dihydro-lH-5-pyrazolone, 3-Cyclopropyl-4-[(4,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3 -B enzy 1-4- [(pyrrol-2-yl)methylene] -2 -pyrazolin-5 -one, 3-(4-Methoxyphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenyloxymethyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Benzyl-4-{[4-(2-carboxyethyl)-3-methylpyrrol-2-yl]methylene}-2-pyrazolin-5- one,
3-Benzyl-4-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-pyrazolin-5- one, 3-(4-Methylphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 2-Amino-4-[)pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenylethyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenylamino-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methylbenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(4-Methylphenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorobenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Chlorophenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(Indol-3-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Methoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3,4-Dimethoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Phenylphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(2-Phenylpropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Phenylpropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Hydroxyphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3-(4-Methylphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3 -Ethoxy-4- [(pyrrol-2-yl)methylene] -2-pyrazolin-5 -one, 3-(4-Nitrophenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(4,5-Dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)pyrrol-2-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one, 3-Cycloρentyloxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Tert-butylureido-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(l-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Ethoxy-4-[(5-methylpyrrol-2-yl)methylene]2-pyrazolin-5-one, 3-(4-Carbamoylphenylethyl)-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(4-methoxycarbonylphenylethyl- 2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]- 2-pyrazolin-5-one,
4-[(5-Ethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(4-hydroxyphenylethyl)-2- pyrazolin-5-one, 3-(Ethoxycarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenylaminocarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin- 5-one,
4-{(3-(2-Carboxyethyl)-4-methylpyrrol-2-yl]methylene}-3-isopropyl-2-pyrazolin-5- one, 3-Cyclopropyl-4-[(pyrrol-2-yl)methylene]-2-ppyrazolin-5-one, 3-Cyclobutyl-4- [(pyrrol-2-yl)methylene] -2-pyrazolin-5 -one, 3-(3-Pyridil)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[[l-(3,5-dichlorophenyl)pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Pyrrol-2-yl)methylene]-3-(2,2,3,3-tetramethylcyclopropyl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopentyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(2-Methylcyclopropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-(Benzothiazol-2-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(4,5-Dimethylpyrrol-2-yl)methylene]-4-(3-pyridyl)]-2-pyrazolin-5-one, 3 -Cyclopropyl-4 [(3 , 5 -dimethy 1-4-ethylpyrro 1-2-y l)methylene] -2 -pyrazolin-5 -one, 3-(Pyrrol-2-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(Benzothiazol-2-yl)-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 4-[3,5-Dimetyl-4-ethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(5-Methylpyrrol-2-yl)methylene]-3-(-3-pyridyl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-ethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Isopropoxy-4-[(5-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Propyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Methyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Isopropylphenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3 -(3 -Pheny lamino)-4- [(pyrrol-2-yl)methylene] -2-pyrazolin-5 -one, 3-Cyclopropyl-4-{[l-(4-hydroxybutyl)pyrrol-2-yl]methylene]-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3-methylpyrrol-2-yl]methylene}-3-isopropoxy-2-pyrazolin- 5-one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Isopropoxy-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5 -one,
4-[(3 ,5 -Dimethyl-4-dimethylaminomethylpyrro 1-2-y l)methylene] -3 -isopropoxy-2- pyrazolin-5-one,
4-[(4-Acetyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-{[3,5-Dimethyl-4-(2-dimetylaminoethyloxycarbonyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimetylaminoethylaminocarbonyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one,
4-[(5-Ethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(5-Carboxypyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-(4-Chlorophenylaminocarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5- one,
3-Cyclopropyl-4-[(5-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(tetrahydrofuran-3-yl)-2- pyrazolin-5-one, 4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5- one, 4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5 -one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 4-[(3,4-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3-methylpyrrol-2-yl]methylene}-3-cyclopropyl-2-pyrazolin-
5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(5-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(2-Methoxycarbonylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Ethoxycarbonyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Isopropyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(trans-2-phenylcyclopropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclohexyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropylamino-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one,
3-Cyclopropyl-4-[(5-moφholinomethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(5-Carboxypyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one,
4-[(4-Chloropyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-[(4-Bromopyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-[(5-Chloropyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4[(4-Chloropyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 4-[(4-Bromopyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one,
3-Pyrazinyl-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(3-Pyridyl)-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3,5-dimethyl-4-(2-dimethylaminoethyloxycarbonyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4(2-dimethylaminoethyloxycarbonyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one maleate,
4-{[3,5-Dimethyl-4-(2-moφholinoethylaminocarbonyl)pyrrol-2-yl]methylene-3- pyrazinyl-2-pyrazolin-5-one,
4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one,
4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one,
4-[(3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,
4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-trifluoroacetamidomethylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4-aminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, 3-(Benzothiazol-2-yl)-4-[(3,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(Benzothiazol-2-yl)-4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
4-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(4-Carboxypyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-diethanolaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-trifluoroacetamidomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-ethoxycarbonyl-3-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5- one,
4- { [3 ,5 -Dimethy l-4-( 1 -pyrrolidinylmethyl)pyrrol-2-yl]methylene} -3 -pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one,
4- [(3 , 5 -Dimethyl-4-dimethylaminomethylpyrrol-2-y l)methy lene] -3 -(3 -pyridyl)-2- pyrazolin-5-one, 4- [(3 ,5 -Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene] -3 -phenyl-2-pyrazolin-5 - one,
4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-phenyl-2-pyrazolin-5-one,
4-[(3,4-Di(ethoxycarbonyl)pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
3-Ethoxy-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-pyridylethyl)-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methyl-2- phenylethyl)-2-pyrazolin-5-one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, 3-Ethoxy-4-[(5-nitropyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Ethoxy-4-[(4-nitropyrrol-2-yl)methylene]-2-pyrazolin-5-one,
4-[(4-Carboxypyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene}-
3-ethoxy-2-pyrazolin-5-one, 4-[(5-Chloro-3-methoxycarbonyl-4-methoxycarbonylmethylpyrrol-2-yl)methylene]-
3-ethoxy-2-pyrazolin-5-one,
4-{[3-(2-Carboxyethyl)-4-methylpyrrol-2-yl]methylene}-3-ethoxy-2-pyrazolin-5- one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one,
3-Ethoxy-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-trifluoromethyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, 3-(3-Aminophenyl)-4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Ethoxy-4-{[2-(4-moφholinoethyl)aminocarbonylpyrrol-2-yl]methylene}-2- pyrazolin-5-one,
4-[(4-Ethoxycarbonyl-3-phenylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one,
4-{[4-(4-Methyl-l-pyperazinylmethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one,
4-[(5-Methyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-{ {3,5-Dimethyl-4-[N-(2-dimethylaminoethyl)-N-methylaminomethylpyπol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-dimethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one,
4-[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-2- pyrazolin-5 -one maleate,
4-{[4-(3-Chloropropionyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(4-hydroxypiperidinomethyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(4-Aminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2 -pyrazolin-5- one maleate,
4-{[4-(4-Benzylpiperidino)methylpyrrol-2-yl]methylene}-3-pyrazinyl-2-pyrazolin-
5 -one,
4-{[3,5-Dimethyl-4-(2-hydroxyethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4- { {3,5-Dimethyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3-pyrazinyl-2- pyrazolin-5-one, 3-Cyclopropyl-4-{{3,5-Dimethyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2- yl} methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3,5-Dimethyl-4-(2-hydroxyethyl)pyrrol-2-yl]methylene}-2- pyrazolin-5-one, 4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(3-Diethylaminopropyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(3-hydroxypropyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminoacetylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one hydrochloride,
4-[(3,5-Dimethyl-4-dimethylaminoacetylpyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, 3-Cyclopropyl-4-{[(2-diethylaminoethyl)-3,5-dimethyl-4-pyrrol-2-yl]methylene}-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimethylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(4-hydroxybutyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(4-Diethylaminobutyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl-N-oxide)-3,5-dimethylpyrrol-2-yl]methylene}-3- pyrazinyl -2 -pyrazolin-5 -one, 4- {[3,5-dimethyl-4-(l-pyrrolidinylacetyl)pyrrol-2-yl]methylene} -3-pyrazinyl-2- pyrazolin-5-one,
4-[(4-Diethylaminoacetyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3-Isopropyl-5-methylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-{[3,5-Dimethyl-4-[3-(l-pyrrolidinylpropyl)]pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(Dimethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-pyrazinyl-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(dimethylaminomethyl-3-isopropyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethoxyoxalyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
3-Benzyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-Benzyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenyloxymethyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-phenyloxymethyl-2-pyrazolin-5-one,
3-(4-Chlorophenyloxymethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methoxybenzyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methylphenyloxymethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methylbenzyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-phenylamino-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methylphenylamino)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylamino)-2-pyrazolin-5-one, 3-(4-Chlorobenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-3-(4-methoxybenzyl)-2-pyrazolin-5- one,
3-(4-Chlorophenylamino)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(3-methoxybenzyl)-2-pyrazolin-5-one, 3-(3,4-dimethoxybenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-hydroxybenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-(3-Chlorophenyloxymethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-(Indol-3-yl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-phenylphenyloxymethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-phenylpropyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(3-phenylpropyl)-2-pyrazolin-5-one, 3-(4-Hydroxyphenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methylphenylethyl)-2-pyrazolin-5-one, 3-Ethoxy-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-phenylethyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-nitrophenylethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-propoxy-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)4-[(indol-3-yl)methylene]- -2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(2-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(7-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(7-Methylindol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3-Cyclopentyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-Isopropoxy-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxycarbonylphenylethyl)-2-pyrazolin-5-one, 3-Isopropoxy-4- [( 1 -isopropylindol-3 -yl)methylene] -2-pyrazolin-5 -one, 3-(4-Hydroxyphenylethyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-(4-Chlorophenylaminocarbonylmethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5- one,
3-Ethoxycarbonylmethyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylaminocarbonylmethyl)-2-pyrazolin- 5-one,
3-Cyclopropyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,
3 -(2- Aminocarbonylethyl)-4- [(indol-3 -yl)methylene] -2-pyrazolin-5 -one,
3 -Cyclobutyl-4- [(indol-3 -yl)methylene] -2-pyrazolin-5-one, . 3-(2-Dimethylaminocarbonylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4- [(Indol-3 -yl)methylene] -3-(4-pyridyl)-2-pyrazolin-5 -one, 3-Cyclopentyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2,2,3,3-tetramethylcyclopropyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-methylcyclopropyl)-2-pyrazolin-5-one, 3-Cyclohexyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-(4-pyridyl)-2-pyrazolin-5-one, 3-(Benzothiazol-2-yl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 3-Dimethylamino-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(pyrrol-2-yl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(6-methoxybenzothiazol-2-yl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(7-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-propyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-methyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-trifluoromethyl-2-pyrazolin-5-one, 4- { [ 1 -(4-Hydroxybutyl)indol-3-yl]methylene} -2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-methyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-trifluoromethyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-(tert-butyl)-2-pyrazolin-5-one, 3-Ethoxycarbonyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-methoxycarbonylethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(trans-2-phenyl-l-cyclopropyl)-2-pyrazolin-5-one, 3-Cyclobutyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methoxy-l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(l,7-dimethylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-(tetrahydrofuran-3-yl)-2-pyrazolin-5-one, 3-Cyclopropylamino-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(l,7-Dimethylindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methoxy-l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-trifluoroacetamido-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Amino-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Ethoxy-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one,
3-(5-Isoxazolyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-tert-butyl-2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-{{l-Methyl-6-[2-(4-moφholino)ethyl]aminocarbonylindol-3-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(Indol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-(4-Hydroxyphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxycarbonylphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Carbamoylphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3-dimethylaminomethylindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(l-methylindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-(tetrahydrofuran-3-yl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-nitroindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-isopropylamino-2-pyrazolin-5-one, 3-(4-Carboxyphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-phenyl-2-pyrazolin-5-one,
3-Isopropoxy-4-[(3-methylindol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-{[3-(2-methoxycarbonyl-2-acetamidoethyl)indol-2-yl]methylene}- 2-pyrazolin-5 -one, 3-Ethoxy-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-Ethoxy-4- {[3-(4-moφholinomethyl)indol-2-yl]methylene} -2-pyrazolin-5-one, 3-Cyclopropyl-4-{[3-(4-moφholinomethyl)indol-2-yl]methylene}-2-pyrazolin-5- one,
4-[(5-Methoxyindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(5-Methoxyindol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 4-[(4-Chloro-6,7-dihydroindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, 4-[(4-Chloro-6,7-dihydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(4-Oxo-l,5,6,7-dihydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4- [(3 -Dimethylaminomethylindol-2-yl)methylene] -3 -ethoxy-2-pyrazolin-5 -one, 4-[(7-Azaindol-3-yl)methylene]-3-benzyl-2-pyrazolin-5-one, 3-Benzyl-4-{[l-(4-hydroxybutyl)-7-azaindol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methoxyphenyloxymethyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Amino-4-[(7-azaindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methoxybenzyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-phenylamino-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methylbenzyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-hydroxyphenylethyl)-2-pyrazolin-5-one, 4- {[ 1 -(4-Hydroxybutyl)-7-azaindol-3-yl]methylene} -3-(4-hydroxyphenylethyl)-2- pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-isopropyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-cyclobutyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-phenyl-2-pyrazolin-5-one, 4- [(7- Azaindol-3 -yl)methylene] -3 -(4-fluorophenylamino)-2 -pyrazolin-5 -one, 4-[(7-Azaindol-3-yl)methylene]-3-propyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-methyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-trifluoromethyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(tert-butyl)-2-pyrazolin-5-one, 4- { [ 1 -(4-Hydroxybutyl)-7-azaindol-3 -yljmethylene} -3 -trifluoromethyl-2-pyrazolin- 5-one,
4-[(7-Azaindol-3-yl)methylene]-3-(4-isopropylphenylamino)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(3-methylphenylamino)-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)-7-azaindol-3-yl]methylene}-3-(3-methylphenylamino)-2- pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3-Benzyl-4-[(4-dimethylaminophenyl)methylene]-2-pyrazolin-5-one, 4-[(4-Dimethylaminophenyl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4- [(4-Dimethylaminophenyl)methylene] -3 -phenylethyl-2 -pyrazolin-5 -one, 3-Cyclopropyl-4-[(4-dimethylaminophenyl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(3-methylpyrazol-4-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-methylpyrazol-4-yl)methylene]-2-pyrazolin-5-one, 4-[(Imidazol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(imidazol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Imidazol-4-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(thien-2-yl)methylene]-2-pyrazolin-5-one,
4[(Indol-3-yl)methylene]-3-isopropyl-l-methyl-2-pyrazolin-5-one, 3-Isopropoxy-4-[(pyrrol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(8-Hydroxyquinolin-5-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-pyrimidinyl)- 2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3-pyridazinyl)- 2-pyrazolin-5 -one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one, 4- {[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene} -3-(2-thienyl)-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4-pyrimidinyl)- 2-pyrazolin-5 -one, 4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5-pyrimidinyl)- 2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4-pyridazinyl)- 2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(2-cyclopropylaminoethyl)-3,5-dimethylpyrrol-2- yl]methylene}-2-pyrazolin-5-one, 3-Cyclopropyl-4-{[3,5-dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-2- pyrazolin-5-one, 3-Cyclopropyl-4-{ {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2- yl} methylene} -2 -pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-cyclopropyl-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-diethylaminomethyl-3-isopropyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(l-pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2- yljmethylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{{3-isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2- y 1 } methylene } -2-pyrazolin- 5 -one,
3-Cyclopropyl-4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2- yljmethylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{ {4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- y 1 } methylene } -2-pyrazo lin- 5 -one, 3 -Cyclopropy 1-4- {[3 -isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2- yljmethylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{{4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5- methylpyrrol-2-yl} methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(4-dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2- yl]methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3-cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-4-(l-pirrolidinylmethyl)-5-methylpyrrol-2- yl]methylene} -2-pyrazolin-5-one, 3-Cyclopropyl-4- { {3 -cyclopropyl-5 -methyl-4- [2-( 1 -pyrrolidinyl)ethyl]pyrro 1-2- yl} methylene} -2 pyrazolin-5 -one,
3-Cyclopropyl-4-{{3-cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5- methylpyrrol-2-yl} methylene} -2-pyrazo lin-5-one, 3-Cyclopropyl-4-{[3-cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2- yl]methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-{ {3-cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5- methylpyrrol-2-yl} methylene} -2-pyrazo lin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol- 2-yl]methylene}-2-ρyrazolin-5-one,
3 -Cyclopropy 1-4- { {3-cyclopropyl-5-methyl-4-[4-(l -pyrrolidinyl)butyl]pyrrol-2- yl}methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4- { {3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
3-Pyrazinyl-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one, 3-Pyrazinyl-4-{{4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- [(3 -Cyclopropyl-4-diethylaminomethyl-5 -methylpyrrol-2-yl)methylene]-3 - pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-2-pyrazinyl-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminoρropyl)-5-methylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyπol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)- 2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one, 4- { {3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(2- furyl)-2-pyrazolin-5-one, 4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2-furyl)-
2-pyrazolin-5 -one,
4- {[4-(l -Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene} -3-(2- furyl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(2- furyl)-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- furyl)-2-pyrazolin-5-one,
3-(2-Furyl)-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -2-pyrazolin-5 -one,
3-(2-Furyl)-4-{[3-isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-
2-pyrazolin-5-one, 3-(2-Furyl)-4- { {4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -2-pyrazo lin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- furyl)-2 -pyrazolin-5 -one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- furyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(2-furyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(2-furyl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-(2- furyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(2-furyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(2-furyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2-furyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2-furyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2- thienyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4- {[3,5-Dimethyl-4-(2-ethylaminoethyl)-ρyrrol-2-yl]methylene} -3-(2- thienyl)-2- pyrazolin-5-one,
4- {[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene} -3-(2- thienyl)-2- pyrazolin-5-one, 4- { {3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- thienyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{4-[3-(l-Pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2-yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, 4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(2- thienyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl} methylene} -3-(2- thienyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl} methylene} -3-(2- thienyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(2- thienyl)-2 -pyrazolin-5 -one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2- thienyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2- thienyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyπOlidinylmethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(4-pyrimidinyl)-
2-pyrazolin-5-one,
4- { [3 ,5 -Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene } -3 -(4-pyrimidinyl)-
2-pyrazolin-5-one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3-(4- pyrimidinyl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyrimidinyl)-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{ {3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
3-(4-Pyrimidinyl)-4-{{4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one, 4- { {4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4- [(3-Cyclopropyl-4-diethylaminomethyl-5 -methylpyrrol-2-yl)methylene] -3 -(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl} methylene} -3-(4-pyrimidinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4- {[3 -Cyclopropyl-5 -methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(4-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-
2-pyrazolin-5 -one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(5-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyπOl-2-yl]methylene}-3-(5-pyrimidinyl)-
2-pyrazolin-5-one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3-(5- pyrimidiny l)-2-pyrazolin-5 -one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one, 4- {[4-(l -Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene} -3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
3-(5-Pyrimidinyl)-4-{{4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, 4- { {4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene} -3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(5-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
3-(2-Pyrimidinyl)-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidmobutyl)pyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5 -one, 4- { {4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene} -3-
(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(2-pyrimidinyl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-4-[3-(2,5-dimethyl-l -pyrrolidinyl)propyl]-5-methylpyrrol-2- yl} methylene} -3-(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yljmethylene} -3-(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(3-pyridazinyl)-
2-pyrazolin-5 -one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(3-ρyridazinyl)-
2-pyrazolin-5-one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3-pyridazinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5 -one,
4-{ {3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
3-(3-Pyridazinyl)-4-{{4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- y 1 } methylene } -2-pyrazolin- 5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one, 4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4- [(3 -Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene] -3 -(3 - pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(3-pyridazinyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl} methylene} -3 -(3-pyridazinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-5-methyl-4-[4-(l -pyrrolidinyl)butyl]pyrrol-2-yl} methylene} -3-
(3-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(3-pyridazinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(4-pyridazinyl)-
2-pyrazo lin- 5 -one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(4-pyridazinyl)-
2-pyrazolin-5-one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one, 4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5 -one, 4- {[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene} -3-(4-pyridazinyl)-2- pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
3-(4-Pyridazinyl)-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl } methylene } -2 -pyrazolin-5 -one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one, 4- { {4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(4-pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2 -pyrazolin-5 -one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl} methylene} -3-(4-pyridazinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(4-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(4-pyridazinyl)-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene} -3-
(4-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4- {[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene} -3-(l ,2,4-triazin-3- yl)-2-pyrazolin-5 -one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3-
(1,2,4- triazin-3-yl)-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(l,2,4-triazin-3-yl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- (l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{{4-[3-(l-Pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one, 4- { {4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-4-[3-(2,5-dimethyl- 1 -pyrrolidinyl)propyl]-5-methylpyrrol-2- yl} methylene} -3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4- { {3 -Cyclopropyl-5 -methyl-4- [4-( 1 -pyrrolidinyl)butyl]pyrrol-2-yl} methylene} -3 -
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4- {[4-(2-Diethylaminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4- { { 5 -Methyl-4- [2-( 1 -pyrrolidinyl ethyl)] -3 -trifluoromethylpyπOl-2-yl } methylene } -
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminoethyl)]-3-trifluoromethylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-trifluoromethylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4-{[4-(2-Aminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {5 -Methyl-4- [2-( 1 -pyrrolidinylethyl)] -3 -tert-butylpyrrol-2-yl} methylene} -3- pyrazinyl-2-pyrazolin-5 -one, 4-{[4-(2-Ethylaminoethyl)-5-methyl-3-tert-butylρyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminoethyl)]-3-tert-butylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-tert-butylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-tert-butylylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-{{3-Ethyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Ethyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4- { {3-Ethyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-ethylpyrrol-2-yl}methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-ethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4- {[3-Cyclobutyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin- 5 -one,
4- { {3 -Cyclobuty 1-5 -methyl-4- [2-( 1 -pyrrolidinylethyl)]pyrrol-2-yl} methylene} -3- pyrazinyl-2-pyrazolin- 5-one,
4-{[3-Cyclobutyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclobutyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclobutylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Aminoethyl)-5-methyl-3-cyclobutylpyrrol-2-yl]methylene} -3-pyrazinyl-2- pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {3-Cyclopentyl-5-methyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopentyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclopentylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4-{[4-(2-Aminoethyl)-5-methyl-3-cyclopentylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one
4-{[3-Cyclohexyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyraziny 1-2-pyrazo lin- 5 -one, 4-{{3-Cyclohexyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclohexyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclohexyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl } methylene } -3 -pyrazinyl-2-pyrazolin-5 -one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclohexylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-cyclohexylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-phenyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyraziny 1-2-pyrazolin- 5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{{5-Methyl-3-phenyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2-yl}methylene}-
3 -pyraziny 1-2-pyrazolin- 5 -one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-phenylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- {[4-(2-Aminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene} -3 -pyraziny 1-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-
3 -pyraziny 1-2-pyrazolin- 5 -one,
4- { {5-Methyl-3-(4-methoxyphenyl)-4-[2-(l -pyrrolidinylethyl)]pyrrol-2- yl} methylene} -3 -pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{{5-Methyl-3-(4-methoxyphenyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l -Imidazoyl)ethyl]-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { { 5-Methyl-3 -(2-pyridyl)-4- [2-( 1 -pyrrolidinylethyl)]pyrrol-2-yl } methylene} -3 - pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {5-Methyl-3-(2-pyridyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2-pyridyl)pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4- { [4-(2-Diethylaminoethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4- { { 5 -Methyl-3-pyrazinyl-4-[2-( 1 -pyrrolidinylethyl)]pyrrol-2-yl } methylene} -3 - pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-pyrazinyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)ethyl]-5-methyl-3-pyrazinylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Cyclopropylaminoethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2-imidazoyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Diethylaminoethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl } methylene} -3 -pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(2-pyrimidinyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(3-isoxazolyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Ethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{{5-Methyl-3-(3-isoxazolyl)-4-[2-(4-pyridylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-
3 -pyraziny 1-2-pyrazo lin-5 -one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-furyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3-ρyrazinyl-
2-pyrazolin-5-one,
4- { {5-Methyl-3-(2-furyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2-furyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin- 5-one,
4-{[4-(2-Diethylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene}- 3-pyrazinyl-2-pyrazolin-5-one,
4- { {5 -Hydroxymethyl-3 -isopropyl-4- [2-( 1 -pyrrolidinylethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Hydroxymethyl-3-isopropyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-hydroxymethyl-3-isopropylpyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{{3,5-Dicyclopropyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Ethylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4- { {3,5-Dicyclopropyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2-yl}methylene} -
3 -pyraziny l-2-pyrazolin-5 -one,
4-{ {4-[2-(l-Imidazoyl)ethyl]-3,5-dicyclopropylpyrrol-2-yl}methylene}-3-pyrazinyl- 2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Dimethylaminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene} -
3-pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-4-[2-(l -pyrrolidinylmethyl)]-3-trifluoromethylpyrrol-2- y 1 } methylene } - 3 -pyrazinyl-2-pyrazolin- 5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-4-[2-(4-pyridiylmethylaminomethyl)]-3-trifluoromethylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{ {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-trifluoromethylpyrrol-2-yl}methylene}-
3 -pyraziny 1-2-pyrazolin- 5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {5-Methyl-4-[2-(l -pyrrolidinylmethyl)]-3-tert-butylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Ethylaminomethyl)-5 -methyl-3 -tert-butylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5 -one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminomethyl)]-3-tert-butylpyrrol-2- yljmethylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-tert-butylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-tert-butylylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5 -one, 4- {[4-(2-Diethylaminomethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene} -3-pyrazinyl-
2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {3-Ethyl-5-methyl-4-[2-(l -ρyrrolidinylmethyl)]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Ethyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4- { {3-Ethyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2-yl]methylene} -
3-pyrazinyl-2-pyrazolin-5-one, 4- { {4- [2-( 1 -Imidazoyl)methyl] -5 -methyl-3-ethylpyrrol-2-yl } methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-ethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[3-Cyclobutyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclobutyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyraziny 1-2-pyrazo lin- 5 -one,
4-{{3-Cyclobutyl-5-methyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- {[3-Cyclobutyl-4-(2-ethylaminomethyl)-5-methylρyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{{3-Cyclobutyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-cyclobutylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Aminomethyl)-5-methyl-3-cyclobutylpyrrol-2-yl]methylene} -3-pyrazinyl-
2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopentyl-5-methyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {3-Cyclopentyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-cyclopentylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Aminomethyl)-5-methyl-3-cyclopentylpyrrol-2-yl]methylene}-3-pyrazinyl- 2-pyrazolin-5-one
4-{[3-Cyclohexyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclohexyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {3 -Cyclohexy 1-5 -methyl-4- [2-( 1 -pyrrolidinylmethyl)]pyrrol-2-yl} methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclohexyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{{3-Cyclohexyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-cyclohexylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-cyclohexylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one, 4- {[4-(2-Diethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3- pyrazinyl-2-ρyrazolin-5 -one,
4- { {5-Methyl-3-phenyl-4-[2-( 1 -pyrrolidinylmethyl)]pyrrol-2-yl} methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazo lin- 5 -one,
4- { {5-Methyl-3-phenyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- y 1 } methylene } -3 -pyrazinyl-2-pyrazolin- 5-one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-phenylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Aminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { [4-(2-Dimethylaminomethyl)-5-methyl-3 -(4-methoxyphenyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-3-(4-methoxyphenyl)-4-[2-(l -pyrrolidinylmethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}- 3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(4-methoxyphenyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{ {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Aminomethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-pyridyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {5-Methyl-3-(2-pyridyl)-4-[2-(4-pyridylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2-pyridyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Aminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3-pyrazinyl- 2-pyrazolin-5-one,
4- { [4-(2-Diethylaminomethyl)-5 -methyl-3 -pyraziny lpyrrol-2-yl]methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {{5-Methyl-3-pyrazinyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl} methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{ {5-Methyl-3-pyrazinyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-pyrazinylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Ethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2-imidazoyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Diethylaminomethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene} -
3-pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Dimethylaminomethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(l -pyrrolidinylmethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Ethylaminomethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4- { {5 -Methyl-3 -(2- pyrimidinyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-pyrimidinyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-3-(3-isoxazolyl)-4-[2-(l -pyrrolidinylmethyl)]pyrrol-2-yl} methylene} -
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-ρyrazolin-5-one, 4- { {5-Methyl-3-(3-isoxazolyl)-4-[2-(4-pyridylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(2-furyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{ {5-Methyl-3-(2-furyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2-furyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {5-Hydroxymethyl-3-isopropyl-4-[2-(l -pyrrolidinylmethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { [4-(2-Ethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene} -
3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Hydroxymethyl-3-isopropyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l-Imidazoyl)methyl]-5-hydroxymethyl-3-isopropylpyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4-{[4-(2-Dimethylaminomethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3,5-Dicyclopropyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { [4-(2-Ethylaminomethyl)-3 ,5-dicyclopropylpyrrol-2-yl]methylene} -3-pyrazinyl- 2-pyrazolin-5-one,
4-{{3,5-Dicyclopropyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-( 1 -Imidazoyl)methyl] -3 ,5 -dicyclopropylpyrrol-2-yl} methylene} -3 - pyrazinyl-2-pyrazolin-5-one, 4-[(4-Cyclopropylaminomethyl-3,5-dicyclopropylpyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[3-Cyclopropylaminomethyl-5-methyl-4-(2-diethylaminoethyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-ρyrazolin-5-one,
4-{[3-Cyclopropylaminomethyl-5-methyl-4-(2-hydroxyethyl)pyrrol-2- yl] methylene } -3 -pyrazinyl-2-pyrazolin-5 -one,
4-{[3-dimethylaminomethyl-5-methyl-4-(2-diethylaminoethyl)pyrrol-2- yljmethylene} -3-pyrazinyl-2-pyrazolin-5-one, and
4-{[3-hydroxymethyl-5-methyl-4-(2-diethylaminoethyl)ρyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one. Compounds of formula I may exist as salts with pharmaceutically acceptable acids. The present invention includes such salts. Examples of such salts include hydrochlorides, hydrobromides, sulphates, methanesulphonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g., (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
Certain compounds of formula I which have acidic substituents may exist as salts with pharmaceutically acceptable bases. The present invention includes such salts. Example of such salts include sodium salts, potassium salts, lysine salts and arginine salts. These salts may be prepared by methods known to those skilled in the art.
Certain compounds of formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof. Certain compounds of formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.
Certain compounds of formula I may contain one or more chiral centers, and exist in different optically active forms. When compounds of formula I contain one chiral center, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Altematively, specific enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.
When a compound of formula I contains more than one chiral center it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. The present invention includes each diastereoisomer of compounds of formula I and mixtures thereof. Certain compounds of formula I may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer of compounds of formula I and mixtures thereof.
Certain compounds of formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of compounds of formula I and mixtures thereof.
Certain compounds of formula I may exist in zwitterionic form and the present invention includes each zwitterionic form of compounds of formula I and mixtures thereof.
The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hypeφroliferative diseases, especially in the process of angiogenesis. For example, certain of these compounds are inhibitors of such receptor kinases as KDR, Flt-1, FGFR, PDGFR, c-Met, or IGF-l-R. Since these compounds are anti-angiogenic, they are important substances for inhibiting the progression disease states where angiogenesis is an important component. Certain compounds of the invention are effective as inhibitors of such serine/threonine kinases as erk, MAP kinases, cdks, Plk-1 or Raf-1. These compounds are useful in the treatment of cancer, and hypeφroliferative disorders. In addition, certain compounds are effective inhibitors of non-receptor kinases such as src, lyn, lck, fyn, blk, hck. These compounds are useful in the treatment of cancer, hypeφroliferative disorders and immunologic diseases.
The present invention provides a method of inhibiting the kinase activity of tyrosine kinases and serine/threonine kinases comprising the administration of a compound represented by formula I to said kinase in sufficient concentration to inhibit the enzyme activity of said kinase.
The present invention further includes the use of these compounds in pharmaceutical compositions with a pharmaceutically effective amount of the above- described compounds and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions can be administered to individuals to slow or halt the process of angiogenesis in angiogenesis-aided diseases, or to treat edema, effusions, exudates, or ascites and other conditions associated with vascular hypeφermeability. Certain pharmaceutical compositions can be administered to individuals to treat cancer and hypeφroliferative disorders by inhibiting serine/threonine kinases such as cdk,
Plk-1, erk, etc.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention have antiangiogenic properties. These antiangiogenic properties are due at least in part to the inhibition of protein tyrosine kinases essential for angiogenic processes. For this reason, these compounds can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, virally-induced angiogemc disorders, fractures, Crow-Fukase syndrome (POEMS), preeclampsia, menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy, retinopathy of prematurity, or age-related macular degeneration. In addition, some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hypeφroliferative disorders such as thyroid hypeφlasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma characteristic of polycystic ovarian syndrome (Stein-Leventhal syndrome)) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis. Further, some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, delayed-type hypersensitivity, ovarian hyperstimulation syndrome, brain tumor- associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hypeφermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease. The compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. keloid, fibrosis, cirrhosis and caφal tunnel syndrome). Increased VEGF production potentiates inflammatory processes such as monocyte recruitment and activation. The compounds of this invention will also be useful in treating inflammatory disorders such as inflammatory bowel disease (IBD) and Crohn's disease.
VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hypeφermeability and the formation of edema. Indeed, vascular hypeφermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production. Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF mediated responses. Vascular hypeφermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc. Hence, VEGF-mediated hypeφermeability can significantly contribute to disorders with these etiologic features. It is envisaged that the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the KDR/VEGFR-2 and/or the Flt-l/VEGFR-1 tyrosine kinases. By inhibiting the activity of these tyrosine kinases, the progression of the listed disorders is inhibited because the angiogenic or vascular hypeφermeability component of the disease state is severely curtailed. The action of certain compounds of this invention, by their selectivity for specific tyrosine kinases, result in a minimization of side effects that would occur if less selective tyrosine kinase inhibitors were used. Certain compounds of the invention are also effective inhibitors of FGFR, PDGFR, c-Met and IGF-l-R. These receptor kinases can directly or indirectly potentiate angiogenic and hypeφroliferative responses in various disorders, hence their inhibition can impede disease progression.
The compounds of this invention have inhibitory activity against protein kinases. That is, these compounds modulate signal transduction by protein kinases. Compounds of this invention inhibit protein kinases from serine/threonine and tyrosine kinase classes. In particular, these compounds selectively inhibit the activity of the KDR/FLK-1 /VEGFR-2 tyrosine kinases. Certain compounds of this invention also inhibit the activity of additional tyrosine kinases such as Flt- 1/VEGFR-l, FGFR, PDGFR, IGF-1R, c-Met, Src-subfamily kinases such as Lck, Src, fyn, yes, etc. Additionally, some compounds of this invention significantly inhibit serine/threonine kinases such as PKC, MAP kinases, erk, CDKs, Plk-1, or Raf-1 which play an essential role in cell proliferation and cell-cycle progression. The potency and specificity of the generic compounds of this invention towards a particular protein kinase can often be altered and optimized by variations in the nature, number and arrangement of the substituents (i.e., R„ R2, R3, R4, R5, Rg and R7) of and conformational restrictions. In addition the metabolites of certain compounds may also possess significant protein kinase inhibitory activity.
The compounds of this invention, when administered to individuals in need of such compounds, inhibit vascular hypeφermeability and the formation of edema in these individuals. These compounds act, it is believed, by inhibiting the activity of KDR tyrosine kinase which is involved in the process of vascular hypeφermeability and edema formation. The KDR tyrosine kinase may also be referred to as FLK-1 tyrosine kinase, NYK tyrosine kinase or VEGFR-2 tyrosine kinase. KDR tyrosine kinase is activated when vascular endothelial cell growth factor (VEGF) or another activating ligand (such as VEGF-C, VEGF-D, VEGF-E or HIV Tat protein) binds to a KDR tyrosine kinase receptor which lies on the surface of vascular endothelial cells. Following such KDR tyrosine kinase activation, hypeφermeability of the blood vessels occurs and fluid moves from the blood stream past the blood vessel walls into the interstitial spaces, thereby forming an area of edema. Diapedesis also often accompanies this response. Similarly, excessive vascular hypeφermeability can disrupt normal molecular exchange across the endothelium in critical tissues and organs (e.g., lung and kidney), thereby causing macromolecular extravasation and deposition. Following this acute response to KDR stimulation which is believed to facilitate the subsequent angiogenic process, prolonged KDR tyrosine kinase stimulation results in the proliferation and chemotaxis of vascular endothelial cells and formation of new vessels. By inhibiting KDR tyrosine kinase activity, either by blocking the production of the activating ligand, by blocking the activating ligand binding to the KDR tyrosine kinase receptor, by preventing receptor dimerization and transphosphorylation, by inhibiting the enzyme activity of the KDR tyrosine kinase (inhibiting the phosphorylation function of the enzyme) or by some other mechanism that interrupts its downstream signaling (D. Mukhopedhyay et al, Cancer Res. 58: 1278-1284 (1998) and references therein), hypeφermeability, as well as associated extravasation, subsequent edema formation and matrix deposition, and angiogenic responses, may be inhibited and minimized.
One group of preferred compounds of this invention have the property of inhibiting KDR tyrosine kinase activity without significantly inhibiting Flt-1 tyrosine kinase activity (Flt-1 tyrosine kinase is also referred to as VEGFR-1 tyrosine kinase). Both KDR tyrosine kinase and Flt-1 tyrosine kinase are activated by VEGF binding to KDR tyrosine kinase receptors and to Flt-1 tyrosine kinase receptors, respectively. Since Flt-1 tyrosine kinase activity may mediate important events in endothelial maintenance and vascular function, an inhibition of this enzyme activity may lead to toxic or adverse effects. At the very least, such inhibition is unnecessary for blocking the angiogenic responses, induction of vascular hypeφermeability and the formation of edema, so it is wasteful and of no value to the individual. Certain preferred compounds of this invention are unique because they inhibit the activity of one VEGF-receptor tyrosine kinase (KDR) that is activated by activating ligands but do not inhibit other receptor tyrosine kinases, such as Flt-1, that are also activated by certain activating ligands. The preferred compounds of this invention are, therefore, selective in their tyrosine kinase inhibitory activity.
The compounds of the present invention are also useful in the treatment of ulcers - bacterial, fungal, Mooren ulcers and ulcerative colitis. The compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Heφes simplex, Heφes Zoster, AIDS, parapoxvirus, psoriasis, Kaposi's sarcoma, protozoan infections and toxoplasmosis, endometriosis, ovarian hyperstimulation syndrome, preeclampsia, menometroπhagia, systemic lupus, sarcoidosis, synovitis, inflammatory bowel disease, Crohn's disease, sickle cell anaemia, Lyme's disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osier- Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, rheumatoid arthritis and osteoarthritis, and edema following burns, trauma, radiation, or stroke. The compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration. The compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, vascular occlusion and carotid obstructive disease.
The compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor-induced pleural or pericardial effusions, and malignant ascites.
The compounds of the present invention are also useful in the treatment of Crow-Fukase (POEMS) syndrome and diabetic conditions such as glaucoma, diabetic retinopathy and microangiopathy.
It is envisaged that the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the VEGF receptors (e.g. KDR and Flt-1). By inhibiting the activity of these receptor tyrosine kinases, the progression of the listed disorders is inhibited because the angiogenic component of the disease state is severely curtailed. The action of the compounds of this invention, by their selectivity for specific tyrosine kinases, result in a minimization of side effects that would occur if less selective tyrosine kinase inhibitors were used.
In another aspect the present invention provides compounds of formula I as defined initially above (including the provisos) for use as medicaments, particularly as inhibitors of protein kinase activity for example tyrosine kinase activity, serine kinase activity and threonine kinase activity. In yet another aspect the present invention provides the use of compounds of formula I as defined initially above (including the provisos) in the manufacture of a medicament for use in the inhibition of protein kinase activity. In this invention, the following definitions are applicable:
" Physiologically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or organic acids such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, lactic acid, tartaric acid and the like.
"Alkyl" refers to a saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups having 1 to 6 carbons or cyclic hydrocarbons having 3 to 6 carbons. "Alkoxy" refers to an "O-alkyl" group, where "alkyl" is defined as described above. Pharmaceutical Formulations
The compounds of this invention can be administered to a human patient by themselves or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate vascular hypeφermeability, edema and associated disorders. Mixtures of these compounds can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions. A therapeutically effective dose further refers to that amount of the compound or compounds sufficient to result in the prevention or attenuation of inappropriate neovascularization, progression of hypeφroliferative disorders, edema, VEGF- associated hypeφermeability and/or VEGF-related hypotension. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. Routes of Administration Suitable routes of administration may, for example, include oral, eyedrop, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Alternatively, one may administer the compound in a local rather than a systemic manner, for example, via injection of the compound directly into an edematous site, often in a depot or sustained release formulation.
Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with endothelial cell-specific antibody. Composition/Formulation
The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by combining the active compound with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this puφose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifiuoromethane, trichlorofiuoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compounds may be formulated for parenteral administration by injection, e.g. bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly or by intramuscular injection). Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
An example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethysulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
Many of the organic molecule compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the coπesponding free base forms. Effective Dosage
Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended puφose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cellular assays. For example, a dose can be formulated in cellular and animal models to achieve a circulating concentration range that includes the IC50 as determined in cellular assays (i.e., the concentration of the test compound which achieves a half-maximal inhibition of a given protein kinase activity). In some cases it is appropriate to determine the IC50 in the presence of 3 to 5% serum albumin since such a determination approximates the binding effects of plasma protein on the compound. Such information can be used to more accurately determine useful doses in humans. Further, the most preferred compounds for systemic administration effectively inhibit protein kinase signaling in intact cells at levels that are safely achievable in plasma. A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) and the ED50 (effective dose for 50% maximal response). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between MTD and ED50. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 pi). In the treatment of crises, the administration of an acute bolus or an infusion approaching the MTD may be required to obtain a rapid response.
Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data; e.g. the concentration necessary to achieve 50-90% inhibition of protein kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
Dosage intervals can also be determined using the MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90% until the desired amelioration of symptoms is achieved. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration. The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. Packaging
The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding
Examples. a) Capsules In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose can be de-aggregated and blended. The mixture can be filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound. b) Tablets
Tablets can be prepared from the following ingredients. Parts by weight
Active compound 10
Lactose 190
Maize starch 22
Polyvinylpyrrolidone 10 Magnesium stearate 3
The active compound, the lactose and some of the starch can be de-aggregated, blended and the resulting mixture can be granulated with a solution of the polyvinylpyrrolidone in ethanol. The dry granulate can be blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound. c) Enteric coated tablets
Tablets can be prepared by the method described in (b) above. The tablets can be enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanohdichloromethane (1:1). d) Suppositories
In the preparation of suppositories, 100 parts by weight of active compound can be incoφorated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients. For example, the compounds of this invention can be administered in combination with one or more additional pharmaceutical agents that inhibit or prevent the production of VEGF, attenuate intracellular responses to VEGF, block intracellular signal transduction, inhibit vascular hypeφermeability, reduce inflammation, or inhibit or prevent the formation of edema or neovascularization. The compounds of the invention can be administered prior to, subsequent to or simultaneously with the additional pharmaceutical agent, whichever course of administration is appropriate. The additional pharmaceutical agents include but are not limited to anti-edemic steroids, NSAIDS, ras inhibitors, anti-TNF agents, anti-IL-1 agents, antihistamines, PAF-antagonists, COX-1 inhibitors, COX-2 inhibitors, NO synthase inhibitors, PKC inhibitors and PI3 kinase inhibitors. The compounds of the invention and the additional pharmaceutical agents act either additively or synergistically. Thus, the administration of such a combination of substances that inhibit angiogenesis, vascular hypeφermeability and/or inhibit the formation of edema can provide greater relief from the deleterious effects of a hypeφroliferative disorder, angiogenesis, vascular hypeφermeability or edema than the administration of either substance alone. In the treatment of malignant disorders combinations with antiproliferative or cytotoxic chemotherapies or radiation are anticipated. The present invention also comprises the use of a compound of formula I as a medicament.
Both the Src and Syk families of kinases play pivotal roles in the regulation of immune function. The Src family currently includes Fyn, Lck, Fgr, Fes, Lyn, Src, Yes, Hck, and Blk. The Syk family is currently understood to include only Zap and Syk. The Janus family of kinases is involved in the transduction of growth factor and proinflammatory cytokine signals through a number of receptors. Although BTK and ITK, members of the Tec family of kinases, play a less well understood role in immunobiology, their modulation by an inhibitor may prove therapeutically beneficial. The kinases RIP, IRAK-1, IRAK-2, NIK, TPL-2/COT, IKK-1 and IKK- 2 are involved in the signal transduction pathways for the key pro-inflammatory cytokines TNF and IL-1. By virtue of their ability to inhibit one or more of these kinases, compounds of formula I may function as immunomodulatory agents useful for the maintenance of allografts and the treatment of autoimmune disorders. Through their ability to regulate T cell activation or the potentiation of an inflammatory process, these compounds could be used to treat such autoimmune diseases. Transplants due to rejection phenomena, either host versus graft for solid organs or graft versus host for bone marrow, are limited by the toxicity of cuπently available immunosuppressive agents and would benefit from an efficacious drug with improved therapeutic index. Gene targeting experiments have demonstrated the essential role of Src in the biology of osteoclasts, the cells responsible for bone resoφtion. Compounds of formula I, through their ability to regulate Src, may also be useful in the treatment of osteoporosis, osteopetrosis, Paget's disease, tumor- induced hypercalcemia and in the treatment of bone metastases.
A number of protein kinases have been demonstrated to be protooncogenes. Chromosome breakage (at the ltk kinase break point on chromosome 5), translocation as in the case of the Abl gene with BCR (Philadelphia chromosome), truncation in instances such as c-Kit or EGFR, or mutation (e.g., Met) result in the creation of dysregulated proteins converting them from protooncogene to oncogene products. In other tumors, oncogenesis is driven by an autocrine or paracrine ligand/growth factor receptor interactions. Members of the src-family kinases are typically involved in downstream signal transduction thereby potentiating the oncogenesis and themselves may become oncogenic by over-expression or mutation. By inhibiting the protein kinase activity of these proteins the disease process may be disrupted. Vascular restenosis may involve process of FGF and/or PDGF - promoted smooth muscle and endothelial cell proliferation. The ligand stimulation of FGFR, PDGFR, IGF1-R and c-Met in vivo is proangiogenic, and potentiates angiogenesis dependent disorders. Inhibition of FGFr, PDGFr , c-Met, or IGF1-R kinase activity may be an efficacious strategy for inhibiting these phenomena. Thus compounds of formula I which inhibit the kinase activity of normal or abeπant c-kit, c-met, c-fms, src-family members, EGFr, erbB2, erbB4, BCR-Abl, PDGFr, FGFr, IGF1-R and other receptor or cytosolic tyrosine kinases may be of value in the treatment of benign and neoplastic proliferative diseases.
In many pathological conditions (for example, solid primary tumors and metastases, Kaposi's sarcoma, rheumatoid arthritis, blindness due to inappropriate ocular neovascularization, psoriasis and atherosclerosis) disease progression is contingent upon persistent angiogenesis. Polypeptide growth factors often produced by the disease tissue or associated inflammatory cells, and their corresponding endothelial cell specific receptor tyrosine kinases (e.g., KDR/VEGFR-2, Flt- 1/VEGFR-l, Tie-2/Tek and Tie) are essential for the stimulation of endothelial cell growth, migration, organization, differentiation and the establishment of the requisite new functional vasculature. As a result of the "vascular permeability factor" activity of VEGF in mediating vascular hypeφermeability, VEGF- stimulation of a VEGFR kinase is also believed to play an important role in the formation of tumor ascites, cerebral and pulmonary edema, pleural and pericardial effusions, delayed-type hypersensitivity reactions, tissue edema and organ dysfunction following trauma, burns, ischemia, diabetic complications, endomefriosis, adult respiratory distress syndrome (ARDS), post-cardiopulmonary bypass-related hypotension and hypeφermeability, and ocular edema leading to glaucoma or blindness due to inappropriate neovascularization. In addition to VEGF, recently identified VEGF-C and VEGF-D, and virally-encoded VEGF-E or HIV-Tat protein can also cause a vascular hypeφermeability response through the stimulation of a VEGFR kinase. Tie-2 is expressed also in a select population of hematopoietic stem cells in which it may play a role in their recruitment, adhesion, regulation and differentiation (Blood , 4317-4326 (1997)); this Tie-2 expressing population may serve as circulating angiogenic endothelial progenitors. Certain agents according to formula I capable of blocking the kinase activity of endothelial cell specific kinases could therefore inhibit disease progression involving these situations.
The compounds of formula I or a salt thereof or pharmaceutical compositions containing a therapeutically effective amount thereof may be used in the treatment of benign and neoplastic proliferative diseases and disorders of the immune system. Such diseases include autoimmune diseases, such as rheumatoid arthritis, thyroiditis, type 1 diabetes, multiple sclerosis, sarcoidosis, inflammatory bowel disease, Crohn's disease, myasthenia gravis and systemic lupus erythematosus; psoriasis, organ transplant rejection (eg. kidney rejection, graft versus host disease), benign and neoplastic proliferative diseases, human cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), and diseases involving inappropriate vascularization for example diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization due to age-related macular degeneration, and infantile hemangiomas in human beings. In addition, such inhibitors may be useful in the treatment of disorders involving VEGF mediated edema, ascites, effusions, and exudates, including for example macular edema, cerebral edema, acute lung injury and adult respiratory distress syndrome (ARDS).
The compounds of the present invention may also be useful in the prophylaxis of the above diseases.
A further aspect of the present invention provides the use of a compound of formula I or a salt thereof in the manufacture of a medicament for treating vascular hypeφermeability, angiogenesis-dependent disorders, proliferative diseases and/or disorders of the immune system in mammals, particularly human beings. The present invention also provides a method of treating vascular hypeφermeability, inappropriate neovascularization, proliferative diseases and/or disorders of the immune system which comprises the administration of a therapeutically effective amount of a compound of formula I to a mammal, particularly a human being, in need thereof.
The in vitro potency of compounds in inhibiting these protein kinases may be determined by the procedures detailed below. The potency of compounds can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., synthetic peptide (Z. Songyang et al, Nature. 373:536-539) by a test compound relative to control. KDR Tyrosine Kinase Production Using Baculovirus System:
The coding sequence for the human KDR intra-cellular domain (aa789-1354) was generated through PCR using cDNAs isolated from HUVEC cells. A poly-His6 sequence was introduced at the N-terminus of this protein as well. This fragment was cloned into transfection vector pVL1393 at the Xba 1 and Not 1 site. Recombinant baculovirus (BV) was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 cells were grown in SF-900-II medium at 2 x 106/ml, and were infected at 0.5 plaque forming units per cell (MOI). Cells were harvested at 48 hours post infection. Purification of KDR
SF-9 cells expressing (His)6KDR(aa789-1354) were lysed by adding 50 ml of Triton X-100 lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, lmM PMSF, lOμg/ml aprotinin, 1 μg/ml leupeptin) to the cell pellet from 1L of cell culture. The lysate was centrifuged at 19,000 φm in a Sorval SS-34 rotor for 30 min at 4°C. The cell lysate was applied to a 5 ml NiCl2 chelating sepharose column, equilibrated with 50 mM HEPES, pH7.5, 0.3 M NaCl. KDR was eluted using the same buffer containing 0.25 M imidazole. Column fractions were analyzed using SDS-PAGE and an ELISA assay (below) which measures kinase activity. The purified KDR was exchanged into 25mM HEPES, pH7.5, 25mM NaCl, 5 mM DTT buffer and stored at -80°C. Human Tie-2 Kinase Production and Purification The coding sequence for the human Tie-2 infra-cellular domain (aa775-l 124) was generated through PCR using cDNAs isolated from human placenta as a template. A poly-His6 sequence was introduced at the N-terminus and this construct was cloned into transfection vector pVL 1939 at the Xba 1 and Not 1 site. Recombinant BV was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 insect cells were grown in SF-900-II medium at 2 x 106/ml, and were infected at MOI of 0.5. Purification of the His-tagged kinase used in screening was analogous to that described for KDR. Human Flt-1 Tyrosine Kinase Production and Purification
The baculoviral expression vector pVL1393 (Phar Mingen, Los Angeles, CA) was used. A nucleotide sequence encoding poly-His6 was placed 5' to the nucleotide region encoding the entire intracellular kinase domain of human Flt-1 (amino acids 786-1338). The nucleotide sequence encoding the kinase domain was generated through PCR using cDNA libraries isolated from HUVEC cells. The histidine residues enabled affinity purification of the protein as a manner analogous to that for KDR and ZAP70. SF-9 insect cells were infected at a 0.5 multiplicity and harvested 48 hours post infection.
EGFR Tyrosine Kinase Source
EGFR was purchased from Sigma (Cat # E-3641 ; 500 units/50 μl) and the EGF ligand was acquired from Oncogene Research Products/Calbiochem (Cat #
PF011-100).
Expression of ZAP70
The baculoviral expression vector used was pVL1393. (Pharmingen, Los
Angeles, Ca.) The nucleotide sequence encoding amino acids M(H)6 LVPR<,S was placed 5' to the region encoding the entirety of ZAP70 (amino acids 1-619). The nucleotide sequence encoding the ZAP70 coding region was generated through PCR using cDNA libraries isolated from Jurkat immortalized T-cells. The histidine residues enabled affinity purification of the protein (vide infra). The LVPRgS bridge constitutes a recognition sequence for proteolytic cleavage by thrombin, enabling removal of the affinity tag from the enzyme. SF-9 insect cells were infected at a multiplicity of infection of 0.5 and harvested 48 hours post infection.
Extraction and purification of ZAP70
SF-9 cells were lysed in a buffer consisting of 20 mM Tris, pH 8.0, 137 mM
NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1 μg/ml leupeptin, 10 μg/ml aprotinin and 1 mM sodium orthovanadate. The soluble lysate was applied to a chelating sepharose HiTrap column (Pharmacia) equilibrated in 50 mM HEPES, pH
7.5, 0.3 M NaCl. Fusion protein was eluted with 250 mM imidazole. The enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50 mM NaCl and 5 mM
DTT. Lck source
Lck or truncated forms of Lck may be commercially obtained ( e.g. from
Upstate Biotechnology Inc. (Saranac Lake, N.Y) and Santa Cruz Biotechnology Inc.
(Santa Cruz, Ca.)) or purified from known natural or recombinant sources using conventional methods. Enzyme Linked Immunosorbent Assay (ELISA) For PTKs
Enzyme linked immunosorbent assays (ELISA) were used to detect and measure the presence of tyrosine kinase activity. The ELISA were conducted according to known protocols which are described in, for example, Voller, et al, 1980, "Enzyme-Linked Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology, Washington, D.C.
The disclosed protocol was adapted for determining activity with respect to a specific PTK. For example, preferred protocols for conducting the ELISA experiments is provided below. Adaptation of these protocols for determining a compound's activity for other members of the receptor PTK family, as well as non- receptor tyrosine kinases, are well within the abilities of those in the art. For puφoses of determining inhibitor selectivity, a universal PTK substrate (e.g., random copolymer of poly(Glu4 Tyr), 20,000-50,000 MW) was employed together with ATP (typically 5 μM) at concentrations approximately twice the apparent Km in the assay.
The following procedure was used to assay the inhibitory effect of compounds of this invention on KDR, Flt-1, Flt-4/VEGFR-3, Tie-2, EGFR, FGFR, PDGFR, IGF-l-R, c-Met and ZAP70 tyrosine kinase activity: Buffers and Solutions: PGTPoly (Glu,Tyr) 4:l
Store powder at -20°C. Dissolve powder in phosphate buffered saline (PBS) for 50mg/ml solution. Store 1ml aliquots at -20°C. When making plates dilute to 250μg/ml in Gibco PBS. Reaction Buffer: 1 OOmM Hepes, 20mM MgCl2, 4mM MnCl2, 5mM DTT, 0.02%BSA, 200μM NaVO4, pH 7.10
ATP: Store aliquots of lOOmM at -20°C. Dilute to 20μM in water Washing Buffer: PBS with 0.1% Tween 20 Antibody Diluting Buffer: 0.1% bovine serum albumin (BSA) in PBS TMB Substrate: mix TMB substrate and Peroxide solutions 9:1 just before use or use K-Blue Substrate from Neogen Stop Solution: 1M Phosphoric Acid
Procedure
1. Plate Prep aration :
Dilute PGT stock (50mg/ml, frozen) in PBS to a 250μg/ml. Add 125μl per well of Corning modified flat bottom high affinity ELISA plates (Coming #25805-96). Add 125μl PBS to blank wells. Cover with sealing tape and incubate overnight 37°C. Wash lx with 250μl washing buffer and dry for about 2hrs in 37°C dry incubator. Store coated plates in sealed bag at 4°C until used.
2. Tyrosine Kinase Reaction:
-Prepare inhibitor solutions at a 4x concentration in 20% DMSO in water.
-Prepare reaction buffer -Prepare enzyme solution so that desired units are in 50μl, e.g. for KDR make to 1 ng/μl for a total of 50ng per well in the reactions. Store on ice.
-Make 4x ATP solution to 20μM from lOOmM stock in water. Store on ice
-Add 50μl of the enzyme solution per well (typically 5-50 ng enzyme/well depending on the specific activity of the kinase) -Add 25 μl 4x inhibitor
-Add 25 μl 4x ATP for inhibitor assay
-Incubate for 10 minutes at room temperature
-Stop reaction by adding 50μl 0.05N HCl per well
-Wash plate **Final Concentrations for Reaction: 5μM ATP, 5% DMSO
3. Antibody Binding
-Dilute lmg/ml aliquot of PY20-HRP (Pierce) antibody(a phosphotyrosine antibody)to 50ng/ml in 0.1% BSA in PBS by a 2 step dilution (lOOx, then 200x) -Add lOOμl Ab per well. Incubate 1 hr at room temp. Incubate lhr at 4C. -Wash 4x plate 4. Color reaction
-Prepare TMB substrate and add lOOμl per well
-Monitor OD at 650nm until 0.6 is reached
-Stop with 1M Phosphoric acid. Shake on plate reader. -Read OD immediately at 450nm
Optimal incubation times and enzyme reaction conditions vary slightly with enzyme preparations and are determined empirically for each lot.
For Lck, the Reaction Buffer utilized was 100 mM MOPSO, pH 6.5, 4 mM MnCl2,
20 mM MgCl2, 5 mM DTT, 0.2% BSA, 200 mM NaVO4 under the analogous assay conditions.
Compounds of formula I may have therapeutic utility in the treatment of diseases involving both identified, including those not mentioned herein, and as yet unidentified protein tyrosine kinases which are inhibited by compounds of formula I.
All compounds exemplified herein significantly inhibit KDR kinase at concentrations of 50 micromolar or below. Some compounds of this invention also significantly inhibit other PTKs such as lck at concentrations of 50 micromolar or below.
Cdc2 source
The human recombinant enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly, MA. USA) or purified from known natural or recombinant sources using conventional methods.
Cdc2 Assay
The protocol used was that provided with the purchased reagents with minor modifications. In brief, the reaction was carried out in a buffer consisting of 50mM Tris pH 7.5, lOOmM NaCl, ImM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and lOmM MgCl2 (commercial buffer) supplemented with fresh 300 μM ATP (31 μCi/ml) and 30 μg/ml histone type IIIss final concentrations. A reaction volume of
80μL, containing units of enzyme, was run for 20 minutes at 25 degrees C in the presence or absence of inhibitor. The reaction was terminated by the addition of 120μL of 10% acetic acid. The substrate was separated from unincoφorated label by spotting the mixture on phosphocellulose paper, followed by 3 washes of 5 minutes each with 75mM phosphoric acid. Counts were measured by a betacounter in the presence of liquid scintillant.
Certain compounds of this invention significantly inhibit cdc2 at concentrations below 50 uM. PKC kinase source
The catalytic subunit of PKC may be obtained commercially (Calbiochem). PKC kinase assay
A radioactive kinase assay was employed following a published procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M., Sakurai, A., Nishizuka, Y. Biochemical and Biophysical Research Communication 5:166, 1220-1227 (1990)). Briefly, all reactions were performed in a kinase buffer consisting of 50 mM Tris- HCl pH7.5, lOmM MgCl2, 2mM DTT, ImM EGTA, 100 μM ATP, 8 μM peptide, 5% DMSO and 33P ATP (8Ci/mM). Compound and enzyme were mixed in the reaction vessel and the reaction initiated by addition of the ATP and substrate mixture. Following termination of the reaction by the addition of 10 μL stop buffer (5 mM ATP in 75mM phosphoric acid), a portion of the mixture was spotted on phosphocellulose filters. The spotted samples were washed 3 times in 75 mM phosphoric acid at room temperature for 5 to 15 minutes. Incoφoration of radiolabel was quantified by liquid scintillation counting. Erk2 enzyme source
The recombinant murine enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly MA. USA) or purified from known natural or recombinant sources using conventional methods. Erk2 enzyme assay In brief, the reaction was carried out in a buffer consisting of 50 mM Tris pH
7.5, ImM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and 10 mM MgCl2 (commercial buffer) supplemented with fresh 100 μM ATP (31 μCi/ml) and 30μM myelin basic protein under conditions recommended by the supplier. Reaction volumes and method of assaying incoφorated radioactivity were as described for the PKC assay (vide supra). In Vitro Models for T-cell Activation
Upon activation by mitogen or antigen, T-cells are induced to secrete IL-2, a growth factor that supports their subsequent proliferative phase. Therefore, one may measure either production of IL-2 from or cell proliferation of, primary T-cells or appropriate T-cell lines as a surrogate for T-cell activation. Both of these assays are well described in the literature and their parameters well documented (in Current Protocols in Immunology, Vol 2, 7.10.1-7.11.2).
In brief, T-cells may be activated by co-culture with allogenic stimulator cells, a process termed the one-way mixed lymphophocyte reaction. Responder and stimulator peripheral blood mononuclear cells are purified by Ficoll-Hypaque gradient (Pharmacia) per directions of the manufacturer. Stimulator cells are mitotically inactivated by treatment with mitomycin C (Sigma) or gamma irradiation. Responder and stimulator cells are co-cultured at a ratio of two to one in the presence or absence of the test compound. Typically 105responders are mixed with 5 x 104 stimulators and plated (200 μl volume) in a U bottom microtiter plate (Costar Scientific). The cells are cultured in RPMI 1640 supplemented with either heat inactivated fetal bovine serum (Hyclone Laboratories) or pooled human AB serum from male donors, 5 x 10"5M 2mercaptoethanol and 0.5% DMSO, The cultures are pulsed with 0.5 μCi of 3H thymidine (Amersham) one day prior to harvest (typically day three). The cultures are harvested (Betaplate harvester, Wallac) and isotope uptake assessed by liquid scintillation (Betaplate, Wallac). The same culture system may be used for assessing T-cell activation by measurement of IL-2 production. Eighteen to twenty- four hours after culture initiation, the supernatants are removed and the IL-2 concentration is measured by ELISA (R and D Systems) following the directions of the manufacturer.
In-vivo Models of T-Cell Activation
The in vivo efficacy of compounds can be tested in animal models known to directly measure T-cell activation or for which T-cells have been proven the effectors. T-cells can be activated in vivo by ligation of the constant portion of the T-cell receptor with a monoclonal anti-CD3 antibody (Ab). In this model, BALB/c mice are given lOμg of anti-CD 3 Ab intraperitoneally two hours prior to exsanguination. Animals to receive a test drug are pre-treated with a single dose of the compound one hour prior to anti-CD3 Ab administration. Serum levels of the proinflammatory cytokines interferon-γ (IFN- γ) and tumor necrosis factor-α(TNF-α), indicators of T-cell activation, are measured by ELISA. A similar model employs in vivo T-cell priming with a specific antigen such as keyhole limpet hemocyanin (KLH) followed by a secondary in vitro challenge of draining lymph node cells with the same antigen. As previously, measurement of cytokine production is used to assess the activation state of the cultured cells. Briefly, C57BL/6 mice are immunized subcutaneously with 100 μg KLH emulsified in complete Freund's adjuvant (CFA) on day zero. Animals are pre-treated with the compound one day prior to immunization and subsequently on days one, two and three post immunization. Draining lymph nodes are harvested on day 4 and their cells cultured at 6 x 106per ml in tissue culture medium (RPMI 1640 supplemented with heat inactivated fetal bovine serum (Hyclone Laboratories) 5 x 10"5M
2-mercaptoethanol and 0.5% DMSO) for both twenty-four and forty-eight hours. Culture supernatants are then assessed for the autocrine T-cell growth factor Interleukin-2 (IL-2) and/or IFN-γ levels by ELISA.
Lead compounds can also be tested in animal models of human disease. These are exemplified by experimental auto-immune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). EAE models which mimic aspects of human multiple sclerosis have been described in both rats and mice (reviewed FASEB J. 5:2560-2566, 1991; murine model: Lab. Invest. 4(3):278, 1981; rodent model:! Immunol 146(4): 1163-8, 1991 ). Briefly, mice or rats are immunized with an emulsion of myelin basic protein (MBP), or neurogenic peptide derivatives thereof, and CFA. Acute disease can be induced with the addition of bacterial toxins such as bordetella pertussis. Relapsing/remitting disease is induced by adoptive transfer of T-cells from MBP/ peptide immunized animals.
CIA may be induced in DBA 1 mice by immunization with type II collagen (J. Immunol: 142(7):2237-2243). Mice will develop signs of arthritis as early as ten days following antigen challenge and may be scored for as long as ninety days after immunization. In both the EAE and CIA models, a compound may be administered either prophylactically or at the time of disease onset. Efficacious drugs should reduce severity and/or incidence.
Certain compounds of this invention which inhibit one or more angiogenic receptor PTK, and/or a protein kinase such as lck involved in mediating inflammatory responses can reduce the severity and incidence of arthritis in these models.
Compounds can also be tested in mouse allograft models, either skin (reviewed in Ann. Rev. Immunol., 10:333-58, 1992; Transplantation: 57(12): 1701-17D6, 1994) or heart (Am.J.Anat.: l 13:273, 1963). Briefly, full thickness skin grafts are transplanted from C57BL/6 mice to BALB/c mice. The grafts can be examined daily, beginning at day six, for evidence of rejection. In the mouse neonatal heart transplant model, neonatal hearts are ectopically transplanted from C57BL/6 mice into the ear pinnae of adult CBA/J mice. Hearts start to beat four to seven days post transplantation and rejection may be assessed visually using a dissecting microscope to look for cessation of beating.
Cellular Receptor PTK Assays The following cellular assay was used to determine the level of activity and effect of the different compounds of the present invention on KDR/VEGFR2.
Similar receptor PTK assays employing a specific ligand stimulus can be designed along the same lines for other tyrosine kinases using techniques well known in the art. VEGF-Induced KDR Phosphorylation in Human Umbilical Vein Endothelial
Cells (HUVEC) as Measured by Western Blots:
1. HUVEC cells (from pooled donors) were purchased from Clonetics
(San Diego, CA) and cultured according to the manufacturer directions. Only early passages (3-8) were used for this assay. Cells were cultured in 100 mm dishes (Falcon for tissue culture; Becton Dickinson; Plymouth, England) using complete
EBM media (Clonetics). 2. For evaluating a compound's inhibitory activity, cells were trypsinized and seeded at 0.5-1.0 x 105 cells/well in each well of 6-well cluster plates (Costar; Cambridge, MA).
3. 3-4 days after seeding, plates were 90-100% confluent. Medium was removed from all the wells, cells were rinsed with 5-10ml of PBS and incubated 18-
24h with 5ml of EBM base media with no supplements added (i.e., serum starvation).
4. Serial dilutions of inhibitors were added in 1ml of EBM media (25 μM, 5μM, or lμM final concentration to cells and incubated for one hour at 37 C. Human recombinant VEGF165 ( R & D Systems) was then added to all the wells in 2 ml of EBM medium at a final concentration of 50ng/ml and incubated at 37 C for 10 minutes. Control cells untreated or treated with VEGF only were used to assess background phosphorylation and phosphorylation induction by VEGF. All wells were then rinsed with 5-10ml of cold PBS containing ImM Sodium Orthovanadate (Sigma) and cells were lysed and scraped in 200μl of RIP A buffer (50mM Tris-HCl) pH7, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, ImM EDTA) containing protease inhibitors (PMSF ImM, aprotinin 1 μg/ml, pepstatin 1 μg/ml, leupeptin 1 μg/ml, Na vanadate ImM, Na fluoride ImM) and 1 μg/ml of Dnase (all chemicals from Sigma Chemical Company, St Louis, MO). The lysate was spun at 14,000 φm for 30min, to eliminate nuclei.
Equal amounts of proteins were then precipitated by addition of cold (-20 C) Ethanol (2 volumes) for a minimum of 1 hour or a maximum of overnight. Pellets were reconstituted in Laemli sample buffer containing 5% -mercaptoethanol (BioRad; Hercules, CA) and boiled for 5min. The proteins were resolved by polyacrylamide gel electrophoresis (6%, 1.5mm Novex, San Deigo, CA) and transfeπed onto a nitrocellulose membrane using the Novex system. After blocking with bovine serum albumin (3%), the proteins were probed overnight with anti-KDR polyclonal antibody (C20, Santa Cruz Biotechnology; Santa Cruz, CA) or with anti- phosphotyrosine monoclonal antibody (4G10, Upstate Biotechnology, Lake Placid, NY) at 4 C. After washing and incubating for 1 hour with HRP-conjugated F(ab)2 of goat anti-rabbit or goat-anti-mouse IgG the bands were visualized using the emission chemiluminescience (ECL) system (Amersham Life Sciences, Arlington Height, IL). Certain examples of the present invention significantly inhibit cellular VEGF- induced KDR tyrosine kinase phosphorylation at concentrations of less than 50 μM. In vivo Uterine Edema Model
This assay measures the capacity of compounds to inhibit the acute increase in uterine weight in mice which occurs in the first few hours following estrogen stimulation. This early onset of uterine weight increase is known to be due to edema caused by increased permeability of uterine vasculature. Cullinan-Bove and Koss (Endocrinology (1993), 755:829-837) demonstrated a close temporal relationship of estrogen-stimulated uterine edema with increased expression of VEGF mRNA in the uterus. These results have been confirmed by the use of neutralizing monoclonal antibody to VEGF which significantly reduced the acute increase in uterine weight following estrogen stimulation (WO 97/42187). Hence, this system can serve as a model for in vivo inhibition of VEGF signaling and the associated hypeφermeability and edema.
Materials: All hormones were purchased from Sigma (St. Louis, MO) or Cal Biochem (La Jolla, CA) as lyophilized powders and prepared according to supplier instructions. Vehicle components (DMSO, Cremaphor EL) were purchased from Sigma (St. Louis, MO).
Mice (Balb/c, 8-12 weeks old) were purchased from Taconic (Germantown, NY) and housed in a pathogen-free animal facility in accordance with institutional Animal Care and Use Committee Guidelines. Method:
Day 1 : Balb/c mice were given an intraperitoneal (i.p.) injection of
12.5 units of pregnant mare's serum gonadotropin (PMSG).
Day 3: Mice received 15 units of human chorionic gonadotropin
(hCG) i.p. Day 4: Mice were randomized and divided into groups of 5-10. Test compounds were administered by i.p., i.v. or p.o. routes depending on solubility and vehicle at doses ranging from 1-100 mg/kg. Vehicle control group received vehicle only and two groups were left untreated.
Thirty minutes later, experimental, vehicle and 1 of the untreated groups were given an i.p. injection of 17 -estradiol (500 μg/kg). After 2-3 hours, the animals were sacrificed by CO2 inhalation. Following a midline incision, each uterus was isolated and removed by cutting just below the cervix and at the junctions of the uterus and oviducts. Fat and connective tissue were removed with care not to disturb the integrity of the uterus prior to weighing (wet weight). Uteri were blotted to remove fluid by pressing between two sheets of filter paper with a one liter glass bottle filled with water. Uteri were weighed following blotting (blotted weight). The difference between wet and blotted weights was taken as the fluid content of the uterus. Mean fluid content of treated groups was compared to untreated or vehicle treated groups. Significance was determined by Student's test. Non-stimulated control group was used to monitor estradiol response. Results demonstrate that certain compounds of the present invention inhibit the formation of edema when administered systemically by various routes.
Certain compounds of this invention which are inhibitors of angiogenic receptor tyrosine kinases can also be shown active in a Matrigel implant model of neovascularization. The Matrigel neovascularization model involves the formation of new blood vessels within a clear "marble" of extracellular matrix implanted subcutaneously which is induced by the presence of proangiogenic factor producing tumor cells (for examples see: Passaniti, A., et al, Lab. Investig. (1992), 67(4), 519- 528; Anat. Rec. (1997), 249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701 ; Vase. Biol. (1995), 15(11), 1857-6). The model preferably runs over 3-4 days and endpoints include macroscopic visual/image scoring of neovascularization, microscopic microvessel density determinations, and hemoglobin quantitation (Drabkin method) following removal of the implant versus controls from animals untreated with inhibitors. The model may alternatively employ bFGF or HGF as the stimulus. Certain compounds of this invention which inhibit one or more oncogenic, protooncogenic, or proliferation-dependent protein kinases, or angiogenic receptor PTK also inhibit the growth of primary murine, rat or human xenograft tumors in mice, or inhibit metastasis in murine models.
EXEMPLIFICATION
The core structure of the compounds of the invention was synthesized via a base catalyzed aldol condensation followed by an elimination reaction. Scheme I is a general representation of this reaction. The appropriate starting materials, II and III, for making the compounds of general formula IV of the present invention synthesized in accordance with general Scheme I are commercially available and/or can be made according to methods well-known in the art and/or are enabled by the description provided herein.
Figure imgf000112_0001
II. III. IV.
Scheme I: General synthesis of 4-[(substituted) methylene]-2-pyrazolin-5-ones. I. 4-[(Pyrrol-2-yl)methylene]-2-pyrazolin-5-ones (V).
Figure imgf000112_0002
Example 1 : 3-Cyclopropyl-4-[(4,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin- 5-one. A reaction mixture of 3-cyclopropyl-2-pyrazolin-5-one (790 mg, 6.3 mmol), 4,5-dimethylpyrrole-2-carboxaldehyde (800 mg, 6.5 mmol), and piperidine 100 mg, in ethanol 50 mL was stirred at 90°C for 3.5 h. The solvent was removed under reduced pressure. The solid residue was purified by flash column chromatography using (3 : 7) ethyl acetate : hexane as the mobile phase, then further purified by recrystallization from toluene.
Example 40: 3-Tert-butylureido-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one. A reaction mixture of 3-amino-4-[(pyπol-2-yl)methylene]-2-pyrazoline-5- one (1.7 mmol) and tert-butylisocyanate (1 mL) in ethyl acetate 5 mL was stirred at 80°C for 2 h. The product was collected by filtration and recrystallized from ethanol. Example 88: 4- {[4-(2-Dimethylaminoethoxycarbonyl)-3, 5 -dimethy lpyrrol-2- yljmethylene} -3-isopropoxy-2-pyrazolin-5-one.
A mixture of 4-[(4-carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3- isopropoxy-2-pyrazolin-5-one (200 mg, 0.68 mmol) in dichloromethane (20 ml) and a drop of DMF, was treated with oxalyldichloride (0.2 ml). The stirring was continued for 24 h and a solution of dimethylaminoethanol (0.6g, 6.7 mmol) in dichloromethane (5ml) was added. The stirring was continued for 24 h. The solvent was evaporated to dryness, the solid residue was treated with NaHCO3 (5%) and extracted with dichloromethane. The solid obtained after elimination of the solvent was recrystallized from n-heptane. Example 194: 4- {[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrole-2-yl]methylene}- 3 -pyrazinyl-2 -pyrazolin-5 -one N-oxide
A mixture of Example 176 (0.2 g, 0.54 mmol) and m-chloroperbenzoic acid (0.2 g, 1.1 mmol) in chloroform (50 ml) was stirred at room temperature over 48 hrs. The solvent was removed to dryness and the residue purified by flash chromatography (dichloromethane/ethanol 9:1). Yield 30%, mp 192°C (ethanol) Table 1 : Other compounds synthesized having structural formula V.
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Table 1 A Physical data for compounds synthesized having structural formula V
Figure imgf000122_0002
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
209 212-216 65 55 65 49 7 15 1 7 38 22.93 22 31
* The molecular weight calculated for the elemental analysis mcludes the solvent in the amount indicated.
Footnote Maleate salts were formed by the addition of an ethanolic solution of maleic acid to the free base in ethanol at room temperature, followed by cooling, and filtration of the crystalline product
II. 4-[(Indol-3-yl)methylene]-2-pyrazolin-5-ones (VI).
Figure imgf000127_0001
Example 210: 3-Benzyl-4-[(mdol-3-yl)methylene]-2-pyrazolm-5-one.
A reaction mixture of 3-benzyl-2-pyrazolme-5-one (905 mg, 5.2 mmol), 3- indole carboxaldehyde (800 mg, 5.6 mmol) and pipendine (100 mg) in ethanol (50 mL) was stirred at 90°C for 3 h. After cooling overnight, the product was collected by filtration, then purified by recrystallization from ethanol
Table 2: Other compounds synthesized having structural formula VI.
Figure imgf000127_0002
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Table 2A- Physical data for compounds synthesized having structural formula VI
Figure imgf000130_0002
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0002
* The molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
Footnote: Maleate salts were formed by the addition of an ethanolic solution of maleic acid to the free base in ethanol at room temperature, followed by cooling, and filtration of the crystalline product.
III. 4-[(Indol-2-yl)methylene]-2-pyrazolin-5-one (Vπ).
Figure imgf000133_0001
Figure imgf000133_0003
Figure imgf000134_0001
Figure imgf000135_0001
Table 3A Physical data for compounds synthesized having structural formula VII.
Figure imgf000135_0002
Figure imgf000136_0002
* The molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
IV. 4-[(7-Azaindol-3-yl)methylene]-2-pyrazolin-5-ones (VIII).
Figure imgf000136_0001
Figure imgf000136_0003
Figure imgf000137_0001
Table 4A: Physical data for compounds synthesized having structural formula VIII.
Figure imgf000137_0002
* The molecular weight calculated for the elemental analysis includes the solvent in the amount indicated.
Footnote: Maleate salts were formed by the addition of an ethanolic solution of maleic acid to the free base in ethanol at room temperature, followed by cooling, and filtration of the crystalline product. V. 4- (Phenylmethylene)-2-pyrazolin-5-ones (IX).
Figure imgf000138_0001
Figure imgf000138_0003
Figure imgf000138_0004
VI. 4-[(Pyrazol-4-yl)methylene]-2-pyrazolin-5-ones (X).
Figure imgf000138_0002
X.
Figure imgf000139_0002
Table 6A: Physical data for compounds synthesized having structural formula X.
Figure imgf000139_0003
VII. 4-[(Imidazol-2-yl)methylene]-2-pyrazolin-5-ones (XI).
Figure imgf000139_0001
Table 7: Compounds synthesized having structural formula XI.
Figure imgf000139_0004
Table 7A: Physical data for compounds synthesized having structural formula XI.
Figure imgf000139_0005
VIII. 4-[(Imidazol-4-yl)methylene]-2-pyrazolin-5-ones (XII) IX.
Figure imgf000140_0001
XII.
Figure imgf000140_0003
Table 8 A: Physical data for compounds synthesized having structural formula XII.
Figure imgf000140_0004
IX. 4-[(Thien-2-yl)methylene]-2-pyrazolin-5-ones (XIII).
Figure imgf000140_0002
Figure imgf000140_0005
Table 9A: Physical data for compounds synthesized having structural formula XIII.
X. 4-[(Indol-3-yl)methylene]-l-methyl-2-pyrazolin-5-ones (XIV).
Figure imgf000141_0001
Table 10: Compound synthesized having structural formula XIV.
Figure imgf000141_0003
Table 10A: Physical data for compounds synthesized having structural formula XIV.
Figure imgf000141_0004
XI. 4-[(Pyrrol-3-yl)methylene]-2-pyrazoline-5-ones (XV)
Figure imgf000142_0001
XV.
Table 11 : Compound synethesized having structural formu a XV.
Example Substituent R1 Recrystallization Solvent % Method on pyrrole Yield
369 none isopropoxy methanol 70 see Example 210
Table 11 A: Physical data for compounds synthesized having structural formula XV.
Figure imgf000142_0003
XII. 4-[(Quinolin-5-yl)methylene]-2-pyrazoline-5-ones (XVI)
Figure imgf000142_0002
XVI.
Figure imgf000143_0002
Table 12 A: Physical data for compounds synthesized having structural formula XVI.
Figure imgf000143_0003
X. Synthesis of Starting Materials.
A. Synthesis of 3-ketoesters (XIX).
The general method used to synthesize 3-ketoesters is shown in Scheme II.
o l
Figure imgf000143_0001
X IX .
Scheme II: Synthesis of 3-ketoesters Example 371 : Ethyl 3-(2,2,3,3-tetramethylcyclopropyl)-3-oxopropionate.
Pyridine (5 g, 0.063 mol) and 2,2,3, 3 -tetramethy .cyclopropyl carbonyl chloride (5 g, 0.031 mol) were added to an ice-cold solution of 2,2-dimethyl-l,3- dioxane-4,7-dione (4.7 g, 0.032 mol) in anhydrous dichloromethane (37 mL) under a nitrogen atmosphere. The temperature was maintained at 0°C for 1 h, then was allowed to raise to room temperature overnight. The mixture was then transferred to a separatory funnel, washed twice with 3% hydrochloric acid and twice with water.
The organic layer was dried over magnesium sulfate, then filtered and concentrated under reduced pressure to give 5 g of a dark red oil. The oil was refluxed for 3 h in anhydrous ethanol (60 mL). The solvent was evaporated and the product was purified by distillation.
Example 377: Ethyl 3-(6-methoxybenzothiazol-2-yl)-3-oxopropionate.
Ethyl acetate (7.2 g, 0.082 mol) was added to sodium hydride (1.5 g of a 50
% dispersion in oil, 0.032 mol), keeping the temperature below 25°C. 2- Ethoxycarbony-2-(6-methoxy)benzofhiazole (5.25 g, 0.022 mol) was added. The mixture was warmed to reflux gently and then stirred at room temperature overnight.
The reaction was quenched with ice water (50 mL) and the pH was adjusted to 7.7 with concentrated hydrochloric acid. The product precipitated out and was collected by filtration, washed with water, then dried. Example 378: Ethyl 4-(4-phenylphenyloxy)-3-oxobutanoate.
Sodium hydride (5.0 g, 0.114 mole) and 4-phenylphenol (15.3 g, 0.09 mol) were stirred at 0°C in 75 mL of dimethyl formamide (hereinafter "DMF") for 2 h.
Ethyl 4-chloroacetoacetate (5.0 g, 0.03 mol) in DMF (75 mL) was added. The mixture was stirred for 1 h at 0°C and for 12 h at room temperature, then neutralized with 50 % phosphoric acid and extracted with dichloromethane. The product was purified by silica gel chromatography using (8 : 2) toluene : ethanol as the mobile phase. Table 13: Compounds synthesized having structural formula XIX.
Figure imgf000145_0002
B. Synthesis of Ethyl Cyclopentyloxythiocarbonylacetate.
Figure imgf000145_0001
XX. XXI. XXII.
Scheme III: Synthesis of ethyl alkyloxy or aryloxy carbonimidoyl acetate hydrochloride (R9 is a substituted or unsubstituted aliphatic or aromatic group). Example 381 : Synthesis of ethyl cyclopentyloxycarbonimidoyl acetate hydrochloride (XXII).
A mixture of dry ethyl cyanoacetate (14 g, 0.12 mol) and dry cyclopentanol (12 g, 0.15 mol) was saturated at 0°C with hydrogen chloride gas for 3 hours, kept at 0°C overnight, then diluted with diethylether. The product precipitated out and was collected by filtration and washed with ether. Yield 22.4 g, (77%) m.p. 110-112°C.
Figure imgf000146_0001
XXII. XXIV.
Scheme IV: Synthesis of ethyl alkyloxythio or aryloxythio carbonylacetate. Example 382: Ethyl cyclopentyloxythiocarbonylacetate (XXTV)
A mixture of ethyl cyclopentyloxycarbonimidoyl acetate hydrochloride (22 g 0.09 mol) in anhydrous pyridine (150 ml) is treated with hydrogen sulfide for 8 hours and kept at room temperature for 48 hours. The mixture reaction was acidified with concentrated hydrochloric acid and extracted with diethyl ether. The ethereal phase was washed with water, dried and purified by distillation.
Yield 15 g, (75%) b.p. 140-142°C (15 mm Hg).
C. Synthesis of 2-pyrazolin-5-ones.
2-Pyrazolin-5-ones were synthesized by the following four methods.
Figure imgf000147_0001
XXV. XXVI.
Scheme V: Method 1 for synthesizing 2-pyrazolin-5-ones.
Figure imgf000147_0002
XXVII. XXVIII
Scheme VI: Method 2 for synthesizing 2-pyrazolin-5-ones.
Figure imgf000147_0003
XXIX. XXX.
Scheme VII: Method 3 for synthesizing 2-pyrazolin-5-ones. Acetic acid
Figure imgf000148_0001
XXXI. XXXII.
Figure imgf000148_0002
Scheme VIII: Method 4 for synthesizing 2-pyrazolin-5-ones. Example 383: 3-(2,2,3,3-Tetramethylcyclopropyl)-2-pyrazolin-5-one.
Hydrazine hydrate (1.1 g, 0.024 mol) was added to a solution of ethyl 3- (2,2,3, 3-tetramethylcyclopropyl-3-oxopropionate (4.41 g, 0.020 mol) in anhydrous ethanol (60 ml). The reaction mixture refluxed for 3 h. After cooling, the solvent was evaporated, and the residue was triturated with hexane to give a white solid. Example 411 : 3-(4-Hydroxybenzyl)-2-pyrazolin-5-one
A stirred suspension of 3-(4-methoxybenzyl)-2-pyrazolin-5-one 2.5 mmol in dichloromethane 100 ml cooled at -78°C, was treated with boron tribromide 7.5 ml (1M in dichloromethane). After 1 hour at -78°C the reaction mixture was stirred at room temperature for 12 hours. The mixture was quenched with water 50 ml. The aqueous phase was separated out, and basified with 5%> sodium bicarbonate solution. The formed precipitate was filtered and crystallized from methanol.
Example 413: 3-(4-Carbamoylphenylethyl)-2-pyrazolin-5-one
A mixture of 3-(4-methoxycarbonylphenylethyl)-2-pyrazolin-5-one (7.7 mmol) in ammonium hydroxide 25%> (30 ml), was stirred at room temperature for 12 hours. The solvent was concentrated in vacuo and the solid product formed was filtered and dried.
Example 414: 3-(2-Aminocarbonylethyl)-2-pyrazolin-5-one
A mixture of 3 -(ethoxycarbony lmethyl)-2 -pyrazolin-5 -one (1 g, 5.8 mmol) and NaCN (28 mg, 0.58 mmol) in 30 ml of 9M ammonia in MeOH was heated to 45°C in sealed tube for 3 days. After cooling, the solvent was evaporated and the residue was suspended in water. The precipitated solid was collected by filtration.
Example 416 : 3-(4-Methoxyphenylamino)-2-pyrazolin-5-one
A mixture of 3-amino-2-pyrazolin-5-one (20 mmol), 4-methoxyaniline (25 mol) in 50 ml of acetic acid was refluxed for 4 hours. The solvent was evaporated, the residue was suspended in water. The solid was filtered and crystallized from methanol.
Table 14: Compounds synthesized having structural formula XXVI.
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
D. Synthesis of Aldehydes
Example 426: l-(4-Acetoxybutyl)-azaindole-3-carboxaldehyde A solution of 7-azaindole-3 -carboxaldehyde (4.19 g, 28 mmol) in dry N,N dimehylformamide (50 ml) was added dropwise, keeping the temperature between 5- 10°C, to a stirring suspension of 60% sodium hydride (oil dispersion) (1.2 g, 30 mmol) in dry DMF (65 ml) under nitrogen atmosphere. After addition was completed, stirring was continued at the same temperature for 30 min., then a solution of 4-bromobutylacetate (6.16 g, 31 mmol) in dry N,N-dimethylforrnamide (15 ml) was added dropwise, and the mixture was allowed to warm to room temperature. The reaction mixture was stirred at room temperature for 137 h, then water (100 ml) was added, and the mixture extracted with dichloromethane (2 x 100 ml). The organic phase was washed with water (3 x 100 ml), dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduce pressure to give an oil (6.8 g, 93%) which was used without further purification. Example 427: l-(4-Hydroxybutyl)-7-azaindole-3-carboxaldehyde A solution of sodium hydroxide (0.2 g, 17.5 mmol) in water (35 ml) was added to a solution of l-(4-acetoxybutyl)-7-azaindole-3-carboxaldehyde (2.3 g, 8.8 mmol) in methanol (40 ml). The mixture was heated at 60°C for 0.5 h, then the solvent was evaporated to dryness. The residue was dissolved in a mixture of ethyl acetate and water (50 ml : 50 ml) and the water layer was separated out. The organic phase was washed with water, dried over magnesium sulfate, filtered and evaporated to dryness. The residue was used without further purification. Yield 78%>. m.p. 90°C. Example 428: l-(4-Hydroxybutyl)pyrrole-2-carboxaldehyde
The product was obtained following the procedure in Example 51 except that pyrrole-2-carboxaldehyde was used instead of 7-azaindole-3-carboxaldehyde. The product was purified by silica gel chromatography using (5:5) ethyl acetate : hexane. Yield 67%. Example 429: 3-Isopropyl-5-methylpyrrole-2-carboxaldehyde
To a solution of anhydrous DMF (2.1 ml, 27 mmol) in anhydrous dichloroethane (50 ml) at 0°C under nitrogen, POCl3 (2.1 ml, 23 mmol) was added dropwise. The solution was allowed to warm at room temperature for lh. Then, the suspension was cooled at 0°C and a solution of 3-isopropyl-5-methylpyrrole (2g, 16 mmol) in dichloroethane (20 ml) was added dropwise over 20 min. After stirring at room temperature for 24 h, water followed by NaOH were added to pH:8. The organic layer was extracted, dried and the solvent removed to dryness. The residue was purified by flash chromatography. Yield 67%, m.p. 90-93°C. Example 430: 3,5-Dimethyl-4-morpholinomethylpyrrole-2-carboxaldehyde
3,5-Dimethylpyrrole-2-carboxaldehyde (0.5g, 4 mmole) was added to a solution of morpholine (0.35 g, 4 mmol), formaldehyde 37% (0.32 g, 4 mmol) and acetic acid (2ml). The mixture was stired overnight at room temperature under nitrogen, then the reaction was diluted with NaHCO3 to pH 8. The aqueous solution was extracted with ethylacetate and the organic layer was dried over Mg SO4. The ethylacetate was evaporated in vacuo to give 0.4 g of pure solid. The following compounds were synthesized by a method analogous to the method described in Example 430:
3,5-Dimethyl-4-dimethylaminomethylpyrrole-2-carboxaldehyde, 3-(4- morpholino)methyl-indole-2-carboxaldehyde, 3,5-dimethyl-4-diethylaminomethylpyrrole-2-carboxaldehyde, 3,5-dimethyl-4-piperidinomethylpyrrole-2-carboxaldehyde, 3,5-dimethyl-4-[(4-methyl-l-piperazinyl)methyl]pyrrole-2-carboxaldehyde, 3,5-dimethyl-4-(l-pyrrolidinylmethyl)pyrrole-2-carboxaldehyde, 5-methyl-4-dimethylaminomethylpyrrole-2-carboxaldehyde, 3,5-dimethyl-4-[N-methyl-N-(2-dimethylaminoethyl)aminomethyl]pyrrole-2- carboxaldehyde,
3,5-dimethyl-4-diethanolaminomethylpyrrole-2-carboxaldehyde, 4-(4-benzylpiperidinomethyl)-3,5-dimethylpyrrole-2-carboxaldehyde, 4-dimethylaminomethyl-3-isopropyl-5-methylpyrrole-2-carboxaldehyde, 3,5-dimethyl-4-(4-hydroxypiperidinomethyl) pyrrole-2-carboxaldehyde, and 3-dimethylaminomethyl-4,5-tetramethylenepyrrole-2-carboxaldehyde. Example 431 : 3,5-Dimethyl-4-trifluoroacetamidomethylpyrrole-2-carboxaldehyde A mixture of 3,5-dimethylpyrrole-2-carboxaldehyde (2.6g, 0.02 mol) and N- (hydroxymethyl)trifluoroacetamide (3g, 0.02 mol) was added in portionwise to sulfuric acid (15 ml) keeping the temperature below 10°C. The mixture of reaction was allowed to warm at room temperature for 4h. The reaction was poured into ice- water (100 ml), the precipitated solid was filtered and washed with water. The white solid (yield, 78%>) was used without further purification. M.p. 200°C. Example 432: 4-Aminomethyl-3,5-dimethylpyrrole-2-carboxaldehyde A mixture of 3,5-dimethyl-4-trifluoroacetamidomethylpyrrole-2- carboxaldehyde (3.9 g, 15.7 mmol), NaOH 10%, (19 ml) and methanol (100 ml) was heated to reflux for lh. The solution was concentrated to half volume under reduced pressure. Water was added and the precipitated solid was filtered. Yield 72%, m.p. 210-20°C (d). Example 433: 3-Acetyl-4-oxopentylacetate
A mechanically stirred mixture of pentane-2,4-dione (60 g, 0.6 mol), 2- bromoefhylacetate (100 g, 0.6 mol), anhydrous potassium carbonate (83 g, 0.6 mol), IK (99.6 g, 0.6 mol) and dry acetone (500 ml) was heated under reflux for 24 h. The mixture was concentrated under reduced pressure and poured into hydrochloric acid (1.7 M, 400 ml). The product was isolated by successive extractions with ether, ethyl acetate and dichloromethane. The combined organic extracts were washed with brine, the solvent removed to dryness and the residue distilled to give 38 g of the acetate b.p. 75-80°C (0.1 mm Hg). 4-Acetyl-5-oxohexyl acetate [yield 60%, b.p. 110°C (0.2 mm Hg)], and 5-
Acetyl-6-oxoheptyl acetate [yield 77%, b.p. 102°C (0.2 mm Hg)] were prepared by the method described in Example 433.
Example 434: tert-Butyl 4-(2-acetoxyethyl)-3,5-dimethylpyrrole-2-carboxylate A stirred solution of tert-butylacetoacetate (26 g, 0.165 mol) in acetic acid (48 ml) was treated below 20°C by the dropwise addition of sodium nitrite (11.3 g, 0.165 mol) in water (17 ml) and left to stand overnight.
A solution of 3-acetyl-4-oxopentylacetate (30 g, 0.161 mol) in acetic acid (56 ml) was heated to 80°C when a mixture of zinc dust (26.2 g, 0.40 mol), and sodium acetate (26.3 g, 0.32 mol) was added portion wise while the above hydroximino derivative (97 ml, 0.165 mol) was added dropwise. The reaction mixture was stirred vigorously during the addition which was regulated so that zinc was always in excess and the temperature remained between 90-100°C. When the addition was complete the mixture was boiled gently for 15 min and stirred to room temperature overnight. The reaction mixture was poured into ice-water and allowed to stand over 2 hr. The solid was filtered and washed with water and recrystallized from aqueous ethanol. Yield 78%, m.p. 92°C. tert-Butyl 4-(3-acetoxypropyl)-3,5-dimethylpyrrole-2-carboxylate [yield 60%, m.p. 73°C (hexane)] and tert-Butyl 4-(4-acetoxybutyl)-3,5-dimethylpyrrole-2- carboxylate [yield 52%o, m.p. 62°C (hexane)] were prepared by the method described in Example 434. Example 435 : 3,5-Dimethyl-4-(2-hydroxyethyl)pyrrole-2-carboxaldehyde. tert-Butyl 4-(2-acetoxyethyl)-3,5-dimethylpyrrole-2-carboxylate (15 g, 53 mmol) was dissolved in TFA (40 ml) and the solution was stirred at 40°C under nitrogen for 10 min. The reaction mixture was then cooled to 0°C and triethylorthoformate (9.6 ml, 58 mmol) was added dropwise. The mixture was allowed to warm up to 20°C and was stirred for lhr before being poured into ice water. This was extracted with dichloromethane and the extracts were washed successively with 10% aqueous ammonia and water and dried over MgSO4. 4-(2- acetoxyethyl)-3,5-dimethylpyrrole-2-carboxaldehyde was purified by silica gel chromatography using (7:3) ethyl acetate:hexane. Yield 45%>, m.p. 125-27°C (water). To a solution of the above compound (5g, 23 mmol) in ethanol (20 ml), NaOH 10%) (10 ml) was added. The mixture was stirred at room temperature for 30 min., and the final solution was concentrated, diluted with water and extracted with dichloromethane. The organic extracts were dried and the solvent was removed to dryness. Yield 98%, m.p. 100°C (ethyl acetate).
3,5-Dimethyl-4-(3-hydroxypropyl)pyrrole-2-carboxaldehyde [yield 60%>, m.p. 85°C (ethyl acetate/hexane)] and 3,5-Dimethyl-4-(4-hydroxybutyl)pyrrole-2- carboxaldehyde [yield 38%, m.p. 99°C (hexane)] were prepared by the method described in Example 435. Example 436: 4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-carboxaldehyde. Methanesulfonyl chloride (4 ml, 51 mmol) in THF anhydrous (4 ml) was added to a stirred solution of 3,5-dimethyl-4-(2-hydroxyethyl)pyrrole-2- carboxaldehyde (4.3 g, 25.7 mmol) and triethylamine (5.2 g, 51 mmol) in THF anhydrous (60 ml) at 0-5°C and the mixture was stirred for 1 h at room temperature. Water was then added to the mixture and the precipitated solid was filtered. Yield 89%, m.p. 142-44°C.
A mixture of the above mesilate (23 mmol), K2CO3 (23 mmol), diethylamine (90 mmol) and 2-propanol (70 ml) was heated to 100°C for 0.5 h. The solvent was removed to dryness and the residue treated with water and extracted with methylenchloride. The organic extracts were dried and the solvent evaporated to dryness. Yield 70%, m.p.70°C (n-heptane). 3,5-Dimethyl-4-[2-(l-pyrrolidinylethyl)]pyrrole-2-carboxaldehyde, 3,5- Dimethyl-4-(2-ethylaminoethyl)pyrrole-2-carboxaldehyde, 4-(3- Diethylaminopropyl)-3,5-dimethylpyrrole-2-carboxaldehyde, 4-(4- Diethylaminobutyl)-3,5-dimethylpyrrole-2-carboxaldehyde, 3,5-Dimethyl-4-[3-(l- pyrrolidinylpropyl)]pyrrole-2-carboxaldehyde were isolated as oils and were prepared by a method analogous to the method described in Example 436. Example 437: 4-(2-Chloroacetyl)-3,5-dimethylpyrrole-2-carboxaldehyde
Anhydrous aluminum chloride (42 g, 315 mmol) was added portionwise over 30 min to a room temperature solution of 3,5-dimethylpyrrol-2-carboxaldehyde (5 g, 40 mmol) in 1,2-dichloroethane (50 ml) under nitrogen. After stirring for 15 min, chloroacetyl chloride (17 g, 150 mmol) was added dropwise over lh. After addition was complete, the mixture was stirred at room temperature for 16 h. The mixture was poured onto crushed ice and the organic layer separated, dried over anhydrous sodium sulfate, and the solvent removed under reduced pressure. Yield 57%, m.p. 205-09°C (toluene).
Example 438: 3,5-Dimethyl-4-(2-diethylaminoacetyl)pyrrole-2-carboxaldehyde
Diethylamine (5 ml) was added to a solution of 4-(2-Chloroacetyl)-3,5- dimethylpyrrole-2-carboxaldehyde (1 g, 5 mmol) in THF (20 ml). The mixture was stirred at room temperature for 24 h. The solvent was removed under reduced pressure and the residue was treated with water, NaHCO3 (5%) and extracted with dichloromethane. After drying and filtering, the solvent was removed and the residue was used without further purification.
3,5-Dimethyl-4-(2-dimethylaminoacetyl)pyrrole-2-carboxaldehyde, 3,5- Dimethyl-4-[2-(l-pyrrolidinyl)acetyl]pyrrole-2-carboxaldehyde were synthesized by a method analogous to the method described in Example 438.
Example 439: 3,5-Dimethyl-4-ethoxyoxalylpyrrole-2-carboxaldehyde
Anhydrous aluminum chloride (37 g, 277 mmol) was added portionwise over 30 min to a room temperature solution of 3,5-dimethylpyrrol-2-carboxaldehyde (7.6 g, 62 mmol) in 1,2-dichloroethane (140 ml) under nitrogen. After stirring for 30 min, nitromethane (11.2 ml, 179 mmol) was added. The mixture was cooled at 0°C and ethyl chlorooxoacetate (12.8 g, 94 mmol) was added dropwise over lh. After addition was complete, the mixture was stirred at room temperature for 4 h. The mixture was poured onto crushed ice and the organic layer separated, dried, and the evaporation afforded a white solid. Yield 45%, m.p. 125-127°C (toluene).
All compounds of the foregoing Examples had NMR spectral data that were consistent with the respective chemical structures.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

CLAIMSWhat is claimed is:
1. A method of inhibiting one or more protein kinase activity comprising the administration of a compound represented by the formula:
Figure imgf000158_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein: R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z; R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or -(CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-5 -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and - NR4R5; R3 for each occurrence is independently selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
2. The method of claim 1 wherein the inhibition of said protein kinase is in a recipient in need thereof.
3. The method of Claim 2 wherein the compound is a mixture of stereoisomers.
4. The method of Claim 3 wherein the stereoisomers are enantiomers.
5. The method of Claim 3 wherein the stereoisomers are E and Z isomers.
6. The method of Claim 2 wherein the compound is a mixture of structural isomers.
7. The method of Claim 6 wherein the structural isomers are tautomers.
8. The method of Claim 2 wherein said protein kinase is either a receptor tyrosine kinase or a non-receptor tyrosine kinase.
9. The method of Claim 8 wherein said tyrosine kinase is selected from the group consisting of KDR, Flt-1, TIE-2, FGFR, PDGFR, IGF-l-R, c-Met, Lck, Src, fyn, Lyn, Blk, and yes.
10. A method of treating or essentially inhibiting hyperproliferative disorders or inflammatory diseases in a recipient in need thereof comprising the administration to said recipient of a compound represented by the formula:
Figure imgf000160_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein: R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z; R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or -(CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR R5 and -
NR4R5;
R3 is selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
11. A method of treating or inhibiting angiogenesis in a recipient in need thereof comprising the administration to said recipient of a compound represented by the formula:
Figure imgf000162_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein:
R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z;
R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)„S-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and -
NR4R5;
R3 for each occurrence is each, independently is selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
12. A method of inducing an anti-angiogenic effect in a recipient in need thereof comprising the administration to said recipient of a compound represented by the formula:
Figure imgf000164_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein:
R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C5)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z;
R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3-
C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-; Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl,
R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and - NR4R5; R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
13. A method of treating or inhibiting the progression of a disease or condition in a recipient in need thereof comprising the administration to said recipient of a compound represented by the formula:
Figure imgf000165_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein: R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; R1 is hydrogen or -A-Z;
R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; A is -(CH2)n-, -(CH2)nNH-, -(CH2)πO-, -(CH2)nS-, -(CH2)nS(O)- or -
(CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and -
NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent moφholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-l,4-diazepin- 1-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3 where said disease or condition is selected from the group consisting of cancer, arthritis, atherosclerosis, restenosis, psoriasis, hemangioma, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, corneal disease, rubeosis, neovascular glaucoma, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, virally induced angiogenic disorders, fractures, diabetic retinopathy, Crohn's disease, inflammatory bowel disorder, cat scratch fever, retinopathy or prematurity, ulcers, thyroid hyperplasia, burns, trauma, acute lung injury, chronic lung disease, stroke, polyps, cysts, synovitis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, pulmonary and cerebral edema, keloid, fibrosis, cirrhosis, carpal tunnel syndrome, sepsis, adult respiratory distress syndrome, multiple-organ dysfunction syndrome, ascites and tumor-associated effusions and edema.
14. A method of affecting vascular hypeφermeability or the production of edema in a recipient in need thereof comprising the administration to said recipient of a compound represented by the formula:
Figure imgf000168_0001
and physiologically acceptable salts and biologically active metabolites thereof, wherein:
R is selected from the group consisting of a substituted or unsubstituted: aliphatic group, aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R1 is hydrogen or -A-Z;
R2 is hydrogen or is selected from the group consisting of a substituted or unsubstituted: lower alkyl group, an aromatic group, a (C3- C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3- C6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group;
A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or - (CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3CO-, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3O-, or a ring system selected from the group consisting of a (C3-C6)cycloalkyl, benzene, pyrrole, isoxazole, isothiazole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, triazine, imidazole, furan, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, aryl, -CN, -C(O)NR4R5 and - NR4R5; R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen or are selected from the group consisting of substituted or unsubstituted: a lower alkyl group, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen to which they are attached represent moφholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamoφholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted with one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3.
15. The method of Claim 14, where the affect on the production of edema is antiedematous.
16. The method of Claim 2, wherein said protein kinase is a serine kinase.
17. The method of Claim 2, wherein said protein kinase is a threonine kinase.
18. A compound represented by the following structural formula:
Figure imgf000170_0001
and physiologically acceptable salts thereof, wherein: R is selected from the group consisting of substituted or unsubstituted: indole, imidazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole,
4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole;
R1 is hydrogen or -A-Z; A is -(CH2)n-, -(CH2)nNH-, -(CH2)nO-, -(CH2)nS-, -(CH2)nS(O)- or -
(CH2)nS(O)2-;
Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, R3OC(O)-, -NR4R5, -C(O)NR4R5, R3CO-, R3O-, or a ring system selected from the group consisting of a C3-C6 cycloalkane, isoxazole, isothiazole, imidazole, benzene, pyrrole, indole, pyridine, pyrazine, pyrimidine, benzothiazole, tetrahydrofuran, thiophene, imidazole, furan, triazine, benzimidazole, pyridazine, quinoxaline, pyrazole, oxazole, thiazole and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R3O-, HO-, HOC(O)-, R3OC(O)-, trihalomethyl, nitro, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR4R5 or -NR4R5;
R3 for each occurrence is, independently, selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;
R4 and R5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C3-C6)cycloalkyl group, heterocyclic group, aralkyl group, (C3-C6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group; optionally, R4 and R5 together with the nitrogen atom to which they are attached represent moφholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamoφholino, azepino or perhydro-l,4-diazepin-l-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C3-C6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C3-C6)cycloalkyl-alkyl group and a heterocyclyl-alkyl group; and n is an integer from 0 to 3; provided that when R is an unsubstituted indol-3-yl then R1 is not -NH2.
19. The compound of Claim 18 wherein:
A is -NH-, -O-, -S-, -S(O)- or -S(O)2- ; and Z is cyclopropyl, 3-pyridyl or pyrazinyl.
20. The compound of Claim 18 wherein:
A is -O-; and
Z is ethyl, n-propyl or isopropyl.
21. The compound of Claim 18 wherein: A is -CH2-; and
Z is phenyl , wherein said phenyl is optionally substituted with one or more moieties selected from the group consisting of halogens, trihalomethyl, hydroxy, -NR4R5, nitro, -CONR4R5, lower alkyl group, R3O-, - C(O)OR4 and -OC(O)R4.
22. The compound selected from the group consisting of: -Cyclopropyl-4- {[(3,5-dimefhyl-4-(4-methy-l-piperazinylmethyl)pyrrol-2- yl]mefhylene} -2-pyrazolin-5-one, -Cyclopropyl-4-[(3,5-dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(4-diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3,5-dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(4-diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3-dimethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene] -2 -pyrazolin-5 -one, - Cyclopropyl-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-
2-pyrazolin-5-one, - Cyclopropyl-4-[(3-diethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene] -2-pyrazolin-5 -one, - Cyclopropyl-4-{[3-(4-methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2- yljmethylene} -2-pyrazo lin-5-one, -Cyclopropyl-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -Cyclopropyl-4- [(3 -pip eridinomethy 1-4, 5 -tetramethylenepyrrol-2-yl)methy lene] -2- pyrazolin-5-one, -Cyclopropyl-4-[(4-dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene]-2- pyrazolin-5-one, - Cyclopropyl-4-[(4-diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, - Cyclopropyl-4-(3,5-dibromo-4-hydroxybenzylidene)-2-pyrazolin-5-one,- Cyclopropyl -4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5- one, - Cyclopropyl -4-[(4-dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, -Cyclopropyl-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropyl-4-[4-(2-dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[4-(2-dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropyl-4-[3-(2-dimethylaminoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin- 5-one, -Cyclopropyl-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Cyclopropyl-4- [4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene] -2- pyrazolin-5-one, -Cyclopropyl-4-[3-(4-moφholinoethoxycarbonylϊndol-2-yl)methylene]-2-pyrazolin-5- one, -Cyclopropyl-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropyl-4-[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-cyclopropyl-2-pyrazolin-5-one,-Cyclopropyl-4-[(5-ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -Cyclopropyl-4-[(5-chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5 -one, -{[(3,5-Dimethyl-4-[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(3- pyridyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(3-pyridyl) -2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(3- pyridyl)-2-pyrazolin-5-one, -(3-Pyridyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5 -one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(3-pyridyl)-2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(3-pyridyl-2-pyrazolin-5-one, -(3-Pyridyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one,- [3 -(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene] -3-(3 -pyridyl)-2-pyrazolin-
5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2- pyτazolin-5-one, -[4-(4-Moφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[4-(4-Moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5- one, -[3-(4-Mθφholinoethylaminocarbonylindol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-
5 -one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3-(3-pyridyl)- 2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-(3-pyridyl)-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(3-pyridyl)-2-pyrazolin-5-one,- [(5 -Ethoxy-4-methoxycarbonylmethyl-3 -methoxycarbonylpyrrol-2-yl)methylene] -3-
(3-pyridyl)-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3-
(3 -pyridyl)-2-pyrazolin- 5 -one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-
5 -one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-
5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5 -one, -Isopropoxy-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -Isopropoxy-4-{[3-(4-methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -Isopropoxy-4- { [3 -( 1 -pyrrolidinyl)methyl-4, 5-tetramethylenepyrrol-2-yl]methylene} -2- pyrazolin-5-one, -Isopropoxy 4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- -2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-isopropoxy-2-, pyrazolin-5 -one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-isopropoxy-2-pyrazolin-5-one, -Isopropoxy-4-[(4-oxo-l ,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-mefhylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, -Isopropoxy-4-[(5-trifluoromethylρyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-
5 -one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, -Isopropoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Isopropoxy-4- [4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene] -2- pyrazolin-5 -one, -Isopropoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, -Isopropoxy-4- [3 -(4-moφholinoethylaminocarbonylindol-2-yl)methylene] -2-pyrazolin-
5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,-{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- isopropoxy-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- isopropoxy-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-ethoxy-
2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5-one, -[(4-Diethylaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5 -one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -Ethoxy-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -Ethoxy-4- {[3 -(4-methyl- 1 -piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -Ethoxy-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5-one, -Ethoxy-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-ethoxy-2-pyrazolin-5- one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-ethoxy-2-pyrazolin-5-one, - [(3 ,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene] -3 -ethoxy-2-pyrazolin- 5-one, -Ethoxy-4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5-one, -Ethoxy-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-ethoxy-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-
5 -one, -Ethoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Ethoxy-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -Ethoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Ethoxy-4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-ethoxy - 2-pyrazolin-5-one, -Ethoxy-4- [(indol-3 -yl)methylene] -2-pyrazolin-5 -one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-ethoxy-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-ethoxy-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- ethoxy -2 -pyrazolin-5 -one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Mθφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-2- pyrazolin-5 -one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-
5 -one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-pyrazinyl-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-[(5-trifluoromethylpyπOl-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[4-(4-Mθφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin- 5-one, -[3-(4-Mθφholinoethoxycarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,-[3-(4-Mθφholinoethylaminocarbonylindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl -2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one, -[(Indol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -[(l-Methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, -Pyrazinyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-pyrazinyl -2 -pyrazolin-5 -one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3-pyrazinyl-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3- pyrazinyl -2- pyrazolin-5-one, - {[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene} -3- pyrazinyl -2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene] -3- pyrazinyl -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3- pyrazinyl-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(imidazol-2yl)-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-(Imidazol-2-yl)-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(imidazol-2-yl)-2- pyrazolin-5-one, -(Imidazol-2-yl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin- 5-one, -(Imidazol-2-yl)-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -(Imidazol-2-yl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-
5-one, -(Imidazol-2-yl)-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(imidazol-2-yl)-2-pyrazolin-5-one,-(Imidazol-2-yl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl) -2- pyrazolin-5-one, -(Imidazol-2-yl) -4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one,-(Imidazol-2-yl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-
(imidazol-2-yl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-
(imidazol-2-yl)-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -(Imidazol-2-yl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(imidazol-2-yl))- 2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3- (imidazol-2-yl) -
2-pyrazolin- 5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(imidazol-2-yl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-mefhoxycarbonylpyrrol-2-yl)methylene]-3- (imidazol-2-yl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(imidazol-2-yl)-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-[(4-Chloropyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-[(5-Chloropyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-(l-Methylcyclopropyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -(l-Methylcycloproρyl)-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]- 2-pyrazolin-5-one, -(l-Methylcyclopropyl)-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene]-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2- pyrazolin-5-one, -( 1 -Methylcyclopropyl)-4- [( 1 -methylindol-3 -yl)methylene] -2-pyrazolin-5 -one,-[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methylcyclopropyl) -2- pyrazolin-5-one, -[(5-Methoxyindol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one,-(l-Methylcyclopropyl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(l- methylcyclopropyl)-2-pyrazolin-5-one, - { [3 ,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-( 1 - methylcyclopropyl)-2-ρyrazolin-5-one, -[(Indol-3-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -[(Pyrrol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(l-methylcyclopropyl)-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methylcyclopropyl))- 2-ρyrazolin-
5-one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-(l- methylcyclopropyl) -2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(l-methylcyclopropyl)-2- pyrazolin-5-one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- (1 -methylcyclopropyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(l- methylcyclopropyl)-2-ρyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(2-furyl)-
2-pyrazolin-5-one, - { [3,5-Dimethyl-4-( 1 -pyrrolidinylmethyl)pyrrol-2-yl]methylene} -3-(2-furyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin- 5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-2- pyrazolin-5-one, -[(3-Diethylaminoethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4-{[3-(4-methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazo lin-5-one, -(2-Furyl)-4- { [3-(l -pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene} -2- pyrazolin-5-one, -(2-Furyl)-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-furyl)-2-pyrazolin-
5 -one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]- 2-pyrazolin-5-one,-(2-Furyl)-4-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]- 2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -[(5-Chloropyπ-ol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(5 -tri fluoromethylpyrrol-2-yl)methylene] -2-pyrazo lin-5 -one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, -(2-Furyl)-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -(2-Furyl)-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2-pyrazolin-
5 -one, -(2-Furyl)-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-(2-Furyl)-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-(2-Furyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,-(2-Furyl)-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(2- furyl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-(2- furyl)-2-pyrazolin-5-one, -(2-Furyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -(2-Furyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(3-(2-furyl))-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3- (2-furyl) -2- pyrazo lin-5 -one, - {[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene} -3-(2-furyl)-2-pyrazolin-5-one,-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
(2-furyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(2- furyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(moφholinomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazo lin-5 -one, -[(3,5-Dimethyl-4-(4-methyl-l-piperazinyl)methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5 -one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Mθφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazo lin-5 -one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -{[3-(4-Methyl-l-piperazinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, -{[3-(l-Pyrrolidinylmethyl)-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-thienyl)-2- pyrazolin-5-one, -[(4-Diefhylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-thienyl)-2-pyrazolin-5-one, -[(4-Oxo-4,5,6,7-tetrahydroindol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2- pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -(2-Thienyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5 -one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5 -one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[4-(4-Moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-
5 -one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-[(l-Methylindol-3-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5- one, -[(5 -Methoxyindol-2-yl)methylene] -3 -(2-thienyl)-2-pyrazolin-5 -one, -[(4,5-Tetramethylenepyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(2- thienyl) -2 -pyrazolin-5 -one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl]methylene}-3-(2- thienyl) -2-pyrazolin-5-one, -[(Indol-3-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(Pyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(2-thienyl) -2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,-{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-(2-thienyl)-2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(2-thienyl)-2-pyrazolin-5-one,- [(5-Ethoxy-4-methoxycarbonylmethyl-3 -methoxycarbonylpyrrol-2-yl)methylene] -3 - (2 -thienyl) -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5 -one, -[(4-Bromopyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-cyclopropoxy-2-pyrazolin-5-one, -Cyclopropoxy-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[4-(2-dimethylaminoefhoxycarbonylpyrrol-2-yl)methylene]-2- pyrazo lin-5 -one, -Cyclopropoxy-4-[4-(2-dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[3-(2-dimethylaminoethoxycarbonylindol-2-yl)methylene]-2- pyrazolin-5-one, -Cyclopropoxy-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methylene]-2- pyrazo lin-5 -one, -Cyclopropoxy-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-
5 -one, -Cyclopropoxy-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5 -one, -Cyclopropoxy-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-
5 -one, -Cyclopropoxy-4-[3-(4-moφholinoethylaminocarbonylindol-2-yl)methylene]-2- pyrazo lin-5 -one, -Cyclopropoxy-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -Cyclopropoxy-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-Cyclopropoxy-4-{[3,5-dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one, -Cyclopropoxy-4-{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2- yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -Cyclopropoxy-4- [(Indol-2-yl)methylene]-2-pyrazolin-5 -one, -Cyclopropoxy-4-[(3,4-diethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-cyclopropoxy -2- pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-cyclopropoxy-2-pyrazolin-5- one, -Cyclopropoxy-4-[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- cyclopropoxy-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[(4-Chloropyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[(5-Chloropyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one,-[2-(5-pyrimidinylethyl)]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5- one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5- one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-
2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]- 2-pyrazo lin-5 -one, -[4-(4-Mθφholinoethylaminocarbonylpyrrol-2-yl)methylene]- 3-[2-(5- pyrimidinylethyl)]-2-pyrazolin-5-one, -[3-(4-Moφholinoethoxycarbonylindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2- pyrazolin-5-one, -[3-(4-Moφholinoethylaminocarbonylindol-2-yl)methylene]- 3-[2-(5- pyrimidinylethyl)] -2-pyrazolin- 5 -one, -[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2- pyrazolin-5-one, -[(l-Methylindol-3-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] - 2-pyrazo lin-5 -one,-[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2- pyrazolin-5-one, -[(5-Methoxyindol-2-yl)methylene]- 3-[2-(5-pyrimidinylethyl)] -2-pyrazolin-5-one,-[2-(5-pyrimidinylethyl)] -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-[2-(5- pyrimidinylethyl)] -2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-[2-
(5-pyrimidinylethyl)] -2-pyrazolin-5-one, -[(Indol-3-yl)methylene]- 3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[2-(5-pyrimidinylethyl)]-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(5-pyrimidinylethyl)]-2-pyrazolin-
5-one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-[2-(5- pyrimidiny lethy 1)] -2-pyrazo lin-5 -one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-[2-(5-pyrimidinylethyl)]-2- pyrazolin-5-one, -[(5 -Ethoxy-4-methoxycarbonylrnethyl-3 -methoxycarbonylpyrrol-2-yl)methylene] -3 -
[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3-
[2-(5-pyrimidinylethyl)]-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(4-Chloropyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(5-Chloropyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -(2-phenylethyl)-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one,-[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-(2-phenylethyl)-2-pyrazolin-5-one,-[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazolin-5 -one, -[4-(4-Mθφholinoethoxycarbonylpyrrol-2-yl)methylene]-3-(2 -phenylethyl)- 2- pyrazolin-5-one, -[4-(4-Moφholinoethylaminocarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazo lin-5 -one, -[3-(4-Mθφholinoethoxycarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-
5 -one, -[3-(4-Mθφholinoethylaminocarbonylindol-2-yl)methylene]-3-(2-phenylethyl)-2- pyrazo lin-5 -one, -[(l-Methylindol-3-yl)methylene]- 3-(2-phenylethyl)-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-
5 -one, -[(5-Methoxyindol-2-yl)methylene]- 3-(2 -phenylethyl) -2-pyrazolin-5-one,-(2-phenylethyl) -4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,-{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-(2- phenylethyl)-2-pyrazolin-5-one, -{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-(2- phenylethyl)-2-pyrazolin-5-one, -[(Indol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]-3-(2-phenylethyl)-2-pyrazolin-5-one,- {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene} -3-(2-phenylethyl)-
2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-(2-phenylethyl)-2-pyrazolin-5- one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]-3- (2-phenylethyl)-2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3-
(2-phenylethyl)-2-pyrazolin-5-one, -[(4-Bromopyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one,-[(4-Chloropyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one,-[(5-Chloropyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl] -2-pyrazo lin-5 -one,-[2-(4-hydroxyphenyl)ethyl]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-
5-one, -[(4-Ethoxycarbonylρyrrol-2-yl)methylene]-3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-
5-one, -[4-(2-Dimethylaminoethoxycarbonylpyrrol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[4-(2-Dimethylaminoethylaminocarbonylpyrrol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl] -2-pyrazo lin-5 -one, -[(3-Ethoxycarbonylindol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]-2-pyrazolin- 5-one, -[3-(2-Dimethylaminoethoxycarbonylindol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[3-(2-Dimethylaminoethylaminocarbonylindol-2-yl)methylene]-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5 -one, -[2-(4-hydroxyphenyl)ethyl]-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-
2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene]-2-pyrazolin-5-one, -[3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]
-2-pyrazolin-5-one, -[2-(4-hydroxyphenyl)ethyl]-4-[(5-methoxyindol-2-yl)methylene]- 2-pyrazolin-5-one,-[2-(4-hydroxyphenyl)ethyl]-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-
5 -one, -{[3,5-Dimethyl-4-(2-dimethylaminoethoxycarbonyl)pyrrol-2-yl]methylene}-3-[2-(4- hydroxyphenyl)ethyl]-2-pyrazolin-5-one, - {[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene]-3-[2- (4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[(3,4-Diethoxycarbonylpyrrol-2-yl)methylene]- 3-[2-(4-hydroxyphenyl)ethyl]- 2- pyrazolin-5-one, - {[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-[2-(4- hydroxyphenyl)ethyl] -2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-[2-(4-hydroxyphenyl)ethyl] -2- pyrazolin-5-one, -[(5-Ethoxy-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene] -3-
[2-(4-hydroxyphenyl)ethyl] -2-pyrazolin-5-one, -[(5-Chloro-4-methoxycarbonylmethyl-3-methoxycarbonylpyrrol-2-yl)methylene]- 3- [2-(4-hydroxyphenyl)ethyl]-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(4-bromopyrrol-2-yl)methylene] -2-pyrazo lin-5 -one,-[2-(4-aminophenyl)ethyl]-4-[(4-chloropyrrol-2-yl)methylene]- 2-pyrazo lin-5 -one,-[2-(4-aminophenyl)ethyl]-4-[(5-chloropyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[2-(4-aminophenyl)ethyl]-4-[(5-trifluoromethylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -[2-(4-aminophenyl)ethyl]-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5- one, -[2-(4-aminophenyl)ethyl]-4-[4-(2-dimethylaminoethoxycarbonylpyrrol-2- yl)methylene]- 2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[4-(2-dimethylaminoethylaminocarbonylpyrrol-2- yl)methylene]- 2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(3-ethoxycarbonylindol-2-yl)methylene]-2-pyrazolin-5- one, -[2-(4-aminophenyl)ethyl]-4-[3-(2-dimethylaminoethoxycarbonylindol-2- yl)methylene]- 2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[3-(2-dimethylaminoethylaminocarbonylindol-2-yl)methyl ene] -2-pyrazolin-5 -one, -[2-(4-aminophenyl)ethyl]- 4-[4-(4-moφholinoethoxycarbonylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[4-(4-moφholinoethylaminocarbonylpyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[3-(4-moφholinoethoxycarbonylindol-2-yl)methylene]-2- pyrazo lin-5 -one, -[2-(4-aminophenyl)ethyl]-4-[3-(4-moφholinoethylaminocarbonylindol-2- yl)methylene]- 2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one,-[2-(4-aminophenyl)ethyl]-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, -[2-(4-aminophenyl)ethyl]-4-{[3,5-dimethyl-4-(2-dimethylaminoethoxycarbonyl) pyrrol-2-yl]methylene}-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4- { [3 ,5-dimethyl-4-(2-dimethylaminoethylamino carbonyl)pyrrol-2-yl]methylene}-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,-[2-(4-aminophenyl)ethyl]-4-[(Indol-2-yl)methylene]-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(3,4-diethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5 -one, -{[3-(2-Acetamido-2-methoxycarbonylethyl)indol-2-yl]methylene}-3-[2-(4- aminophenyl)ethyl]-2-pyrazolin-5-one, -{[3-(2-Amino-2-carboxyethyl)indol-2-yl]methylene}-3-[2-(4-aminophenyl)ethyl]-2- pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(5-ethoxy-4-methoxycarbonylmethyl-3- methoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[2-(4-aminophenyl)ethyl]-4-[(5-chloro-4-methoxycarbonylmethyl-3- methoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5 -one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimefhylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazo lin-5 -one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-
2-pyrazolin-5 -one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one, -(4-Pyrimidinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazo lin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4- pyrimidiny l)pyrazolin- 5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(4-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimefhylaminomethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazo lin-5 -one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(4-pyrimidinyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, - [(3 ,5 -Dimethyl-4-( 1 -pyrrolidinylmethylpyrrol-2-yl)methylene]-3 -(5 -pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-diethylaminomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5 -one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazo lin-5 -one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5.-pyrimidinyl)- 2-pyrazolin-5-one, - { [3-(4-Methyl- 1 -piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene} -3-(5- pyrimidinyl)-2-pyrazolin-5-one, -(5 -Pyrimidiny l)-4- { [3 -( 1 -pyrrolidinyl)methyl-4,5 -tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(5-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(5-pyrimidinyl)-2-pyrazolin-5-one,-[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one, - [(3 ,5 -Dimethyl-4-( 1 -pyrrolidinylmethylpyrrol-2-yl)methylene] -3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, - { [3-(4-Methyl- 1 -piperazinyl)methyl-4,5 -tetramethylenepyrrol-2-yl]methylene} -3 - (2-pyrimidinyl)-2-pyrazolin-5-one, -(2-Pyrimidinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(2-pyrimidinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazo lin-5 -one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(2-pyrimidinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(2-pyrimidinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5 -one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazo lin-5 -one, -[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, - [(4-Diethanolaminomethyl-3 , 5 -dimethy lpyrrol-2-yl)methylene] -3 -(3 -pyridazinyl)-
2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazo lin-5 -one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5 -one, - {[3-(4-Methyl- 1 -piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene} -3- (3 -pyridazinyl)-2-pyrazo lin-5 -one, -(3-Pyridazinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)mefhylene] -3-(3-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(3-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(3-pyridazinyl)-2-pyrazolin-5- one, - [(4-Dimethylaminomethyl-5 -methylpyrrol-2-yl)methylene] -3 -(3 -pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5 -one, -[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazo lin-5 -one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-(piperidinomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5 -one, -[(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazo lin-5 -one, -{[3-(4-Methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2-yl]methylene}-3- (4-pyridazinyl)-2-pyrazolin-5-one, -(4-Pyridazinyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazo lin-5-one, -[(3-Piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(4-pyridazinyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(4-pyridazinyl)-2-pyrazolin-5-one,-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazo lin-5 -one, -[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(4-pyridazinyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazolin-5 -one, -[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- isoxazolyl)-2-pyrazolin-5-one, -[(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-
2-pyrazolin-5-one, -[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(4-Diethanolaminomethyl-3,5-Dimethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)- 2-pyrazolin-5-one, - [(3 -Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene] -3 -(5 - isoxazolyl)-2-pyrazolin-5-one, -(5-Isoxazolyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -[(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5- isoxazolyl)-2-pyrazolin-5-one, -(5-Isoxazolyl)4- {[3-(4-methyl-l-piperazinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene}~ 2 -pyrazolin-5 -one, -(5-isoxazolyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazo lin-5-one, -(5-Isoxazolyl)-4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-
2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-isoxazolyl)-2- pyrazolin-5-one, -[(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, -(3,5-Dibromo-4-hydroxybenzylidene)-3-(5-isoxazolyl)-2-pyrazolin-5-one,-[(4-Oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-3-(5-isoxazolyl)-2-pyrazolin-5- one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, (3,5 -Dimethy 1-4-moφholinomethylpyrro 1-2-y l)methy lene] -3 -(5 -methyl-3 - isoxazolyl)-2-pyrazo lin-5 -one,
(3,5-Dimethyl-4-{[(4-methyl-l-piperazinylmethyl)pyrrol-2-yl]methylene}-3-(5- methyl-3-isoxazolyl)-2-pyrazolin-5-one,
(3,5-Dimethyl-4-[(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
(4-Diethanolaminomethyl-3,5-dimethyl-pyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-methyl- 3-isoxazolyl)-2-pyrazolin-5-one, - 5-Methyl-3-isoxazolyl)-4-[(3-moφholinomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]- 2-pyrazolin-5-one,
(3-Diethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one, -ι 5-Methyl-3-isoxazolyl)4-{[3-(4-methyl-l-piperazinyl)methyl-4,5- tetramethylenepyrrol-2-yl]methylene} ~2-pyrazo lin-5 -one, -ι 5-Methyl-3-isoxazolyl)-4-{[3-(l-pyrrolidinyl)methyl-4,5-tetramethylenepyrrol-2- yl]methylene} -2-pyrazolin-5-one, -ι 5-Methyl-3-isoxazolyl)4-[(3-piperidinomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one, -[(4-Dimethylamino-4,5,6,7-tetrahydroindol-2-yl)methylene] -3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
(4-Diethylaminoethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
3,5-Dibromo-4-hydroxybenzylidene)-3-(5-methyl-3-isoxazolyl)-2-pyrazolin-5- one,
(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazolin-5-one,
5-Methyl-3-isoxazolyl)-4-[(4-oxo-l,5,6,7-tetrahydroindol-2-yl)methylene]-2- pyrazolin-5-one, -[(4-Dimethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazo lin-5 -one, -cyclopropyl-4-(l-3-[(dimethylamino)methyl]-4,5,6,7-tetrahydro-lH-2- indolylmethylidene)-4,5-dihydro-lH-5-pyrazolone, -cyclopropyl-4-(l-4-[(l,l-dimethylammonio)methyl]-3,5-dimethyl-lH-2- pyrrolylmethylidene)-4,5-dihydro-lH-5-pyrazolone maleate, -[l-(4-[[2-(dimethylamino)ethyl](methyl)amino]methyl-3,5-dimethyl-lH-2- pyrrolyl)methylidene]-3-(2-pyrazinyl)-4,5-dihydro-lH-5-pyrazolone-(l-4-[2-(diethylamino)ethyl]-3,5-dimethyl-lH-2-pyrrolylmethylidene)-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone, -l-[4-(3-chloropropanoyl)-3,5-dimethyl-lH-2-pyrrolyl]methylidene-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone, 4-(l-3-[(dimethylamino)methyl]-4,5,6,7-tetrahydro-lH-2-indolylmethylidene)-3-(2- pyrazinyl)-4,5-dihydro-lH-5-pyrazolone, 4-(l-4-[(dimethylamino)methyl]-3,5-dimethyl-lH-2-pyrrolylmethylidene)-3-(5- methyl-3-isoxazolyl)-4,5-dihydro-lH-5-pyrazolone, 3-Cyclopropyl-4-[(4,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Benzyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenyloxymethyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Benzyl-4-{[4-(2-carboxyethyl)-3-methylpyrrol-2-yl]methylene}-2-pyrazolin-5- one,
3-Benzyl-4-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-pyrazolin-5- one, 3-(4-Methylphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 2-Amino-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenylethyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Phenylamino-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methylbenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3 -(4-Methylphenylamino)-4- [(pyrrol-2-yl)methylene] -2-pyrazolin-5 -one, 3-(4-Methoxyphenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorobenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Chlorophenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(Indol-3-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Methoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3,4-Dimethoxybenzyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Phenylphenyloxymethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(2-Phenylpropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Phenylpropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Ηydroxyphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3-(4-Methylphenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Ethoxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Nitrophenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(4,5-Dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)pyrrol-2-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one, 3-Cyclopentyloxy-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Tert-butylureido-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(l-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Ethoxy-4-[(5-methylpyrrol-2-yl)methylene]2-pyrazolin-5-one, 3-(4-Carbamoylphenylethyl)-4-[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(4-methoxycarbonylphenylethyl- 2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]- 2-pyrazo lin-5-one,
4-[(5-Ethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(4-hydroxyphenylethyl)-2- pyrazolin-5-one, 3-(Ethoxycarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxyphenylaminocarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin- 5 -one,
4-{(3-(2-Carboxyethyl)-4-methylpyrrol-2-yl]methylene}-3-isopropyl-2-pyrazolin-5- one, 3-Cyclopropyl-4-[(pyrrol-2-yl)methylene]-2-ppyrazolin-5-one, 3-Cyclobutyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Pyridil)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[[l-(3,5-dichlorophenyl)pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Pyrrol-2-yl)methylene]-3-(2,2,3,3-tetramethylcyclopropyl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethylρyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopentyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(2-Methylcyclopropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-(Benzothiazol-2-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(4,5-Dimethylpyrrol-2-yl)methylene]-4-(3-pyridyl)]-2-pyrazolin-5-one, 3-Cyclopropyl-4[(3,5-dimethyl-4-ethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(Pyrrol-2-yl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(Benzothiazol-2-yl)-4-[(4-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 4-[3,5-Dimetyl-4-ethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4- [(5-Methylpyrrol-2-yl)methylene]-3 -(-3 -pyridyl)-2-pyrazolin-5 -one, 3-Cyclopropyl-4-[(5-ethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Isopropoxy-4-[(5-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Propyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Methyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Isopropylphenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(3-Phenylamino)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-{[l-(4-hydroxybutyl)pyrrol-2-yl]methylene]-2-pyrazolin-5-one, 4- {[4-(2-Carboxyethyl)-3-methylpyrrol-2-yl]methylene} -3-isopropoxy-2-pyrazolin- 5 -one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Isopropoxy-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5 -one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyπOl-2-yl)methylene]-3-isopropoxy-2- pyrazolin-5-one,
4-[(4-Acetyl-3,5-dimethylpyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-{[3,5-Dimethyl-4-(2-dimetylaminoethyloxycarbonyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimetylaminoethylaminocarbonyl)pyrrol-2-yl]methylene}-3- isopropoxy-2-pyrazolin-5-one,
4-[(5-Ethoxycarbonylpyrrol-2-yl)methylene]-3-isoproρoxy-2-pyrazolin-5-one, 4-[(5-Carboxypyrrol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-(4-Chlorophenylaminocarbonylmethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5- one,
3-Cyclopropyl-4-[(5-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(tetrahydrofuran-3-yl)-2- pyrazolin-5-one, 4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5- one,
4-[(3,5-dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin- 5 -one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-2- pyrazolin-5 -one,
4-[(3,4-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Carboxyethyl)-3-methylpyrrol-2-yl]methylene}-3-cyclopropyl-2-pyrazolin- 5-one, 3-Cyclopropyl-4-[(3,5-dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Cycloρropyl-4-[(5-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-(2-Methoxycarbonylethyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Ethoxycarbonyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isopropyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(trans-2-phenylcyclopropyl)-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclohexyl-4-[(pyrrol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropylamino-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5- one, 3-Cyclopropyl-4-[(5-moφholinomethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(5-Carboxypyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 4-[(4-Chloropyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-[(4-Bromopyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-[(5-Chloropyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4[(4-Chloropyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 4-[(4-Bromopyrrol-2-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one,
3-Pyrazinyl-4-[(4,5-tetramefhylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(3-Pyridyl)-4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-2-pyrazolin-5-one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3,5-dimethyl-4-(2-dimethylaminoethyloxycarbonyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4(2-dimethylaminoethyloxycarbonyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazo lin-5 -one maleate,
4-{[3,5-Dimethyl-4-(2-moφholinoethylaminocarbonyl)pyrrol-2-yl]methylene-3- pyrazinyl -2 -pyrazolin-5 -one,
4-[(3,5-DimethylpyπOl-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one,
4-[(4,5-tetramethylenepyrrol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one,
4-[(3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2-pyrazolin-5-one,
4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-dimethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-trifluoroacetamidomethylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(4-aminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin- 5-one,
3-(Benzothiazol-2-yl)-4-[(3,5-dimethylpyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-(Benzothiazol-2-yl)-4-[(3,5-dimethyl-4-moφholinomethylpyrrol-2-yl)methylene]-
2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(4-Ethoxycarbonylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
4-[(4-Carboxypyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-diethanolaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-trifluoroacetamidomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5 -one,
3-Cyclopropyl-4-[(4-ethoxycarbonyl-3-phenylpyrrol-2-yl)methylene]-2-pyrazolin-5- one,
4-{[3,5-Dimethyl-4-(l-pyrrolidinylmethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(3-pyridyl)-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-phenyl-2-pyrazolin-5- one,
4-[(3,5-Dimethyl-4-ethylpyrrol-2-yl)methylene]-3-phenyl-2-pyrazolin-5-one,
4-[(3,4-Di(ethoxycarbonyl)pyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
3-Ethoxy-4-[(4-ethoxycarbonylpyrrol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(2-pyridylethyl)-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(l-methyl-2- phenylethyl)-2-pyrazolin-5-one,
4-[(4-Carboxy-3,5-dimethylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, 3-Ethoxy-4-[(5-nitropyrrol-2-yl)methylene]-2-pyrazolin-5-one,
3-Ethoxy-4-[(4-nitropyrrol-2-yl)methylene]-2-pyrazolin-5-one,
4-[(4-Carboxypyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimethylaminoethylaminocarbonyl)pyrrol-2-yl)methylene}-
3-ethoxy-2-pyrazolin-5-one, 4-[(5-Chloro-3-methoxycarbonyl-4-methoxycarbonylmethylpyrrol-2-yl)methylene]-
3-ethoxy-2-pyrazolin-5-one,
4- { [3-(2-Carboxyethyl)-4-methylpyrrol-2-yl]methylene} -3-ethoxy-2-pyrazolin-5- one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5- one,
3-Ethoxy-4-[(4,5-tetramethyleneρyrrol-2-yl)methylene]-2-pyrazolin-5-one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-trifluoromethyl-2- pyrazo lin-5 -one,
4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one,
3-(3-Aminophenyl)-4-[(3,5-Dimethyl-4-ethoxycarbonylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Ethoxy-4-{[2-(4-moφholinoethyl)aminocarbonylpyrrol-2-yl]methylene}-2- pyrazolin-5-one, 4-[(4-Ethoxycarbonyl-3-phenylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one,
4-{[4-(4-Methyl-l-pyperazinylmethyl)-3,5-dimethy]pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5 -one,
4-[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-piperidinomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-isoxazolyl)-2- pyrazolin-5-one, 4-[(5-Methyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazo lin-5 -one,
4-{{3,5-Dimethyl-4-rN-(2-dimethylaminoethyl)-N-methylaminomethylpyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-dimethylaminomethyl-4,5-tetramethylenepyrrol-2- yl)methylene]-2-pyrazolin-5-one,
4-[(3-Dimethylaminomethyl-4,5-tetramethylenepyrrol-2-yl)methylene]-3-pyrazinyl-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one maleate,
4-{[4-(3-Chloropropionyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-[(3,5-Dimethyl-4-dimethylaminomethylpyrrol-2-yl)methylene]-3-(5-methyl-3- isoxazolyl)-2-pyrazo lin-5 -one,
4- { [3 ,5 -Dimethyl-4-(4-hydroxypiperidinomethyl)pyrrol-2-yl]methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-[(4-Aminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5- one maleate,
4-{[4-(4-Benzylpiperidino)methylpyrrol-2-yl]methylene}-3-pyrazinyl-2-pyrazolin-
5-one,
4- { [3 ,5 -Dimethyl-4-(2-hydroxyethyl)pyrrol-2-yl]methylene} -3 -pyrazinyl-2- pyrazolin-5-one, 4-{{3,5-Dimethyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-pyrazinyl-2- pyrazolin-5-one,
3-Cyclopropyl-4- { {3,5-Dimethyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2- yl} methylene} -2-pyrazo lin-5-one,
3-Cyclopropyl-4-{[3,5-Dimethyl-4-(2-hydroxyethyl)pyrrol-2-yl]methylene}-2- pyrazolin-5 -one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(3-Diethylaminopropyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazo lin-5 -one, 4-{[3,5-Dimethyl-4-(3-hydroxypropyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(3,5-Dimethyl-4-dimethylaminoacetylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazolin-5-one hydrochloride,
4- [(3 , 5 -Dimethy 1-4-dimethy 1 aminoacetylpyrrol-2-yl)methylene] -3 -ethoxy-2 - pyrazolin-5-one,
3-Cyclopropyl-4-{[(2-diethylaminoethyl)-3,5-dimethyl-4-pyrrol-2-yl]methylene}-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-dimethylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-{[3,5-Dimethyl-4-(4-hydroxybutyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-{[4-(4-Diethylaminobutyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl-N-oxide)-3,5-dimethylpyrrol-2-yl]methylene}-3- pyrazinyl-2 -pyrazo lin- 5 -one, 4-{[3,5-dimethyl-4-(l-pyrrolidinylacetyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(4-Diethylaminoacetyl-3,5-dimethylpyrrol-2-yl)methylene]-3-pyrazinyl-2- pyrazo lin-5 -one,
4-[(3-Isopropyl-5-methylpyrrol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-{[3,5-Dimethyl-4-[3-(l-pyrrolidinylpropyl)]pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-[(Dimethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-pyrazinyl-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(dimethylaminomethyl-3-isopropyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethoxyoxalyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
3-Benzyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-Benzyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenyloxymethyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-phenyloxymethyl-2-pyrazolin-5-one,
3-(4-Chlorophenyloxymethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methoxybenzyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methylphenyloxymethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methylbenzyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-phenylamino-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methylphenylamino)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylamino)-2-pyrazolin-5-one,
3-(4-Chlorobenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-3-(4-methoxybenzyl)-2-pyrazolin-5- one,
3-(4-Chlorophenylamino)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(3-methoxybenzyl)-2-pyrazolin-5-one,
3-(3,4-dimethoxybenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-(4-hydroxybenzyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-(3-Chlorophenyloxymethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-(Indol-3-yl)-4-[(indol-3-yl)mefhylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylethyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-phenylphenyloxymethyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(2-phenylpropyl)-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(3-phenylpropyl)-2-pyrazolin-5-one,
3-(4-Hydroxyphenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methylphenylethyl)-2-pyrazolin-5-one,
3 -Ethoxy-4- [(indol-3-yl)methylene] -2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-isopropoxy-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-phenylethyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-nitrophenylethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-propoxy-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)4-[(indol-3-yl)methylene]- -2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(2-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(7-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(7-Methylindol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3-Cyclopentyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-Isopropoxy-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-methoxycarbonylphenylethyl)-2-pyrazolin-5-one, 3-Isopropoxy-4-[(l-isopropylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-Hydroxyphenylethyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Isopropyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
3-(4-Chlorophenylaminocarbonylmethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5- one,
3-Ethoxycarbonylmethyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(Indol-3-yl)methylene]-3-(4-methoxyphenylaminocarbonylmethyl)-2-pyrazolin- 5-one,
3-Cyclopropyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 3-(2-Aminocarbonylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Cyclobutyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-(2-Dimethylaminocarbonylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(4-pyridyl)-2-pyrazolin-5-one, 3-Cyclopentyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2,2,3,3-tetramethylcyclopropyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-methylcyclopropyl)-2-pyrazolin-5-one,
3-Cyclohexyl-4-{[l-(4-hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-(4-pyridyl)-2-pyrazolin-5-one, 3-(Benzothiazol-2-yl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 3-Dimethylamino-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(pyrrol-2-yl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(6-methoxybenzothiazol-2-yl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(7-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4- [( 1 -Methylindol-3 -yl)methylene]-3 -(3 -pyridyl)-2-pyrazo lin-5 -one, 4-[(Indol-3-yl)methylene]-3-propyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-methyl-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-trifluoromethyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-methyl-2-pyrazolin-5-one,
4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-trifluoromethyl-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)indol-3-yl]methylene}-3-(tert-butyl)-2-pyrazolin-5-one, 3-Ethoxycarbonyl-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(2-methoxycarbonylethyl)-2-pyrazolin-5-one, 4-[(Indol-3-yl)methylene]-3-(trans-2-phenyl-l-cyclopropyl)-2-pyrazolin-5-one, 3-Cyclobutyl-4- {[1 -(4-hydroxybutyl)indol-3-yl]methylene} -2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methoxy-l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(l,7-dimethylindol-3-yl)methylene]-2-pyrazolin-5-one, 4- [( 1 -Methylindol-3-yl)methylene] -3-(tetrahydrofuran-3 -yl)-2 -pyrazolin-5 -one, 3-Cyclopropylamino-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4-[(l,7-Dimethylindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methoxy-l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-Fluorophenylamino)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-trifluoroacetamido-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-Amino-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 3-(4-Chlorophenylethyl)-4-[(indol-3-yl)methylene]-2-pyrazolin-5-one, 3-Ethoxy-4-[(l -methylindol-3-yl)methylene]-2-pyrazolin-5-one,
3-(5-Isoxazolyl)-4-[(l-methylindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(l-Methylindol-3-yl)methylene]-3-tert-butyl-2-pyrazolin-5-one, 4-[(6-Carboxy-l-methylindol-3-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-{{l-Methyl-6-[2-(4-moφholino)ethyl]aminocarbonylindol-3-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(Indol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-(4-Hydroxyphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Aminophenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Methoxycarbonylphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-(4-Carbamoylphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3-dimethylaminomethylindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 3-Isopropoxy-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, 3 -Isopropoxy-4- [( 1 -methylindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-(tetrahydrofuran-3-yl)-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-methoxyindol-2-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(5-nitroindol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-isopropylamino-2-pyrazolin-5-one, 3-(4-Carboxyphenylethyl)-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Indol-2-yl)methylene]-3-phenyl-2-pyrazolin-5-one, 3-Isopropoxy-4-[(3-methylindol-2-yl)methylene]-2-pyrazolin-5-one, 3-Isoρropoxy-4-{[3-(2-methoxycarbonyl-2-acetamidoethyl)indol-2-yl]methylene}- 2-pyrazolin-5-one, 3-Ethoxy-4-[(indol-2-yl)methylene]-2-pyrazolin-5-one,
3-Ethoxy-4-{[3-(4-moφholinomethyl)indol-2-yl]methylene}-2-pyrazolin-5-one, 3-Cyclopropyl-4-{[3-(4-moφholinomethyl)indol-2-yl]methylene}-2-pyrazolin-5- one,
4-[(5-Methoxyindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(5-Methoxyindol-2-yl)methylene]-3-(2-pyridyl)-2-pyrazolin-5-one, 4-[(4-Chloro-6,7-dihydroindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, 4-[(4-Chloro-6,7-dihydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(4-Oxo-l,5,6,7-dihydroindol-2-yl)methylene]-3-pyrazinyl-2-pyrazolin-5-one, 4-[(3-Dimethylaminomethylindol-2-yl)methylene]-3-ethoxy-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-benzyl-2-pyrazolin-5-one, 3-Benzyl-4-{[l-(4-hydroxybutyl)-7-azaindol-3-yl]methylene}-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methoxyphenyloxymethyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Amino-4-[(7-azaindol-3-yl)methylene]-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methoxybenzyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-phenylamino-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-methylbenzyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-hydroxyphenylethyl)-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)-7-azaindol-3-yl]methylene}-3-(4-hydroxyphenylethyl)-2- pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-isopropyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-cyclopropyl-2-pyrazolin-5-one, 4-[(7- Azaindol-3 -yl)methylene] -3 -cyclobutyl-2 -pyrazolin-5 -one, 4-[(7-Azaindol-3-yl)methylene]-3-(3-pyridyl)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-phenyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(4-fluorophenylamino)-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-propyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-methyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-trifluoromethyl-2-pyrazolin-5-one, 4-[(7-Azaindol-3-yl)methylene]-3-(tert-butyl)-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)-7-azaindol-3-yl]methylene}-3-trifluoromethyl-2-pyrazolin- 5 -one,
4-[(7-Azaindol-3-yl)methylene]-3-(4-isopropylphenylamino)-2-pyrazolin-5-one, 4- [(7- Azaindol-3 -yl)methylene] -3 -(3 -methylphenylamino)-2-pyrazolin-5-one, 4-{[l-(4-Hydroxybutyl)-7-azaindol-3-yl]methylene}-3-(3-methylphenylamino)-2- pyrazolin-5 -one,
4-[(7-Azaindol-3-yl)methylene]-3-phenylethyl-2-pyrazolin-5-one, 3 -Benzyl-4- [(4-dimethylaminophenyl)methylene] -2-pyrazolin-5 -one, 4-[(4-Dimethylaminophenyl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 4- [(4-Dimethylaminophenyl)methylene] -3 -phenylethyl-2 -pyrazolin-5 -one, 3-Cyclopropyl-4-[(4-dimethylaminophenyl)methylene]-2-pyrazolin-5-one, 3-Isopropoxy-4-[(3-methylpyrazol-4-yl)methylene]-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-methylpyrazol-4-yl)methylene]-2-pyrazolin-5-one, 4-[(Imidazol-2-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(imidazol-2-yl)methylene]-2-pyrazolin-5-one, 4-[(Imidazol-4-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one, 3-Cyclopropyl-4-[(thien-2-yl)methylene]-2-pyrazolin-5-one, 4[(Indol-3-yl)methylene]-3-isopropyl-l-methyl-2-pyrazolin-5-one,
3-Isopropoxy-4-[(pyrrol-3-yl)methylene]-2-pyrazolin-5-one,
4-[(8-Hydroxyquinolin-5-yl)methylene]-3-isopropoxy-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-pyrimidinyl)- 2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3-pyridazinyl)-
2-pyrazo lin-5 -one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-thienyl)-2- pyrazolin-5-one,
4- { [4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene} -3-(4-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5-pyrimidinyl)- 2-pyrazolin-5-one,
4- { [4-(2-Diethylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene} -3-(4-pyridazinyl)-
2-pyrazolin-5-one,
3-Cyclopropyl-4-[(3,5-dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-2- pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(2-cyclopropylaminoethyl)-3,5-dimethylpyrrol-2- yl]methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3,5-dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-2- pyrazolin-5-one,
3-Cyclopropyl-4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-cyclopropyl-2- pyrazolin-5-one, 3-Cyclopropyl-4-[(4-diethylaminomethyl-3-isopropyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
3 -Cyclopropyl-4- { [4-( 1 -pirrolidinylmethyl)-3 -isopropyl-5-methylpyrrol-2- yl]methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4- { {3-isoproρyl-5-methyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2- yl}methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2- yl]methylene}-2-pyrazolin-5-one,
3-Cycloproρyl-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- y 1 } methylene } -2-pyrazolin- 5-one, 3-Cyclopropyl-4-{[3-isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2- yl]methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-{{4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5- methylpyrrol-2-yl}methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[4-(4-dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2- yl]methylene} -2-pyrazolin-5-one, 3-Cyclopropyl-4-[(3-cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2- yl)methylene]-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-4-(l-pirrolidinylmethyl)-5-methylpyrrol-2- yl]methylene} -2-pyrazolin-5-one, 3 -Cyclopropyl-4- { {3-cyclopropyl-5-methyl-4-[2-(l -pyrrolidinyl)ethyl]pyrrol-2- yl} methylene} -2 pyrazolin-5-one,
3-Cyclopropyl-4-{{3-cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5- methylpyrrol-2-yl} methylene} -2-pyrazo lin-5-one, 3-Cyclopropyl-4-{[3-cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2- yl]methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{{3-cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5- methylpyrrol-2-yl}methylene}-2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol- 2-yl]methylene}-2-pyrazolin-5-one,
3 -Cyclopropyl-4- { {3-cyclopropyl-5-methyl-4-[4-(l -pyrrolidinyl)butyl]pyrrol-2- yl} methylene} -2-pyrazolin-5-one,
3-Cyclopropyl-4-{[3-cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2- yl]methylene} -2-pyrazolin-5-one, 4- {[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene} -3-pyrazinyl-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{{3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazo lin-5 -one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
3-Pyrazinyl-4-{ {4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one, 3-Pyrazinyl-4- { {4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one, 4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-2-pyrazinyl-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl} methylene} -3 -pyrazinyl-2 -pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {3-Cyclopropyl-5-methyl-4-[4-(l -pyrrolidinyl)butyl]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazo lin-5 -one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-furyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)- 2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one, 4- { {3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3-(2- furyl)-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2-furyl)-
2-pyrazolin-5-one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- furyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-furyl)-2- pyrazolin-5-one,
4- { {3-Isopropyl-5-methyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3-(2- furyl)-2-pyrazolin-5-one, 4- {[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene} -3-(2- furyl)-2-pyrazolin-5-one,
3-(2-Furyl)-4- { {4- [3 -( 1 -pyrrolidinyl)propyl] -3 -isopropyl-5 -methylpyrrol-2- yl} methylene} -2-pyrazolin-5-one,
3-(2-Furyl)-4-{[3-isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}- 2-pyrazolin-5-one,
3-(2-Furyl)-4-{ {4-[3-(4-pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- furyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- furyl)-2-pyrazolin-5-one, 4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(2-furyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(2-furyl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-(2- furyι)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(2-furyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(2-furyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2-furyι)-2-pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2-furyl)-2-pyrazolin-5 -one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(2-thienyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2- thienyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4- {[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene} -3-(2- thienyl)-2- pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(2- thienyl)-2- pyrazolin-5-one, 4-{{3,5-Dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- thienyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2 -pyrazolin-5 -one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(2- thienyl)-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{4-[3-(l-Pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2-yl}methylene}-3-(2- thienyl)-2 -pyrazolin-5 -one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -3-(2- thienyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- thienyl)-2-pyrazolin-5-one, 4- { {3-Cyclopropyl-5-mefhyl-4-[2-(l -pyrrolidinyl)ethyl]pyrrol-2-yl}methylene} -3-
(2- thienyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene} -3-(2- thienyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4- { { 3 -Cyclopropyl-4- [3 -(2,5 -dimethyl- 1 -pyrrolidiny l)propy 1] - 5 -methy lpyrrol-2- yl} methylene} -3-(2- thienyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(2- thienyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2- thienyl)-2 -pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2- thienyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(4-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(4-pyrimidinyl)-
2-pyrazo lin-5 -one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5 -one, 4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2 -pyrazolin-5 -one,
3-(4-Pyrimidinyl)-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene} -3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazo lin-5 -one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyrimidinyl)-2-pyrazolin-5-one, 4- { {3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene} -3-
(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(4-pyrimidinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(4- pyrimidinyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene} -3-(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(4-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(4-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(5-pyrimidinyl)-
2-pyrazolin-5-one,
4- [(4-Diethylaminomethyl-3 ,5 -dimethy lpyrrol-2-yl)methylene] -3 -(5 -pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylammoethyl)-pyrrol-2-yl]methylene}-3-(5-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(5-pyrimidinyl)-
2 -pyrazo lin- 5-one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(5-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4- { [4-( 1 -Pirrolidinylmethyl)-3 -isopropyl-5 -methylpyrrol-2-yl]methylene} -3 -(5 - pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, 4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
3-(5-Pyrimidinyl)-4-{{4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl} methylene } -2-pyrazo lin-5 -one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(5- pyrimidinyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(5- pyrimidinyl)-2-pyrazolin-5-one, 4- { {3-Cyclopropyl-5-methyl-4-[2-(l -pyrrolidinyl)ethyl]pyrrol-2-yl}methylene} -3-
(5 -pyrimidinyl)-2-pyrazo lin- 5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-(5- pyrimidinyl)-2-pyrazolin- 5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4- { [3 -Cyclopropyl-5 -methyl-4-(3 -pheny lmethylaminopropyl)pyrro 1-2- yl]methylene}-3-(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(5-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(5-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyπOl-2-yl)methylene]-3-(2-pyrimidinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(2-pyrimidinyl)-2- pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoefhyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-
2-pyrazolin-5-one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(2-pyrimidinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-(2- pyrimidinyl)-2-pyrazo lin-5 -one, 4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidiny l)-2-pyrazolin- 5 -one,
3 -(2-Pyrimidinyl)-4- { {4- [3-( 1 -pyrrolidinyl)propyl] -3 -isopropyl-5-methylpyrrol-2- yl } methylene} -2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]mefhylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(2- pyrimidinyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(2- pyrimidinyl)-2-pyrazolin-5-one, 4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{ {3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(2-pyrimidinyl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-(2- pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- y 1 } methylene } -3 -(2-pyrimidinyl) -2 -pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(2-pyrimidinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(2-pyrimidinyl)-2-pyrazolin-5-one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyπOl-2-yl)methylene]-3-(3-pyridazinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(3-pyridazinyl)-2- pyrazo lin-5 -one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(3-pyridazinyl)-
2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(3-pyridazinyl)-
2-pyrazolin- 5 -one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(3-pyridazinyl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4- { [4-( 1 -Pirrolidinylmethyl)-3 -isopropyl-5-methylpyrrol-2-yl]methylene} -3 -(3 - pyridazinyl)-2-pyrazo lin-5 -one,
4- { {3-Isopropyl-5-methyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3-(3- pyridazinyl)-2-pyrazolin-5-one, 4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
3-(3-Pyridazinyl)-4- { {4-[3-(l -pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4- { [4-(4-Dimethylaminobutyl)-3 -isopropyl-5 -methylpyrrol-2-yl]methylene} -3 -(3 - pyridazinyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(3- pyridazinyl)-2-pyrazolin-5-one, 4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(3-pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(3- pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4- {[3 -Cyclopropyl-5 -methyl-4-(3 -pheny lmethylaminopropyl)pyrrol-2- yl]methylene}-3-(3-pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(3-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(3 -pyridazinyl)-2-pyrazolin-5 -one, 4-[(3,5-Dimethyl-4-(l-pyrrolidinylmethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-
2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(4-pyridazinyl)-2- pyrazo lin-5 -one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(4-pyridazinyl)-
2-pyrazolin-5 -one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(4-pyridazinyl)-
2-pyrazo lin-5 -one, 4- { {3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene} -3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5 -one,
4-{[4-(l-Pirrolidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(4-pyridazinyl)-2- pyrazolin-5-one,
4- { {3-Isopropyl-5 -methyl-4- [2-( 1 -pyrrolidinylethyl)]pyrrol-2-yl } methylene} -3 -(4- pyridazinyl)-2-pyrazolin-5-one, 4-{[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
3-(4-Pyridazinyl)-4-{{4-[3-(l-pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2- yl } methylene } -2-pyrazo lin-5 -one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(4-ρyridazinyl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(4- pyridazinyl)-2-pyrazolin-5-one, 4-{ {3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl} methylene} -3-(4-pyridazinyl)-2-pyrazolin-5-one, 4-{[3-Cyclopropyl-4-(3-diethylaminopropyl)-5-methylpyrrol-2-yl]methylene}-3-(4- pyridazinyl)-2-pyrazoιin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl} methylene} -3 -(4-pyridazinyl)-2-pyrazolin-5 -one,
4-{[3-Cyclopropyl-5-methyl-4-(3-phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(4-pyridazinyl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one,
4-{[3-Cycloproρyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(4-pyridazinyl)-2-pyrazolin-5-one, 4- [(3 ,5 -Dimethyl-4-( 1 -pyrrolidinylmethylpyrrol-2-yl)methylene] -3 -( 1 ,2,4-triazin-3- yl)-2-pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3,5-dimethylpyrrol-2-yl)methylene]-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dimethylpyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-ethylaminoethyl)-pyrrol-2-yl]methylene}-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one,
4-{[3,5-Dimethyl-4-(2-phenylaminoethyl)pyrrol-2-yl]methylene}-3-(l,2,4-triazin-3- yl)-2-pyrazolin-5-one, 4-{{3,5-dimethyl-4-[2-(4-pyridylmethylamino)ethyl]pyrrol-2-yl}methylene}-3-
( 1 ,2,4-triazin-3 -yl)-2-pyrazolin-5 -one,
4-{[4-(2-Carboxyethyl)-3,5-dimethylρyrrol-2-yl]methylene}-3-(l,2,4-triazin-3-yl)-2- pyrazolin-5-one,
4-[(4-Diethylaminomethyl-3-isopropyl-5-methylpyrrol-2-yl)methylene]-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{[4-(l-PiπOlidinylmethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Isopropyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4- {[4-(2-cyclopropylaminoethyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene} -3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{ {4-[3-(l-Pyrrolidinyl)propyl]-3-isopropyl-5-methylpyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[3-Isopropyl-5-methyl-4-(4-piperidinobutyl)pyrrol-2-yl]methylene}-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one,
4-{{4-[3-(4-Pyridylmethylamino)propyl]-3-isopropyl-5-methylpyrrol-2- yl}methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[4-(4-Dimethylaminobutyl)-3-isopropyl-5-methylpyrrol-2-yl]methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4-[(3-Cyclopropyl-4-diethylaminomethyl-5-methylpyrrol-2-yl)methylene]-3-(l,2,4- triazin-3-yl)-2-pyrazolin-5-one, 4-{{3-Cyclopropyl-5-methyl-4-[2-(l-pyrrolidinyl)ethyl]pyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[2-di(methoxyethyl)aminoethyl]-5-methylpyrrol-2- yl}methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4- {[3-Cyclopropyl-4-(3-diefhylaminopropyl)-5-methylpyrrol-2-yl]methylene} -3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-4-[3-(2,5-dimethyl-l-pyrrolidinyl)propyl]-5-methylpyrrol-2- yl}methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4- { [3 -Cyclopropyl-5-methyl-4-(3 -phenylmethylaminopropyl)pyrrol-2- yl]methylene}-3-(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{{3-Cyclopropyl-5-methyl-4-[4-(l-pyrrolidinyl)butyl]pyrrol-2-yl}methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one,
4-{[3-Cyclopropyl-5-methyl-4-(4-cyclobutylaminobutyl)pyrrol-2-yl]methylene}-3-
(l,2,4-triazin-3-yl)-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(l-pyrrolidinylethyl)]-3-trifluoromethylpyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]mefhylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminoethyl)]-3-trifluoromethylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)ethyl]-5-methyl-3-trifluoromethylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Aminoethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-4-[2-(l -pyrrolidinylethyl)]-3-tert-butylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminoethyl)]-3-tert-butylpyrrol-2- yl]methylene} -3 -pyrazinyl-2 -pyrazolin-5 -one, 4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-tert-butylρyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-tert-butylylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{{3-Ethyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]ρyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Ethyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4- { {3-Ethyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazo lin-5 -one, 4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-ethylpyrrol-2-yl}methylene}-3-pyrazinyl-
2-pyrazo lin-5 -one,
4-{[4-(2-Aminoethyl)-5-methyl-3-ethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one, 4-{[3-Cyclobutyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
4-{{3-Cyclobutyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclobutyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclobutyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclobutylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Aminoethyl)-5-methyl-3-cyclobutylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopentyl-5-methyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclopentyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclopentylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Aminoethyl)-5-methyl-3-cyclopentylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one
4-{[3-Cyclohexyl-4-(2-diethylaminoethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {3-Cyclohexyl-5-methyl-4-[2-(l -pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3- pyraziny 1-2-pyrazo lin-5 -one,
4-{[3-Cyclohexyl-4-(2-ethylaminoethyl)-5-methylpyrrol-2-yl]mefhylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {3-Cyclohexyl-5-methyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-cyclohexylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-cyclohexylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-3-phenyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene} -3- pyraziny 1-2 -pyrazolin- 5 -one, 4- {[4-(2-Ethylaminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene} -3-pyrazinyl-2- pyrazolin-5-one, 4-{{5-Methyl-3-phenyl-4-[2-(4-pyridiylmefhylaminoethyl)]pyrrol-2-yl}methylene}-
3 -pyrazinyl-2-pyrazo lin-5 -one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-phenylpyrrol-2-yl}methylene}-3- pyrazinyl-2 -pyrazolin-5 -one, 4- {[4-(2-Aminoethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene} -3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4- {{ 5 -Methyl-3 -(4-methoxyphenyl)-4- [2-( 1 -pyrrolidinylethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Ethylaminoethyl)-5 -methyl-3 -(4-methoxyphenyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{ {5-Methyl-3-(4-methoxyphenyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-pyridyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2 -pyrazolin-5 -one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(2-pyridyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)ethyl]-5-methyl-3-(2-pyridyl)pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminoethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-pyrazinyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Ethylaminoethyl)-5 -methyl-3 -pyraziny lpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-pyrazinyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- y 1 } methylene } -3 -pyrazinyl-2-pyrazo lin-5 -one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-pyrazinylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one, 4- {{5-Methyl-3-(2-imidazoyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl} methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)efhyl]-5-methyl-3-(2-imidazoyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{ {5-Methyl-3-(2- pyrimidinyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Ethylaminoethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Cyclopropylaminoethyl)-5 -methyl-3 -(2 -pyrimidinyl)pyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
4- { { 5 -Methyl-3 -(3 -isoxazolyl)-4-[2-( 1 -pyrrolidinyl ethyl)]pyrrol-2-yl} methylene} -3 - pyrazinyl-2-pyrazo lin-5 -one, 4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
4-{ {5-Methyl-3-(3-isoxazolyl)-4-[2-(4-pyridylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)ethyl]-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{{5-Methyl-3-(2-furyl)-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazo lin-5-one,
4-{{5-Methyl-3-(2-furyl)-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-methyl-3-(2-furyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one, 4-{ {5-Hydroxymethyl-3-isopropyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4- { {5-Hydroxymethyl-3-isopropyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)ethyl]-5-hydroxymethyl-3-isopropylpyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminoethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{{3,5-Dicyclopropyl-4-[2-(l-pyrrolidinylethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one, 4-{[4-(2-Ethylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazo lin-5 -one,
4- { {3,5-Dicyclopropyl-4-[2-(4-pyridiylmethylaminoethyl)]pyrrol-2-yl}methylene} -
3-pyrazinyl-2-pyrazolin-5-one,
4-{ {4-[2-(l-Imidazoyl)ethyl]-3,5-dicyclopropylpyrrol-2-yl}methylene}-3-pyrazinyl- 2-pyrazo lin-5 -one,
4-{[4-(2-Cyclopropylaminoethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Diethylaminomethyl)-5 -methyl-3 -trifluorom ethy lpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-4-[2-(l -pyrrolidinylmethyl)]-3-trifluoromethylpyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-4-[2-(4-pyridiylmethylaminomethyl)]-3-trifluoromethylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-trifluoromethylpyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Aminomethyl)-5-methyl-3-trifluoromethylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyraziny 1-2-pyrazolin- 5 -one,
4- { [4-(2-Dimethylaminomethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4- { {5-Methyl-4-[2-(l -pyrrolidinylmethyl)]-3-tert-butylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-tert-butylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-4-[2-(4-pyridiylmethylaminomethyl)]-3-tert-butylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-tert-butylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-tert-butylylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one, 4-{[4-(2-Diethylaminomethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-3-ethyl-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {3 -Ethyl-5 -methyl-4- [2-( 1 -pyrrolidinylmethyl)]pyrrol-2-yl } methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[3-Ethyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4- { {3-Ethyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2-yl]methylene} -
3 -pyrazinyl-2-pyrazolin-5 -one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-ethylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-ethylpyrrol-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[3-Cyclobutyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclobutyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{3-Cyclobutyl-5-methyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[3-Cyclobutyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{ {3-Cyclobutyl-5-methyl-4-[2-(4-pyridiylmethylaminomefhyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-cyclobutylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-cyclobutylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[3-Cyclopentyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- { {3-Cyclopentyl-5-methyl-4-[2-(l -pyrrolidinylmethyl)]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopentyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one,
4-{{3-Cyclopentyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)methyl]-5-methyl-3-cyclopentylpyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Aminomethyl)-5-methyl-3-cyclopentylpyrrol-2-yl]methylene} -3-pyrazinyl-
2-pyrazolin-5-one 4-{[3-Cyclohexyl-4-(2-diethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclohexyl-4-(2-dimethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin- 5 -one, 4-{ {3-Cyclohexyl-5-methyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclohexyl-4-(2-ethylaminomethyl)-5-methylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{ {3-Cyclohexyl-5-methyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-cyclohexylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-cyclohexylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5-one, 4-{[4-(2-Diethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-phenyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-phenylpyrrol-2-yl]methylene}-3-pyrazinyl-
2-pyrazolin-5 -one,
4-{ {5-Methyl-3-phenyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-phenylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-phenylpyπOl-2-yl]methylene}-3-pyrazinyl-2- pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { [4-(2-Dimethylaminomethyl)-5 -methyl-3 -(4-methoxyphenyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(4-methoxyphenyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2 -Ethylaminomethyl)-5 -methyl-3 -(4-methoxypheny l)pyrrol-2-yl]methylene} -
3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(4-methoxyphenyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(4-methoxyphenyl)pyrrol-2- yl}mefhylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-(4-methoxyphenyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one, 4- {[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene} -3- pyraziny 1-2-pyrazolin- 5 -one, 4-{ {5-Methyl-3-(2-pyridyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(2-pyridyl)-4-[2-(4-pyridylmethylaminomethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{ {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2-pyridyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Aminomethyl)-5-methyl-3-(2-pyridyl)pyrrol-2-yl]methylene}-3-pyrazinyl- 2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{ {5-Methyl-3-pyrazinyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-pyrazinyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{ {4-[2-(l-Imidazoyl)methyl]-5-methyl-3-pyrazinylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-pyrazinylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- {[4-(2-Diethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-
3 -pyrazinyl-2 -pyrazolin-5 -one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}- 3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(2-imidazoyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-methyl-3-(2-imidazoyl)pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-imidazoyl)pyrrol-2- y 1] methylene } -3 -pyrazinyl-2 -pyrazolin-5 -one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene}- 3-pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Dimethylaminomethyl)-5 -methyl-3 -(2- pyrimidinyl)pyrrol-2- yl]methylene} -3 -pyrazinyl-2-pyrazo lin-5 -one,
4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2- yl } methylene } -3 -pyrazinyl-2 -pyrazolin- 5-one, 4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazo lin-5 -one, 4- { {5-Methyl-3-(2- pyrimidinyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4-[2-(l -Imidazoyl)methyl]-5-methyl-3-(2- pyrimidinyl)pyrrol-2-yl}methylene} -
3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-pyrimidinyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminoethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4-{{5-Methyl-3-(3-isoxazolyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { {5-Methyl-3-(3-isoxazolyl)-4-[2-(4-pyridylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { {4- [2-( 1 -Imidazoyl)methyl] -5-methyl-3 -(3 -isoxazolyl)pyrrol-2-yl} methylene} -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(3-isoxazolyl)pyrrol-2- yl]methylene} -3 -pyrazinyl-2 -pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5 -one,
4-{[4-(2-Dimethylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{{5-Methyl-3-(2-furyl)-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one,
4- {[4-(2-Ethylaminomethyl)-5 -methyl-3 -(2-furyl)pyrrol-2-yl]methylene} -3 - pyrazinyl-2 -pyrazolin-5 -one,
4-{{5-Methyl-3-(2-furyl)-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4- { {4- [2-( 1 -Imidazoyl)methyl]-5 -methyl-3 -(2-furyl)pyrrol-2-yl} methylene } -3 - pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Cyclopropylaminomethyl)-5-methyl-3-(2-furyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Diethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Dimethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4- { { 5-Hydroxymethyl-3 -isopropyl-4- [2-( 1 -pyrrolidinylmethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2-yl]methylene}-
3-pyrazinyl-2-pyrazolin-5-one,
4-{{5-Hydroxymethyl-3-isopropyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one, 4-{{4-[2-(l-Imidazoyl)methyl]-5-hydroxymethyl-3-isopropylpyrrol-2- yl} methylene} -3-pyrazinyl-2-pyrazolin-5-one, 4-{[4-(2-Cyclopropylaminomethyl)-5-hydroxymethyl-3-isopropylpyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Diethylaminomethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4- { [4-(2-Dimethylaminomethyl)-3 ,5-dicyclopropylpyrrol-2-yl]methylene} -3- pyrazinyl-2-pyrazolin-5 -one,
4- { {3,5-Dicyclopropyl-4-[2-(l-pyrrolidinylmethyl)]pyrrol-2-yl}methylene} -3- pyrazinyl-2-pyrazolin-5-one,
4-{[4-(2-Ethylaminomethyl)-3,5-dicyclopropylpyrrol-2-yl]methylene}-3-pyrazinyl- 2-pyrazolirι-5-one,
4-{{3,5-Dicyclopropyl-4-[2-(4-pyridiylmethylaminomethyl)]pyrrol-2- yl}methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{{4-[2-(l-Imidazoyl)methyl]-3,5-dicyclopropylpyrrol-2-yl}methylene}-3- pyrazinyl-2-pyrazolin-5-one, 4-[(4-Cyclopropylaminomethyl-3,5-dicyclopropylpyrrol-2-yl)methylene]-3- pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopropylaminomethyl-5-methyl-4-(2-diethylaminoethyl)pyrrol-2- yl]methylene}-3-pyrazinyl-2-pyrazolin-5-one,
4-{[3-Cyclopropylaminomethyl-5-methyl-4-(2-hydroxyethyl)pyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one,
4-{[3-dimethylaminomethyl-5-methyl-4-(2-diethylaminoethyl)pyrrol-2- yl]methylene} -3-pyrazinyl-2-pyrazolin-5-one, and
4-{[3-hydroxymethyl-5-methyl-4-(2-diethylaminoethyl)pyrrol-2-yl]methylene}-3- pyrazinyl-2-pyrazolin-5-one.
23. The compound of Claim 18 wherein the compound is a mixture of stereoisomers.
24. The compound of Claim 23 wherein the stereoisomers are enantiomers.
25. The compound of Claim 24 wherein the stereoisomers are E and Z isomers.
26. The compound of Claim 18 wherein the compound is a mixture of structural isomers.
27. The compound of Claim 26 wherein the structural isomers are tautomers.
28. A method of inhibiting one or more protein kinase activities comprising the administration of a compound of Claim 18.
29. The method according to Claim 28 wherein said compound is administered to a recipient in need of having one or more protein kinase inhibited.
30. The method of Claim 29 wherein the compound is a mixture of stereoisomers.
31. The method of Claim 30 wherein the stereoisomers are enantiomers.
32. The method of Claim 30 wherein the stereoisomers are E and Z isomers.
33. The method of Claim 29 wherein the compound is a mixture of structural isomers.
34. The method of Claim 29 wherein the structural isomers are tautomers.
35. The method of Claim 29 wherein said protein kinase is a tyrosine kinase.
36. The method according to Claim 35 wherein said tyrosine kinase is selected from the group consisting of KDR, Flt-1, TIE-2, Lck, Src, fyn, Lyn, Blk, and yes.
37. A method of affecting hypeφroliferative disorders in a recipient comprising the administration of a compound of Claim 18 to said recipient.
38. A method of affecting angiogenesis in a recipient comprising the administration of a compound of Claim 18 to said recipient.
39. A pharmaceutical composition comprising a compound of Claim 18 and a pharmaceutically acceptable carrier or diluent.
40. A pharmaceutical composition comprising a compound of Claim 22 and a pharmaceutically acceptable carrier or diluent.
41. A compound according to Claim 18 wherein R is substituted with one or more substituents, each independently selected from the group consisting of halogens, lower alkyl groups, R3O-, hydroxy, HOC(O)-, R3OC(O)-, R3OC(O)R6-, R3OR6-, trihalomethyl, trihalomethylcarbonyl, nitro, - C(O)NR4R5, -NR4R5, R3CO-, -(CH2)n-R7, -C(O)(CH2)n-R7, -C(O)-(CH2)n- C(O)-R\ -O(CH2)nR7, -C(O)NR4(CH2)nR7, -C(O)O(CH2)nR7, - OC(O)(CH2)nR7, -NR4C(O)(CH2)nR7, -R6NR4R5, -R6N(R4)-R6-R7, -R6N(R6-
R7)2, -R6C(O)NR4(CH2)nR7, -R6C(O)O(CH2)nR7, -R6OC(O)(CH2)nR7, - R6NR4C(O)(CH2)nR7, -R6CH(C(O)OR4)(NR5C(O)R4), an optionally substituted aryl and an optionally substituted aralkyl group; wherein the optionally substituted aryl and optionally substituted aralkyl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxy, - NR4R5, nitro, -CONR4R5, lower alkyl group, R3O-, -C(O)OR4 and -OC(O)R3; R6 is a lower alkyl group or an aryl group; and R7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxy, R3O-, R3C(O)- or -NR4R5.
42. A compound of Claim 41 , wherein R is pyrrolyl, indolyl, azaindolyl, phenyl, pyrazolyl, imidazolyl, thienyl, 4,5,6,7-tetrahydroindolyl, or quinolinyl.
43. A compound of Claim 42, wherein R is pyrrol-2-yl, pyrrol-3-yl, indol-2-yl, indol-3-yl, azaindol-3-yl, pyrazol-4-yl, imidazol-2-yl, imidazol-4-yl, thien-2- yl or quinolin-5-yl.
44. A compound of Claim 18 or 43, wherein R1 is trifluoromethyl, amino, cyclopropylamino, methyl, ethyl, propyl, isopropyl, cyclopropyl, 2- methylcyclopropyl, 2,2,3, 3-tetramethylcyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH2)p-O-phenyl, -(CH2)p-O-(4- methoxyphenyl), -(CH2)p-O-(4-chlorophenyl), -(CH2)p-O-(4-methylphenyl), - (CH2)p-O-(3-methylphenyl), -(CH2)p-O-(4-phenylphenyl), -(CH2)p-O-(4- hydroxyphenyl), -(CH2)p-O-(4-nitrophenyl), -(CH2)p-O-(4-aminophenyl), - (CH2)p-O-(4-carbamoylphenyl), -(CH2)p-O-(4-methoxycarbonylphenyl), -
NH-phenyl, -NH-(4-methoxyphenyl), -NH-(4-chlorophenyl), -NH-(4- fluorophenyl), -NH-(4-isopropylphenyl), isopropoxy, ethoxy, cyclopentyloxy, -(CH2)p-indolyl, -(CH2)p-pyridyl, -(CH2)p-benzothiazolyl, - (CH2)p-pyrrolyl, -(CH2)p-tetrahydrofuryl, -(CH2)p-pyrazinyl, -(CH2)p-furyl, - (CH2)p-thienyl, -(CH2)p-phenyl, -(CH2)p-isoxazolyl, -(CH2)p-(5- methylisoxazolyl), -(CH2)p-pyrimidinyl, -(CH2)p-pyridazinyl, -(CH2)n-C(O)-
OMe, -(CH2)n-C(O)-OEt and benzyl optionally substituted with one or more of Cl, F, OMe, methyl or amino where p is an integer from 1 to 3.
45. A compound of Claim 44, wherein R is optionally substituted with one or more moieties selected from the group consisting of Br, Cl, F, aminomethyl, N,N-dimethylaminomethyl, carboxy, carboxymethyl, carboxyethyl, carbonylmethyl, carbonylethyl, methoxycarbonyl, ethoxycarbonyl, phenyl, 4- moφholinomethyl, -C(O)-O-(CH2)2-N(Me)2, -C(O)-O-(CH2)2-N(Et)2, -C(O)- O-CH2-N(Me)2, -C(O)-O-(CH2)2-N(Me)2, -C(O)-NH-(CH2)2-N(Me)2, -CH2- NH-C(O)-CF3 and an optionally substituted moiety selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl and phenyl, where said optionally substituted moiety is optionally substituted with one or more of
Br, Cl, F, hydroxy, nitro, amino or lower alkyl.
PCT/US2000/020628 1999-07-30 2000-07-28 2-pyrazolin-5-ones_as tyrosine kinase inhibitors WO2001009121A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA002380644A CA2380644A1 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
IL14775700A IL147757A0 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
NZ516850A NZ516850A (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
HU0400540A HUP0400540A3 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-one derivatives, their use and pharmaceutical compositions containing them
EP00950852A EP1218373A2 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones as tyrosine kinase inhibitors
PL00354144A PL354144A1 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
MXPA02001088A MXPA02001088A (en) 1999-07-30 2000-07-28 2 pyrazolin 5 ones.
JP2001514324A JP2003506368A (en) 1999-07-30 2000-07-28 2-pyrazolin-5-one
BR0012896-1A BR0012896A (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
AU63889/00A AU6388900A (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
SK151-2002A SK1512002A3 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones
KR1020027001343A KR20020091829A (en) 1999-07-30 2000-07-28 2-Pyrazolin-5-ones
NO20020487A NO20020487L (en) 1999-07-30 2002-01-30 2-pyrazoline-5-ones
BG106392A BG106392A (en) 1999-07-30 2002-02-06 2-pyrazolin-5-ones
HK02109301.3A HK1049154A1 (en) 1999-07-30 2002-12-23 2-pyrazolin-5-ones as tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14656399P 1999-07-30 1999-07-30
US60/146,563 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001009121A2 true WO2001009121A2 (en) 2001-02-08
WO2001009121A3 WO2001009121A3 (en) 2002-05-02

Family

ID=22517965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020628 WO2001009121A2 (en) 1999-07-30 2000-07-28 2-pyrazolin-5-ones_as tyrosine kinase inhibitors

Country Status (21)

Country Link
EP (1) EP1218373A2 (en)
JP (1) JP2003506368A (en)
KR (1) KR20020091829A (en)
CN (1) CN1193026C (en)
AR (1) AR032279A1 (en)
AU (1) AU6388900A (en)
BG (1) BG106392A (en)
BR (1) BR0012896A (en)
CA (1) CA2380644A1 (en)
CZ (1) CZ2002302A3 (en)
HK (1) HK1049154A1 (en)
HU (1) HUP0400540A3 (en)
IL (1) IL147757A0 (en)
MX (1) MXPA02001088A (en)
NO (1) NO20020487L (en)
NZ (1) NZ516850A (en)
PL (1) PL354144A1 (en)
SK (1) SK1512002A3 (en)
TR (1) TR200200928T2 (en)
WO (1) WO2001009121A2 (en)
ZA (1) ZA200200477B (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
WO2005000281A2 (en) * 2003-06-24 2005-01-06 Actelion Pharmaceuticals Ltd. Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007054508A1 (en) * 2005-11-11 2007-05-18 Pfizer Italia Srl Pyrrolopyridines as kinase inhibitors
WO2007065518A1 (en) * 2005-12-05 2007-06-14 Merck Patent Gmbh Pyridiazinone derivatives for tumour treatment
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2009116774A2 (en) * 2008-03-18 2009-09-24 이화여자대학교 산학협력단 Composition for treatment or prevention of restenosis
WO2010059241A2 (en) 2008-11-20 2010-05-27 Cambria Pharmaceuticals, Inc. Treatment of amyotrophic lateral sclerosis
US7754699B2 (en) 2005-12-09 2010-07-13 Roche Palo Alto Llc Antiviral nucleosides
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8629263B2 (en) 2009-05-20 2014-01-14 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8912321B2 (en) 2006-10-10 2014-12-16 Gilead Pharmasset Llc Preparation of nucleosides ribofuranosyl pyrimidines
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
US9284342B2 (en) 2009-05-20 2016-03-15 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2876109A4 (en) * 2012-07-23 2016-03-16 Yuhan Corp Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9862708B2 (en) 2014-02-14 2018-01-09 Tempest Therapeutics, Inc. Pyrazolone compounds and uses thereof
KR20200049361A (en) * 2018-10-31 2020-05-08 주식회사 큐로젠 Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives
US11040036B2 (en) 2017-08-15 2021-06-22 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US11957680B2 (en) 2017-08-15 2024-04-16 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005012255A1 (en) * 2003-08-01 2006-09-14 三菱ウェルファーマ株式会社 Treatment for inflammatory joint diseases
WO2005034985A1 (en) * 2003-10-14 2005-04-21 Kringle Pharma Inc. Agent for improving mental disorders
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
EP1900728A1 (en) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
WO2006129583A1 (en) * 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. Pyrazolone derivative
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
KR20110104074A (en) 2008-12-23 2011-09-21 파마셋 인코포레이티드 Synthesis of purine nucleosides
MX2012005284A (en) 2009-11-06 2012-06-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
CN105037269B (en) * 2015-07-10 2018-01-19 中国人民解放军第二军医大学 Substituted pyrazolecarboxylic ketone secretory protease inhibitors and preparation method thereof
CN111793032B (en) * 2019-04-08 2021-11-19 四川省中医药科学院 Pyrazolone compounds and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369310A (en) * 1979-11-19 1983-01-18 Ciba-Geigy Ltd. Bleachable dyes
EP0211363A2 (en) * 1985-07-29 1987-02-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 3-phenylthiomethylstyrene derivative, process for preparing the same, and antiallergic agent and tyrosinekinase inhibiting agent containing the same
EP0460616A1 (en) * 1990-06-04 1991-12-11 Fuji Photo Film Co., Ltd. Silver halide photographic material

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (en) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369310A (en) * 1979-11-19 1983-01-18 Ciba-Geigy Ltd. Bleachable dyes
EP0211363A2 (en) * 1985-07-29 1987-02-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 3-phenylthiomethylstyrene derivative, process for preparing the same, and antiallergic agent and tyrosinekinase inhibiting agent containing the same
EP0460616A1 (en) * 1990-06-04 1991-12-11 Fuji Photo Film Co., Ltd. Silver halide photographic material

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ABDELRAZEK, FATHY MOHAMED ET AL: "Substituted acrylonitriles in heterocyclic synthesis. The reaction of.alpha.-substituted.beta.-(2-furyl)acryl onitriles with some active methylene heterocycles" retrieved from STN Database accession no. 104:68786 XP002158262 & SYNTHESIS (1985), (4), 432-4 , *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BARNIKOW, GUENTER ET AL: "Thionocarboxylic acid esters. II. Reactions of monothionomalonic acid esters with amino compounds" retrieved from STN Database accession no. 67:21866 XP002158252 & CHEM. BER. (1967), 100(5), 1661-6 , *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IMAI, NAOHIRO ET AL: "Diisopropylbenzylidene-substituted heterocycles" retrieved from STN Database accession no. 106:213918 XP002158250 & JP 62 029570 A (KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD., JAPAN) 7 February 1987 (1987-02-07) *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JAIN, S. M. ET AL: "Synthesis and antiinflammatory activity of some glycosidated 4-benzylidene-3-methylpyrazolin-5-(4H)-one s" retrieved from STN Database accession no. 111:39711 XP002158249 & INDIAN J. CHEM., SECT. B (1988), 27B(11), 1019-23 , *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MACH-PHUOC-SINH ET AL: "Analgesic and antiinflammatory compounds in the 1-phenyl-5- pyrazolone series" retrieved from STN Database accession no. 69:25832 XP002158251 & CHIM. THER. (1968), 3(1), 17-33 , *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHMIDT, DIANE GROB ET AL: "Substituted.gamma.-butyrolactones. Part 32. Ring construction using 3-(arylmethylene)-2,4(3H,5H)-furandione: synthesis of pyrazolones and furo[3,4-cÜ[1,5Übenzothiazepinones" retrieved from STN Database accession no. 99:194936 XP002158263 & J. ORG. CHEM. (1983), 48(23), 4367-70 , *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SELIM, MAGHRABY ALI ET AL: "Activated nitriles in heterocyclic synthesis: synthesis of pyrano[2,3-cÜpyrazole derivatives" retrieved from STN Database accession no. 123:228052 XP002158253 & ORIENT. J. CHEM. (1994), 10(3), 199-204 , *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831075B2 (en) 1999-11-04 2004-12-14 Cephalon, Inc. Heterocyclic substituted pyrazolones
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
US7452873B2 (en) 2001-08-03 2008-11-18 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
US6916798B2 (en) * 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
WO2005000281A2 (en) * 2003-06-24 2005-01-06 Actelion Pharmaceuticals Ltd. Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
WO2005002574A1 (en) * 2003-06-24 2005-01-13 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
WO2005000281A3 (en) * 2003-06-24 2005-04-14 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006124874A3 (en) * 2005-05-12 2007-04-05 Kalypsys Inc Inhibitors of b-raf kinase
WO2007054508A1 (en) * 2005-11-11 2007-05-18 Pfizer Italia Srl Pyrrolopyridines as kinase inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EA014667B1 (en) * 2005-12-05 2010-12-30 Мерк Патент Гмбх Pyridiazinone derivatives for tumor treatment
US8173653B2 (en) 2005-12-05 2012-05-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pyridiazinone derivatives for the treatment of tumours
WO2007065518A1 (en) * 2005-12-05 2007-06-14 Merck Patent Gmbh Pyridiazinone derivatives for tumour treatment
US7754699B2 (en) 2005-12-09 2010-07-13 Roche Palo Alto Llc Antiviral nucleosides
US8912321B2 (en) 2006-10-10 2014-12-16 Gilead Pharmasset Llc Preparation of nucleosides ribofuranosyl pyrimidines
US9085573B2 (en) 2007-03-30 2015-07-21 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8906880B2 (en) 2007-03-30 2014-12-09 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8735372B2 (en) 2007-03-30 2014-05-27 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US10426760B2 (en) 2007-07-17 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009116774A3 (en) * 2008-03-18 2009-11-26 이화여자대학교 산학협력단 Composition for treatment or prevention of restenosis
WO2009116774A2 (en) * 2008-03-18 2009-09-24 이화여자대학교 산학협력단 Composition for treatment or prevention of restenosis
US9809556B2 (en) 2008-11-20 2017-11-07 Northwestern University Treatment of amyotrophic lateral sclerosis
US10167263B2 (en) 2008-11-20 2019-01-01 Northwestern University Treatment of amyotrophic lateral sclerosis
WO2010059241A2 (en) 2008-11-20 2010-05-27 Cambria Pharmaceuticals, Inc. Treatment of amyotrophic lateral sclerosis
EP2367798A2 (en) * 2008-11-20 2011-09-28 Cambria Pharmaceuticals, Inc. Treatment of amyotrophic lateral sclerosis
EP2367798A4 (en) * 2008-11-20 2013-03-13 Cambria Pharmaceuticals Inc Treatment of amyotrophic lateral sclerosis
AU2009318098B2 (en) * 2008-11-20 2015-07-16 Northwestern University Treatment of amyotrophic lateral sclerosis
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
US10526289B2 (en) 2008-11-20 2020-01-07 Northwestern University Substituted pyrazolone compounds for use in treatment of amyotrophic lateral sclerosis
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9284342B2 (en) 2009-05-20 2016-03-15 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9206217B2 (en) 2009-05-20 2015-12-08 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9637512B2 (en) 2009-05-20 2017-05-02 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8629263B2 (en) 2009-05-20 2014-01-14 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8633309B2 (en) 2009-05-20 2014-01-21 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8642756B2 (en) 2009-05-20 2014-02-04 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9493478B2 (en) 2012-07-23 2016-11-15 Yuhan Corporation Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same
EP2876109A4 (en) * 2012-07-23 2016-03-16 Yuhan Corp Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same
US9862708B2 (en) 2014-02-14 2018-01-09 Tempest Therapeutics, Inc. Pyrazolone compounds and uses thereof
US11040036B2 (en) 2017-08-15 2021-06-22 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US11364240B2 (en) 2017-08-15 2022-06-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US11464775B2 (en) 2017-08-15 2022-10-11 Agios Pharmaceuticals, Inc. Pyruvate kinase modulators and use thereof
US11590132B2 (en) 2017-08-15 2023-02-28 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US11872225B2 (en) 2017-08-15 2024-01-16 Agios Pharmaceuticals, Inc. Pyruvate kinase modulators and use thereof
US11957680B2 (en) 2017-08-15 2024-04-16 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
KR20200049361A (en) * 2018-10-31 2020-05-08 주식회사 큐로젠 Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives
KR102625224B1 (en) 2018-10-31 2024-01-15 주식회사 큐로젠 Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives

Also Published As

Publication number Publication date
NZ516850A (en) 2004-09-24
HUP0400540A2 (en) 2004-06-28
TR200200928T2 (en) 2002-09-23
CN1193026C (en) 2005-03-16
NO20020487D0 (en) 2002-01-30
BG106392A (en) 2002-12-29
PL354144A1 (en) 2003-12-29
AR032279A1 (en) 2003-11-05
HK1049154A1 (en) 2003-05-02
BR0012896A (en) 2002-06-18
EP1218373A2 (en) 2002-07-03
MXPA02001088A (en) 2003-09-22
ZA200200477B (en) 2003-06-25
AU6388900A (en) 2001-02-19
CA2380644A1 (en) 2001-02-08
WO2001009121A3 (en) 2002-05-02
KR20020091829A (en) 2002-12-06
CZ2002302A3 (en) 2002-06-12
CN1377346A (en) 2002-10-30
NO20020487L (en) 2002-03-12
JP2003506368A (en) 2003-02-18
SK1512002A3 (en) 2002-11-06
HUP0400540A3 (en) 2004-09-28
IL147757A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
WO2001009121A2 (en) 2-pyrazolin-5-ones_as tyrosine kinase inhibitors
US6297238B1 (en) Therapeutic agents
EP1114052B1 (en) 4-aminopyrrolopyrimidines as kinase inhibitors
WO2000075139A2 (en) Benzothiazinone and benzoxazinone compounds
US20030187001A1 (en) 4-aminopyrrolopyrimidines as kinase inhibitors
US20040006083A1 (en) Pyrazolopyrimidines as therapeutic agents
US20030225098A1 (en) Kinase inhibitors
KR20010086005A (en) Tricyclic pyrazole derivatives
CA2385769A1 (en) Kinase inhibitors as therapeutic agents
JP2003533514A (en) Tricyclic pyrazole derivatives as protein kinase inhibitors
EP1165544B1 (en) Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
WO1999055335A1 (en) Substituted tricyclic pyrazole derivatives with protein kinase activity
US7060822B1 (en) 2-pyrazolin-5-ones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00057/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/00477

Country of ref document: ZA

Ref document number: 200200477

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 147757

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-302

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 516850

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2380644

Country of ref document: CA

Ref document number: 1512002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020027001343

Country of ref document: KR

Ref document number: PA/a/2002/001088

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 63889/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 106392

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000950852

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008136823

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002/00928

Country of ref document: TR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-302

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000950852

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027001343

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 516850

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516850

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000950852

Country of ref document: EP